Document:

EX-10.5

    

Exhibit 10.5

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT
MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
  

RESEARCH COLLABORATION

AND EXCLUSIVE LICENSE AGREEMENT

 
 THIS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT
(this “Agreement”), effective as of April 1, 2013 (the “Effective Date”), by and between AGENSYS, INC., a corporation organized and existing under the laws of the State of California
(“Agensys”) and AMBRX, INC., a corporation organized and existing under the laws of the State of Delaware (“Ambrx”).

 

RECITALS:
  

WHEREAS, Ambrx has developed Ambrx Know-How (as hereinafter defined) and has rights to Ambrx Patent Rights (as hereinafter defined);

 
 WHEREAS, Agensys, together with its
Affiliates (as hereinafter defined), is a biotechnology company engaged in research, development, and commercialization of human therapeutic and diagnostic products.

 
 WHEREAS, Agensys and Ambrx desire to
enter into a research collaboration to identify and optimize candidate Antibody Drug Conjugates (as hereinafter defined) which are developed against one or more of the Targets (as hereinafter defined), using, among other things Ambrx’s
ReCODETM Technology (as hereinafter defined) and/or EuCODETM Technology (as hereinafter defined), upon the terms and conditions set forth herein; and

 
 WHEREAS, Agensys desires to obtain a
license under the Ambrx Patent Rights and Ambrx Know-How upon the terms and conditions set forth herein, and Ambrx desires to grant such a license, in order to research, develop, make, have made, use, sell, offer for sale, export and import
Compounds (as hereinafter defined) and Products (as hereinafter defined) for the diagnosis, prevention or treatment of any and all human diseases and human conditions in the Territory (as hereinafter defined).

 
 NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 
 ARTICLE
1
 DEFINITIONS

 
 Unless specifically set forth to the contrary herein, the following terms shall
have the respective meanings set forth below:
  

		1.1	“Act” shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§ 262 et
seq., as such may be amended from time to time.

  

		1.2	“Active Selected Target” shall mean Targets which are the subject of the Research Program (“Research Stage Targets”) and/or for which pre-clinical development of a

 
 

 
 

   

  

Compound against such Target is continued beyond the achievement of the Research Milestone through the initiation of an IND-Enabling Pharmacology and Toxicology Study for
such Target; provided however, such Active Selected Targets may be replaced or new Active Selected Targets added pursuant to Section 2.1.3 such that a maximum of four (4) Targets are Research Stage Targets at any one time during the Research Term.
As of the Effective Date, the Active Selected Targets are Target 1, Target 2 and Target 3; following the Effective Date, the Active Selected Targets shall be determined as set forth in Section 2.1.3. For clarity, once a given Target becomes an Open
Terminated Target, it shall not longer be considered a “Target”, “Active Selected Target” or “Commercial Target” for purposes of this Agreement. In addition, once an IND-Enabling Pharmacology and Toxicology Study
is initiated for a Compound directed to an Active Selected Target, such Target shall thereafter be considered a “Commercial Target.”
  

		1.3	“Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such Person. A Person shall be deemed to control another Person if
such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of fifty percent (50%) or more of the voting securities of such Person, by contract or otherwise.
For clarity, the use of “Affiliate” in this Agreement shall exclude any Third Party that becomes an Affiliate of Ambrx after the Effective Date due to a Change of Control involving Ambrx and such Third Party; and in all cases, all
information and materials included within the rights licensed to Agensys hereunder prior to the time that such Change of Control occurs shall continue to be included in the licensed rights following such Change of Control.

 

		1.4	“Agensys” shall have the meaning set forth in the introductory paragraph to this Agreement.

 

		1.5	“Agensys Antibody(ies)” shall mean any Antibody(ies) Controlled by Agensys during the Term.

 

		1.6	“Agensys Background Know-How” shall mean all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, compositions of matter, data, inventions, know-how (including any Agensys
Payload Technology and Agensys Antibody(ies)) and/or trade secrets, patentable or otherwise, which (i) are Controlled by Agensys or any of its Affiliates as of the Effective Date or during the Research Term, (ii) are not generally known or available
and (iii) Agensys chooses to make available for use in connection with the performance of activities under the Research Program. Notwithstanding the foregoing, Agensys Background Know-How shall exclude (x) the Agensys Collaboration Information and
Inventions and (y) Agensys’ rights in Joint Collaboration Information and Inventions. For the avoidance of doubt, an Agensys Antibody which has undergone a EuCODE Modification and/or a ReCODE Modification under the Research Plan will be deemed
an Improvement to Agensys Background Technology but any such Agensys Antibody which is

  
 

-
2
 - 

   

  

incorporated in a Compound shall be subject to the terms and conditions of this Agreement.

 

		1.7	“Agensys Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to practice and/or otherwise
made under the Research Program solely by employees of Agensys (or any of its Affiliates) or other persons (not employed by Ambrx (or any of its Affiliates)) acting on behalf of Agensys (or any of its Affiliates).

 

		1.8	“Agensys Know-How” shall mean the Agensys Background Know-How, the Agensys Collaboration Information and Inventions and Agensys’ rights in Joint Collaboration Information and
Inventions.

  

		1.9	“Agensys Patent Rights” shall mean any and all Patent Rights in the Territory which are Controlled by Agensys or any of its Affiliates and (i) which claim or cover Agensys Know-How or (ii) claim or cover the research,
development, manufacture, marketing, use or sale of any Compound and/or Product.

  

		1.10	“Agensys Payload Technology” shall mean all Payload Technology owned or Controlled by Agensys as of the Effective Date or during the Research Term.

 

		1.11	“Agensys Terminated Compound” shall mean any Compound (a) for which Agensys’ exclusive licenses under Ambrx intellectual property as set forth in Sections 3.1.1(d) and 3.1.1(e) are terminated as a result of the
termination of this Agreement in its entirety, termination of this Agreement on a Target-by-Target basis or Product-by-Product basis, as applicable, or replacement or abandonment of a Target pursuant to Section 2.14; and (b) that contains Agensys
Know-How and/or is covered by claims within Agensys Patent Rights.

  

		1.12	“Agensys Terminated Target” shall mean (i) a Research Stage Target or an Active Selected Target which Agensys has replaced as set forth in Section 2.1.3 or with respect to which Agensys has abandoned efforts under the Research
Program or (ii) such Commercial Target to which a Compound or Product has Primary Activity and which Commercially Reasonable Efforts are no longer being applied by Agensys for such Compound or Product or the First Commercial Sale has occurred but no
royalties are being paid for such Product, in each of (i) and (ii) that is covered by one or more claims in the Agensys Patent Rights.

 

		1.13	“Agreement” shall have the meaning set forth in the introductory paragraph to this Agreement.

 

		1.14	“Ambrx” shall have the meaning set forth in the introductory paragraph to this Agreement.

 

		1.15	“Ambrx Background Know-How” shall mean all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, compositions of

 
 

-
3
 - 

   

  

matter, data, inventions, know-how (including any Ambrx Payload Technology) and/or trade secrets, patentable or otherwise, which (i) are Controlled by Ambrx as of the
Effective Date or during the Research Term, (ii) are not generally known or available and (iii) Ambrx chooses to make available for use by Agensys in connection with the performance of activities under the Research Program. For clarity, the Ambrx
Background Know-How shall include all know-how under the ReCODETM Technology and all know-how under the EuCODETM Technology. Notwithstanding the foregoing, “Ambrx Background Know-How” shall exclude (x) the Ambrx Collaboration
Information and Inventions and (y) Ambrx’s rights in Joint Collaboration Information and Inventions.
  

		1.16	“Ambrx Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to practice and/or otherwise made
under the Research Program solely by employees of Ambrx (or any of its Affiliates) or other persons (not employed by Agensys (or any of its Affiliates)) acting on behalf of Ambrx (or any of its Affiliates).

 

		1.17	“Ambrx Know How” shall mean, the Ambrx Background Know-How, the Ambrx Collaboration Information and Inventions and Ambrx’s rights in Joint Collaboration Information and
Inventions.

  

		1.18	“Ambrx Patent Rights” shall mean any and all Patent Rights in the Territory which are Controlled by Ambrx as of the Effective Date or during the Term and which (i) claim or cover the research, development, manufacture,
marketing, use or sale of any component of a Compound and/or Product (including any Ambrx Collaboration Information and Inventions or Ambrx’s rights in Joint Collaboration Information and Inventions); (ii) claim or cover Ambrx Know-How
(including any Ambrx Collaboration Information and Inventions or Ambrx’s rights in Joint Collaboration Information and Inventions); or (iii) claim or cover ReCODETM Modification or EuCODETM Modification.

 

		1.19	“Ambrx Payload Technology” shall mean all Payload Technology owned or Controlled by Ambrx as of the Effective Date or during the Research Term.

 

		1.20	“Antibody(ies)” shall mean any antibody or protein comprising at least one (1) CDR (complementarity determining region) portion thereof (including bispecific antibodies, single chain antibodies and domain antibodies) and/or
similar binding protein, whether polyclonal, monoclonal, human, humanized, chimeric, murine, synthetic or from any other source.

 

		1.21	“Antibody Drug Conjugate” or “ADC” shall mean an Antibody which has undergone a EuCODE Modification and/or a ReCODE Modification conjugated to Payload Technology.

 

		1.22	“Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in carrying out activities

 
 

-
4
 - 

   

  

hereunder or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject, and shall include all statutes, enactments,
acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, policies, directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority or other
governmental entity in such jurisdictions, including the Act.
  

		1.23	“Back-up Compound(s)” shall mean those certain Antibody Drug Conjugates Discovered in performance of the Research Program with Primary Activity in the Field directed against the same Target as the applicable
Compound.

  

		1.24	“Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

 

		1.25	“Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.

 

		1.26	“Cancer” shall mean a disease in humans primarily characterized by uncontrolled growth or spread of abnormal and anaplastic cells, metastases, neoplasm, malignant tumors and/or invasion by abnormal and anaplastic cells into
tissues. For the avoidance of doubt, “Cancer” shall not include inflammation, infection, transplantation, auto-immunity or conditions characterized by hypertrophy or hyperplasticity of normal cells.

 

		1.27	“Change of Control” shall mean with respect to a Person: (i) the sale of all or substantially all of such Person’s assets or business relating to the subject matter of this Agreement; (ii) a merger, reorganization or
consolidation involving such Person in which the voting securities of such Person outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such
merger, reorganization or consolidation; or (iii) a person or entity, or group of persons or entities, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Person (other than in
connection with an arrangement principally for bona fide equity financing purposes of such Person in which the Person is the surviving corporation).

 

		1.28	“Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial, or Phase III Clinical Trial, as applicable.

 

		1.29	“Collaboration Information and Inventions” shall mean any protocol, formula, data, know-how, information, trade secret, process, method, composition of matter (including composition of matter of any Antibody Drug Conjugates),
compound (including any Antibody Drug Conjugates), material, article of manufacture, discovery, invention or finding, patentable or otherwise, that is first conceived, discovered, developed, invented, reduced to practice and/or otherwise made (as
would be necessary to establish inventorship under United States patent law (regardless of where the applicable activities occurred)) in performance of the Research Program. For clarity, “Collaboration Information and Inventions” shall
exclude Patent Rights.

  
 

-
5
 - 

   

  

		1.30	“Combination Product” shall mean a Product which includes one or more active ingredients other than a Compound in combination with a Compound. All references to Product in this Agreement shall be deemed to include Combination
Product.

  

		1.31	“Commercial Target” shall mean up to five (5) Active Selected Targets, identified in writing by Agensys prior to filing of the first IND for a Product against such Active Selected Target, for which (i)
Agensys has progressed at least one (1) Compound related to such Target through IND-Enabling Pharmacology and Toxicology Studies or (ii) has at least one (1) Compound directed to such Target that is the subject of ongoing Clinical Trials or is being
commercialized (e.g., a First Commercial Sale has occurred and royalties are being paid under this Agreement). For clarity, once a given Target becomes a Commercial Target, it shall not longer be considered an Active Selected Target. In addition,
once a given Target becomes an Open Terminated Target, it shall not longer be considered a “Target”, “Active Selected Target” or “Commercial Target” for purposes of this Agreement.

 

		1.32	“Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with respect to any objective, reasonable, diligent, good faith efforts to accomplish such objective as such Party would
normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the research, discovery, development or commercialization of any Product (or Compound, as applicable) by either Party,
such efforts shall be substantially equivalent to those efforts and resources commonly used by such Party for a product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar
market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval, the
profitability and commercial potential of the product to the applicable Party (including the amounts payable to licensors of patent or other intellectual property rights), alternative products and other relevant factors. Commercially Reasonable
Efforts shall be determined on a market-by-market and Product-by-Product basis, and it is anticipated that the level of effort will be different for different markets, and will change over time, reflecting changes in the status of the Product (or
Compound, as applicable) and the market(s) involved.

  

		1.33	“Compound” shall mean (a) any and all Antibody Drug Conjugates Discovered in performance of the Research Program with Primary Activity directed against the applicable Active Selected Target or
Commercial Target; and (b) any Back-up Compounds for such Antibody Drug Conjugates. For clarity, once a given Compound becomes a Terminated Compound, it shall not longer be considered a “Compound” for purposes of this
Agreement.

  

		1.34	“Confidential Information” shall mean any and all proprietary and/or confidential information and data, including all scientific, pre-clinical, clinical, regulatory, process, formulation,
manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided

 
 

-
6
 - 

   

  

by one Party to the other Party prior to or in connection with this Agreement. The Parties acknowledge having entered into a Non-Disclosure Agreement as
of 06-October-2010 and agree that upon the Effective Date such Non-Disclosure Agreement shall be superseded by the Confidentiality / Non-Disclosure obligations of this Agreement.

 

		1.35	“Control”, “Controls” or “Controlled by” shall mean with respect to any Patent Rights, know-how or other intellectual property assets or other items or rights, as applicable, the
possession of (whether by ownership or license or other right, other than pursuant to a license under this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, such item or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense.

 

		1.36	“Discover” shall mean, with respect to a given Antibody or Antibody Drug Conjugate, that such Antibody or Antibody Drug Conjugate was actually identified, made (and tested in a physical form),
developed, created, derived, discovered, characterized, selected or otherwise optimized in performance of the Research Program.

 

		1.37	“EuCODETM Modification” shall mean the design, creation, modification and/or generation of compounds against a Target through the incorporation, substitution or addition of one or more non-naturally encoded amino acids
(i.e., amino acids other than the 20 naturally-encoded amino acids), including non-naturally encoded amino acids providing one or more points of site-specific attachment for a drug, into the amino acid sequence of the Antibody comprising such
compounds against a Target using EuCODETM Technology.

  

		1.38	“EuCODETM Technology” shall mean Ambrx Patent Rights and Ambrx Know-How (i) necessary for performing EuCODETM Modification and/or (ii) directed to or necessary for expressing, or chemically
modifying, Compounds resulting from EuCODETM Modification.

  

		1.39	“Field” shall mean the therapeutic use of a Compound and/or Product for the treatment of Cancer in humans.

 

		1.40	“Filing” of an NDA (or IND, as applicable) shall mean the acceptance by a Regulatory Authority of an NDA (or IND, as applicable) for filing; provided that such Regulatory Authority has not issued a
refusal to file letter or a letter identifying deficiencies for which the Regulatory Authority will suspend its review following submission of the filing.

 

		1.41	“First Commercial Sale” shall mean, with respect to a given Product in a given country in the Territory, the first shipment to a Third Party of commercial quantities of such Product sold in such country to a Third Party on
arm’s length terms by Agensys (or its Affiliate or sub-licensee) for end use or consumption of such Product in such country in the Territory (following, in all cases, receipt of Marketing Authorization for such

 
 

-
7
 - 

   

  

Product in such country), excluding, however, any sale or other distribution for use in a Clinical Trial or for compassionate or similar use. For clarity, First Commercial
Sale shall be determined on a Product-by-Product and country-by-country basis.
  

		1.42	“Full Time Equivalent” or “FTE” shall mean the equivalent of a full-time scientist’s work time over a Calendar Year consisting of a total of one thousand seven hundred and sixty (1760) hours per
Calendar Year of work devoted to, and directly related to, conducting activities under the Research Program in accordance with this Agreement. Any individual who devotes less than one thousand seven hundred and sixty (1760) hours per Calendar Year
to conducting activities under the Research Program shall be treated as an FTE on a pro-rata basis taking into account the actual number of hours worked on conducting activities under the Research Program divided by one thousand seven hundred and
sixty (1760) hours. No individual may be charged at greater than one (1) FTE in a given Calendar Year.

  

		1.43	“FTE Rate” shall mean [***] per Calendar Year; provided that the “FTE Rate” shall be increased annually for each Calendar Year after 2013 (i.e., commencing with Calendar Year 2014) to be equal to (i) the FTE
Rate for the previous Calendar Year multiplied by (ii) [***] (e.g., the FTE Rate for Calendar Year 2014 shall be [***] and the FTE Rate for Calendar Year 2015 shall be [***], and so on).

 

		1.44	“GLP” or “Good Laboratory Practice” shall mean the applicable then-current standards for laboratory activities for pharmaceuticals or biologicals, as set forth in the Act, as amended from time to time,
together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory.

 

		1.45	“Improvement to Agensys Background Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Agensys Background Know-How (including any Agensys
Payload Technology or Agensys Antibody(ies) within the Agensys Background Know-How).

  

		1.46	“Improvement to Agensys Payload Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Agensys Background Know-How (including any Improvement
to Agensys Payload Technology Solely Developed by Agensys).

  

		1.47	“Improvement to Ambrx Background Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Ambrx Background Know-How (including any Improvement
to Ambrx Payload Technology Solely Developed by Ambrx). Notwithstanding the foregoing, “Improvement to Ambrx Background Technology” shall exclude any Collaboration Information and Invention that is (i) an Improvement to Ambrx Payload
Technology (other than an Improvement to Ambrx Payload Technology Solely Developed by Ambrx), (ii) an Improvement to Agensys Background Technology and/or

  
 ***Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
8
 - 

   

  
 (iii) an Active
Selected Target, Commercial Target, Agensys Antibody(ies), Compound or Product (or specifically related to, or applicable to, an Active Selected Target, Commercial Target, Compound, Agensys Antibody(ies) or Product).

 

		1.48	“Improvement to Ambrx Payload Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Ambrx Payload Technology within the Ambrx Background
Know-How.

  

		1.49	“Improvement to Ambrx Payload Technology Solely Developed by Ambrx” shall mean any Improvement to Ambrx Payload Technology that is conceived, discovered, developed, invented, reduced to practice and/or otherwise made solely by
employees of Ambrx or other persons (not employed by Agensys (or any of its Affiliates)) acting on behalf of Ambrx.

 

		1.50	“IND” shall mean an Investigational New Drug application, or similar application, to conduct human clinical investigations filed with or submitted to the applicable Regulatory Authority in conformance with the requirements of
such Regulatory Authority.

  

		1.51	“IND-Enabling Pharmacology and Toxicology Study” shall mean a genotoxicity, acute toxicology, safety pharmacology and sub-chronic toxicology study, in species that satisfy applicable regulatory requirements, using applicable
GLP, that meets the standard necessary for submission as part of an IND filing with the applicable Regulatory Authority, as reasonably determined by Agensys.

 

		1.52	“Initiates” or “Initiation” shall mean, with respect to a Clinical Trial, the administration of the first dose to a patient in such Clinical Trial.

 

		1.53	“Joint Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to practice and/or otherwise made
under the Research Program jointly by employee(s) of Agensys and/or its Affiliate and/or a Third Party acting on behalf of Agensys or its Affiliate, on the one hand, and employee(s) of Ambrx and/or a Third Party acting on behalf of Ambrx, on the
other hand.

  

		1.54	“Joint Patent Rights” shall mean all Patent Rights to the extent claiming patentable Joint Collaboration Information and Inventions.

 

		1.55	“JPT” shall mean the joint project team established to facilitate the Research Program, as more fully described in Section 2.4.

 

		1.56	“Major Markets” shall mean the following countries: the United States, Japan, the United Kingdom, France, Germany, Italy and Spain.

 

		1.57	“Major Market in the EU” shall mean any one of the following countries: the United Kingdom, France, Germany, Italy or Spain.

 
 

-
9
 - 

   

  

		1.58	“Marketing Authorization” shall mean all approvals from the relevant Regulatory Authority necessary to market and sell a Product in a given country in the Territory (including all applicable pricing and governmental
reimbursement approvals legally required to sell Product in such country).

  

		1.59	“MTA” shall mean a material transfer agreement entered into between the Parties setting forth a plan for research activities directed towards a Target.

 

		1.60	“NDA” shall mean a New Drug Application, Biologics License Application, Worldwide Marketing Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the Act, or similar application or submission
for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in a given country or group of countries.

 

		1.61	“Net Sales” shall mean the gross invoice price (not including value added taxes, sales taxes, or similar taxes) of Product sold by Agensys or its Related Parties to the first Third Party after deducting, if not previously
deducted, from the amount invoiced or received:

  

		(a)	trade and quantity discounts actually given other than early payment cash discounts;

 

		(b)	returns, rebates, chargebacks and other similar fees and allowances actually taken;

  

		(c)	retroactive price reductions that are actually allowed or granted;

  

		(d)	deductions to gross invoice price of Product imposed by Regulatory Authorities or other governmental entities;

 

		(e)	sales commissions, distribution fees and other similar fees paid to Third Party distributors and/or selling agents actually paid;

 

		(f)	early payment cash discounts, transportation and insurance, and custom duties actually taken; and

 

		(g)	the standard inventory cost of devices or delivery systems used for dispensing or administering or delivering Product.

 
 Any individual items that are estimated and deducted
in calculating Net Sales shall be periodically (but at least on a Calendar Quarter basis) trued up and adjusted by Agensys consistent with its customary practices and in accordance with generally accepted accounting principles
(“GAAP”). Any deductions subsequently reversed shall be included in Net Sales for the royalty period in which such deductions are reversed. The calculation of Net Sales hereunder shall be in accordance with GAAP and Agensys’
and/or its Affiliates’ customary accounting policies, applied consistently across periods.
  
 

-
10
 - 

   

  
 With respect
to sales of Combination Products, Net Sales shall be calculated on the basis of the gross invoice price of Product(s) containing the same strength of Compound sold without other active ingredients. In the event that Product is sold only as a
Combination Product, Net Sales shall be calculated on the basis of the gross invoice price of the Combination Product multiplied by a fraction, the numerator of which shall be the inventory cost of Compound in the Product and the denominator of
which shall be the inventory cost of all of the active ingredients in the Combination Product. Inventory cost shall be determined in accordance with Agensys’ and/or its Affiliates’ customary accounting policies, applied consistently
across periods. The deductions set forth in paragraphs (a) through (g) above will be applied in calculating Net Sales for a Combination Product. In the event that Product is sold only as a Combination Product and either Party reasonably believes
that the calculation set forth in this Paragraph does not fairly reflect the value of the Product relative to the other active ingredients in the Combination Product, the Parties shall negotiate, in good faith, other means of calculating Net Sales
with respect to Combination Products.
  

		1.62	“Open Terminated Compound” shall mean any Compound (a) that does not contain Agensys Know-How and is not covered by claims within Agensys Patent Rights and (b) for which Agensys’ exclusive licenses under Ambrx
intellectual property as set forth in Sections 3.1.1(d) and 3.1.1(e) are terminated as a result of the termination of this Agreement in its entirety, termination of this Agreement on a Target-by-Target basis or Product-by-Product basis, as
applicable, or replacement or abandonment of a Target pursuant to Section 2.14. For clarity, once a given Compound becomes an Open Terminated Compound, it shall no longer be considered a “Compound” for purposes of this
Agreement.

  

		1.63	“Open Terminated Product” shall mean any pharmaceutical or biological preparation in final form containing an Open Terminated Compound. For clarity, once a given Product becomes an Open Terminated Product, it shall no longer
be considered a “Product” for purposes of this Agreement.

  

		1.64	“Open Terminated Target” shall mean (i) a Research Stage Target or an Active Selected Target which Agensys has replaced as set forth in Section 2.1.3 or with respect to which Agensys has abandoned efforts under the Research
Program or (ii) such Commercial Target to which a Compound or Product has Primary Activity and which Commercially Reasonable Efforts are no longer being applied by Agensys for such Compound or Product or the First Commercial Sale has occurred but no
royalties are being paid for such Product, in each of (i) and (ii) that is not covered by one or more claims in the Agensys Patent Rights. For clarity, once a given Target becomes an Open Terminated Target, it shall no longer be considered a
“Target” (whether “Research Stage Target,” “Active Selected Target” or “Commercial Target”) for purposes of this Agreement.

 

		1.65	“Party” shall mean Agensys or Ambrx, individually, and “Parties” shall mean Agensys and Ambrx, collectively.

 
 

-
11
 - 

   

  

		1.66	“Patent Rights” shall mean (i) patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) and
(ii) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent
applications, and any and all foreign equivalents of the foregoing in the Territory.

  

		1.67	“Payload Technology” shall mean any technology (including any information, processes, methods and know-how), patentable or otherwise, in which a functional group is used to link or attach, by a
covalent bond or otherwise, one or more cytotoxic agents to an Antibody to form an antibody drug conjugate.

  

		1.68	1.60 1.61 “Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity
not specifically listed herein.

  

		1.69	“Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent
thereof.

  

		1.70	“Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b), as may be amended, or the foreign equivalent
thereof.

  

		1.71	“Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c), as may be amended, or the foreign equivalent
thereof.

  

		1.72	“Primary Activity” shall mean that the Antibody targeting moiety directed to a Target has preferential binding activity in an in vitro assay meant to measure such activity against such
Target.

  

		1.73	“Product” shall mean any pharmaceutical or biological preparation in final form containing a Compound, including any Combination Product. For clarity, different formulations or dosage strengths of a given Product shall be
considered the same Product for purposes of this Agreement.

  

		1.74	“Program Payload Technology” shall mean any Payload Technology that is a Collaboration Information and Invention.

 

		1.75	“ReCODETM Modification” shall mean the design, creation, modification and/or generation of compounds against a Target through the incorporation, substitution or addition of one or more non-naturally encoded amino acids
(i.e., amino acids other than the 20 naturally-encoded amino acids), including non-naturally encoded amino acids providing one or more points of site-specific attachment for a drug, into the amino acid

 
 

-
12
 - 

   

  

sequence of the Antibody comprising such compounds against a Target using ReCODETM Technology.

 

		1.76	“ReCODETM Technology” shall mean Ambrx Patent Rights and Ambrx Know-How (i) necessary for performing ReCODETM Modification and/or (ii) directed to or necessary for expressing, or chemically
modifying, Compounds resulting from ReCODETM Modification.

  

		1.77	“Regulatory Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Product in the Territory, including, in the
United States, the United States Food and Drug Administration and any successor governmental authority having substantially the same function.

 

		1.78	“Related Party” shall mean each of Agensys, its Affiliates, and their respective sublicensees (which term does not include distributors), as applicable.

 

		1.79	“Research Plan” shall mean the plan for conducting activities under the Research Program as set forth on Schedule 1.79, as such plan may be updated from time to time in accordance with this
Agreement.

  

		1.80	“Research Program” shall mean the research activities undertaken by the Parties to discover, identify and optimize Compounds developed against the Active Selected Targets, using, among other things, ReCODETM Technology
and/or EuCODETM Technology, as more fully set forth in Article 2 and the Research Plan.

  

		1.81	“Research Term” shall mean that period of time beginning on the Effective Date and ending on the fourth (4th) anniversary of the Effective Date, subject to early termination or extension as
set forth in Section 2.8.

  

		1.82	“Royalty Product” shall mean a Product that (i) contains a Compound that was Discovered under the Research Program and (ii) is used against a Commercial Target.

 

		1.83	“Scripps License” shall mean that certain License Agreement by and between The Scripps Research Institute (“Scripps”) and Ambrx, dated as of August 26, 2003, as amended by Amendment No. 1, dated December 19,
2005, and as the same may be amended from time to time.

  

		1.84	“Target” shall mean a cell surface molecule to which the Antibody portion of the Antibody Drug Conjugate preferentially binds to deliver a cytotoxic compound with the goal of Primary Activity in the
Field.

  

		1.85	“Target 1” shall mean the Target known as [***] as more particularly described in Schedule 1.85, and shall include all naturally occurring variants, naturally occurring

 
 ***Certain information on this page has been omitted
and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
13
 - 

   

  
 fragments and
naturally occurring homologs and other naturally occurring derivatives thereof.
  

		1.86	“Target 2” shall mean the Target known as [***] as more particularly described in Schedule 1.85, and shall include all naturally occurring variants, naturally occurring fragments and naturally occurring homologs and
other naturally occurring derivatives thereof.

  

		1.87	“Target 3” shall mean the Target known as [***] as more particularly described in Schedule 1.85, and shall include all naturally occurring variants, naturally occurring fragments and naturally occurring homologs and
other naturally occurring derivatives thereof.

  

		1.88	“Territory” shall mean all of the countries in the world, and their territories and possessions.

 

		1.89	“Third Party” shall mean an entity other than Agensys and its Affiliates, and Ambrx.

 

		1.90	“UC Berkeley License” shall mean that certain Exclusive License for Cycloadditions in Biological Systems Promoted by Strained II-Bonds by and between The Regents of the University of California (“UC
Berkeley”) and Ambrx, dated as of December 16, 2009, as the same may be amended from time to time in accordance with this Agreement and the UC Berkeley Sublicense.

 

		1.91	“UC Berkeley Technology” shall mean (i) any and all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, data, inventions, know-how and/or trade secrets, patentable or
otherwise, and (ii) any and all Patent Rights, in each case of (i) and (ii), which are licensed to Ambrx pursuant to the that certain UC Berkeley License.

 

		1.92	“Valid Patent Claim” shall mean a claim of an issued and unexpired patent included within (i) the Ambrx Patent Rights and/or (ii) Joint Patent Rights, in either case, that claim (A) the applicable
Compound as a composition of matter or (B) the manufacture, use or sale of the applicable Compound and/or Product, which claim has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent
jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or
otherwise.

  

		1.93	“Violation” shall mean that a Party or any of its officers or directors or any other personnel (or other permitted agents of such Party performing activities hereunder) has been: (1) convicted of any
of the felonies identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector

 
 ***Certain information on this page has been omitted
and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
14
 - 

   

  
 General (OIG)
website, including 42 U.S.C. 1320a-7(a) (http://oig.hhs.gov/exclusions/authorities.asp); (2) identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or the U.S. General Services
Administration’s list of Parties Excluded from Federal Programs (http://www.epls.gov); or (3) listed by any US Federal agency as being suspended, debarred, excluded or otherwise ineligible to participate in Federal procurement or
non-procurement programs, including under 21 U.S.C. 335a (http://www.fda.gov/ora/compliance_ref/debar/) (each of (1), (2) and (3) collectively the “Exclusions Lists”).

 

		1.94	Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:

 

	Term	Section
	“AAA”	10.6.1
	“Additional Third Party Licenses”	5.4.7(b)
	“Agensys Indemnified Parties”	9.2
	“Ambrx Indemnified Parties”	9.1
	“Code”	8.4(d)
	“Development/Commercialization Milestones”	5.3.2
	“Development Milestone 1”	5.3.2
	“Development Milestone 2”	5.3.2
	“Development Milestone 3”	5.3.2
	“Development Milestones”	5.3.2
	“Eliminated FTE”	5.2.4
	“Excluded Claim”	10.6.6
	“Exclusions Lists”	1.93
	“Human Materials”	2.2.2
	“Indemnified Party”	9.3
	“Indemnifying Party”	9.3
	“License Payments”	5.8
	“MTA”	2.1.4
	“Materials”	2.9
	“New Target Notice”	2.1.3(a)
	“Officials”	2.11.1
	“Payment”	2.11.1
	“Project Leader”	2.4.3
	“Providers”	2.2.2
	“Regeneron Licenses”	5.4.7(a)
	“Research Milestone”	5.3.1
	“Research Stage Targets”	1.2
	“Royalty Term”	5.4.4
	“Sensitive Information”	10.2
	“Taxes”	5.8

  
 

-
15
 - 

   

  

	“Term”	8.1
	“Third Party MTA Research Costs”	5.2.2
	“Third Party Research Costs”	5.2.1(a)
	“Valid Scientific Reasons”	2.1.3(a)

  

ARTICLE 2

RESEARCH PROGRAM
  

		2.1	General; Research Stage Targets and Active Selected Targets and Research Plans 

 

		2.1.1	Research Program in General. During the Research Term, Ambrx and Agensys shall engage in the Research Program upon the terms and conditions set forth in this Agreement and as directed by the JPT. Subject to Sections 2.1.3(b) and 2.1.4, at
any one time, up to four (4) Research Stage Targets or MTAs may be the subject of research activities under the Research Program. The activities to be undertaken in the course of the Research Program shall be set forth in the Research Plan, and
updated on an annual basis (or more frequently upon the addition or substitution of a Research Stage Target, or otherwise in the discretion of the JPT). The Research Plan shall provide that Ambrx shall solely be responsible for (a) making the
research quantities of recombinant Antibodies incorporating non-natural amino acids under the Research Plan for use in the Research Program and (b) EuCODETM Modification activities and ReCODETM Modification activities involving the use or
application of EuCODETM Technology or ReCODETM Technology under the Research Plan (subject to Section 2.5.2) for the Research Program, in each case, during the Research Term.

 

		2.1.2	Identification of Active Selected Targets. The Parties hereby agree and acknowledge that three (3) Active Selected Targets (Target 1, Target 2 and Target 3) have been identified by the Parties as of the Effective Date and are more
particularly described on Schedule 1.85.

  

		2.1.3	Substitution of Targets; Addition of Targets.

  

		(a)	Substitution of Research Stage Target(s) by New Target(s). Agensys may replace up to three (3) Research Stage Targets for Valid Scientific Reasons prior to the initiation of IND-Enabling Pharmacology and Toxicology Studies for a Compound
with Primary Activity against a particular Research Stage Target pursuant to the procedure set forth in this Section 2.1.3(a). In addition, the JPT, by unanimous decision, may determine to replace up to three (3) Research Stage Targets. For clarity,
no more than three (3) Research Stage Targets may be replaced during the Research Term, whether at the request of Agensys or by unanimous decision of the JPT.

 
 If Agensys wishes, in its sole
discretion but pursuant to the procedure set forth in this Section 2.1.3(a), or under agreement by the JPT, to replace a Research Stage Target with another Target, it shall provide written notice to Ambrx of the

 
 

-
16
 - 

   

  

proposed new Research Stage Target (the “New Target Notice”). Within thirty (30) days of receipt of the New Target Notice, Ambrx shall provide written
notice to Agensys that such new Research Stage Target may proceed as part of the Research Program. If Ambrx has a contractual or strategic limitation on accepting the new Target as an Active Selected Target or Commercial Target hereunder or if Ambrx
reasonably believes that the Target is not directed to the Field, the JPT shall decide whether to permit such new Target as an Active Selected Target. A contractual limitation shall consist of an executed material transfer agreement or license
agreement with a Third Party with respect to such new Target; a strategic limitation shall consist solely of an active internal Ambrx program4 at the time of receipt of the New Target Notice. If Ambrx has a contractual or strategic
limitation on accepting the new Target, Agensys may propose an alternate new Target. Upon acceptance of the new Research Stage Target, the JPT shall amend the Research Plan to include such new Target to set forth the proposed research activities for
such new Target.
  
 For purposes of this Section 2.1.3(a), “Valid
Scientific Reasons,” with respect to a Research Stage Target, shall be valid scientific and/or technical data available during the Research Term, whether generated pursuant to the Research Program or by a Third Party, specifically not
including commercial reasons or decisions or any strategic decision by Agensys related to such Target or the Field.
  

		(b)	Addition of Active Selected Targets. In the event that Agensys files an IND for a Compound during the Research Term: (i) upon [***], Agensys may propose one (1) additional Research Stage Target at any time during the Research Term; or
(ii) upon [***], Agensys may propose two (2) additional Research Stage Targets during the Research Term. For clarity, if Agensys [***], up to three (3) Research Stage Targets may be the subject of the Research Program (with a new Research Stage
Target replacing the Active Selected Target [***]), and if Agensys [***], up to four (4) Research Stage Targets may be the subject of the Research Program.

 
 If Agensys wishes to propose additional Research
Stage Target(s) pursuant to this Section 2.1.3(b), it shall provide written notice to Ambrx of the additional Active Selected Target(s) (the “Additional Target Notice”). Within thirty (30) days of receipt of the Additional Target
Notice, Ambrx shall provide written notice to Agensys and to the JPT that such new Research Stage Target may proceed as part of the Research Program. If Ambrx has a contractual or strategic limitation on accepting the new Target as an Active
Selected Target or Commercial Target hereunder or if Ambrx reasonably believes that the Target is not directed to the Field, the JPT shall decide whether to permit such new Target as an Active Selected Target. A contractual limitation shall consist
of an executed material
  

		4	The Parties to determine the criteria for determining whether Ambrx has an “active internal program.”

 
 ***Certain information on this page has been omitted
and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
17
 - 

   

  
 transfer
agreement or license agreement with a Third Party with respect to such new Target; a strategic limitation shall consist solely of an active internal Ambrx program (see, 2.1.3(c)) at the time of receipt of the Additional Target Notice. If Ambrx has a
contractual or strategic limitation on accepting the new Target, Agensys may propose an alternate new Target. Upon acceptance of the new Active Selected Target(s), the JPT shall amend the Research Plan to include such new Active Selected Target(s)
to set forth the proposed research activities for such new Active Selected Target(s).
  

		(c)	The Parties further agree that for the purposes of this Agreement, an active internal Ambrx program shall consist of Ambrx having completed an in vivo efficacy study of an Antibody Drug Conjugate against such additional Active Selected
Target.

  

		2.1.4	MTAs. In the event there are either no or one (1) Active Selected Target(s) in the Research Program (e.g., an Active Selected Target has dropped out of the Research Program or an IND-Enabling Pharmacology and Toxicology Study has been
initiated for at least two (2) of the Active Selected Targets), Agensys may propose that Ambrx and Agensys enter into up to three (3) material transfer agreements for research purposes only (each, an “MTA”). The form of MTA to be
used is attached hereto as Exhibit 2.1.4. For each MTA, Agensys will nominate in writing up to three (3) Antibodies to a single Target suitable for the creation of an Antibody containing an Ambrx non-natural amino acid and/or Antibody Drug
Conjugates with Primary Activity against such Target. The Parties will mutually agree to a research plan associated with each MTA and, in connection with such MTA research plan, Ambrx will deliver (i) Antibodies containing the Ambrx non-natural
amino acid and (ii) Ambrx linker and toxins in sufficient quantities for Agensys to evaluate Antibody(ies) containing an Ambrx non-natural amino acid and/or Antibody Drug Conjugates in standard in vitro and in vivo rodent efficacy
models. The term of each MTA will be no longer than the Research Term, unless Ambrx agrees otherwise.

  

		2.1.5	Research Plan. The Parties hereby acknowledge and agree that the initial Research Plan for the activities under the Research Program is attached hereto as Schedule 1.79. Ambrx shall use Commercially Reasonable Efforts to provide
the FTEs set forth in the Research Plan. Within ninety (90) days of the acceptance (or deemed acceptance) of a new Target by Ambrx and/or the JPT as a replacement or additional Active Selected Target or the execution of an MTA, the JPT shall create
and approve the plan for conducting activities under the Research Program which incorporate research activities directed at the new Research Stage Target (or Antibodies in the case of an MTA), which plan shall contain similar elements and level of
detail as the initial Research Plan. Upon approval by the JPT, such plan shall become the amended Research Plan provided that any such amended Research Plan and MTA may not obligate Ambrx to incur additional expenses (other than provision of the
number of FTEs or other expenses as set forth in the then-applicable Research Plan and the then-effective MTAs) unless 

 
 

-
18
 - 

   

  

(x) Ambrx agrees in writing or (y) Agensys agrees to fund such additional expense (which may include FTEs and Third Party Costs, as applicable, in accordance with Section
5.2).
  

		2.1.6	Limitation on FTEs. Notwithstanding anything in this Agreement, Ambrx shall not be obligated to provide more than eight (8) FTEs per Calendar Quarter pursuant to the Research Plan and any effective
MTAs.

  

		2.1.7	Research Collaboration Procedure; General. The Parties agree that the Research Plan, as set forth in Schedule 1.79, shall control the activities conducted under the Research Program. Generally, the activities under the Research
Plan, shall require Agensys to transfer to Ambrx an Antibody which shall be modified using either a EUCODE Modification or RECODE Modification. Upon a EUCODE Modification or RECODE Modification, Ambrx shall transfer the naked Antibody(ies) or
Antibody Drug Conjugates to Agensys for evaluation. The following table shows the procedure for the Research Collaboration:

 

	 	 	Activity	Description	Performed by
	1	 	[***]	[***]	[***]
	2	 	[***]	[***]	[***]
	3	 	[***]	[***]	[***]
	4	 	[***]	[***]	[***]
	5	 	[***]	[***]	[***]
	6	 	[***]	[***][***][***][***]	[***]

  

***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

-
19
 - 

   

  

	 	 	Activity	Description	Performed by
	7	 	[***]	[***]	[***]

  

		2.2	Conduct of Research 

  

		2.2.1	Activities and Efforts. Ambrx and Agensys each shall use Commercially Reasonable Efforts to accomplish the objectives of the Research Program, including to perform all activities to be performed by such Party as set forth in the Research
Plan, and in connection therewith, each Party shall maintain and utilize sufficient equipment, laboratories, offices and other facilities, and use personnel with sufficient skills and experience, in each case, as are required to accomplish the
Research Program in accordance with the terms of this Agreement and the Research Plan, as applicable.

  

		2.2.2	Compliance. Ambrx and Agensys each shall conduct the Research Program in compliance with all Applicable Laws. In addition, if animals are used in research under the Research Program hereunder, the Parties will comply with the Animal
Welfare Act or any other applicable local, state, national and international laws and regulations relating to the care and use of laboratory animals, and are encouraged to use the highest standards, such as those set forth in the Guide for the Care
and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Any animals which are used in the course of the Research Program, or products derived from those animals, such as eggs or milk, will not
be used for food purposes, nor will these animals be used for commercial breeding purposes. In addition, if any human cell lines, tissue, human clinical isolates or similar human-derived materials (“Human Materials”) have been or
are to be collected and/or used in the Research Program, each Party represents and warrants (i) that it has complied, or shall comply, with all Applicable Laws relating to the collection and/or use of the Human Materials and (ii) that it has
obtained, or shall obtain, all necessary approvals and appropriate informed consents, in writing, for the collection and/or use of such Human Materials, and such Party shall provide documentation of such approvals and consents to the other upon
request. Each Party shall notify the other Party in writing of any deviations from applicable regulatory or legal requirements. Each Party hereby certifies that it has not employed or otherwise used in any capacity, and will not employ or otherwise
use in any capacity, the services of any person debarred under United States law, including but not limited to Section 21 USC 335a, or foreign equivalent thereof, in performing any portion of the Research Program. Each Party shall notify the other
Party in writing immediately if any such debarment occurs or comes to its attention, and shall, with respect to any

 
 ***Certain information on this page has been omitted
and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
20
 - 

   

  
 person or entity
so debarred promptly remove such person or entity from performing any Research Program activities, function or capacity related to the Research Program.
  

		2.2.3	Subcontractors. Agensys shall be entitled to utilize the services of its Affiliates and Third Parties to perform its Research Program activities as specifically set forth in the Research Plan. Ambrx shall be entitled to utilize the
services of Third Parties to perform its Research Program activities only upon Agensys’ prior written consent, not to be unreasonably withheld, or as specifically set forth in the Research Plan. Each Party shall remain at all times fully
liable for its respective responsibilities under the Research Program. In all cases, the rights granted to any subcontractor shall be subject and subordinate to the applicable terms and conditions of this Agreement. The applicable Party engaging a
subcontractor shall oversee the performance by its subcontractors of the subcontracted activities in a manner that would be reasonably expected to result in their timely and successful completion of such activities, and such Party shall remain
responsible and primarily and fully liable for the performance of such activities in accordance with this Agreement. Each Party hereby expressly waives any requirement that the other Party exhaust any right, power or remedy, or proceed against such
subcontractor for any obligation or performance hereunder, prior to proceeding directly against the Party engaging such subcontractor. The Party engaging a subcontractor shall ensure compliance with the applicable terms of this Agreement by any such
subcontractor with respect to the applicable activities to be performed by such subcontractor hereunder, including with respect to provisions on confidentiality and intellectual property ownership and compliance with legal requirements. Without
limiting the foregoing, to the extent that a Party utilizes Third Party contractors to perform Research Program activities, such Party shall ensure that such Third Party contractors are obligated to assign rights to any Collaboration Information and
Inventions made by such Third Party contractors so that such rights can be conveyed in accordance with the terms and conditions of this Agreement, including Section 2.7.

 

		2.3	Use of Research Funding 

  

Ambrx shall apply the research funding it receives from Agensys under this Agreement to carry out its Research Program activities in accordance with the
Research Plan and the terms and conditions of this Agreement.
  

		2.4	Joint Project Team 

  

The Parties hereby establish a JPT to facilitate the Research Program as follows:

 

		2.4.1	Composition of the JPT. The Research Program shall be conducted under the direction of the JPT comprised of three (3) representatives of Agensys (and/or its Affiliate) and three (3) representatives of Ambrx. Each Party shall provide the
other with a list of its initial members of the JPT no later than thirty (30) days after the Effective Date, and each Party may change its representatives to the JPT

 
 

-
21
 - 

   

  

from time to time, in its sole discretion, effective upon notice to the other Party of such change. These representatives shall have appropriate technical credentials,
experience and knowledge, and ongoing familiarity with the Research Program. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend JPT meetings, subject to such representative’s
or consultant’s written agreement to comply with the requirements of Section 4.1. The JPT shall be chaired by a representative of Agensys (or its Affiliate), who shall prepare written initial draft minutes of all JPT meetings within thirty
(30) days following such meetings, and shall circulate such minutes to the JPT members. Ambrx shall provide written comments within twenty (20) days of receipt from Agensys. Final minutes shall be ratified at the next JPT meeting. Decisions of the
JPT shall be made unanimously by the representatives, with each Party having a single vote. In the event that the JPT cannot or does not, after good faith efforts, reach agreement on an issue, the issue will be communicated to the President of
Agensys and the CEO of Ambrx, who shall endeavor to facilitate a resolution of such issue. If the Parties have not resolved such issue within fifteen (15) business days following the communication of the issue to them, then such matter shall be
subject to dispute resolution pursuant to Section 10.6). Except as agreed by the Parties in the Research Plan or an MTA, each Party shall bear its own expenses related to the attendance of such meetings by its representatives.

 

		2.4.2	Meetings and Responsibilities.

  

		(a)	During the Research Term, the JPT shall meet in accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter, by means of teleconference, videoconference or other
similar communications equipment; provided, however that the JPT will meet in person at least once each Calendar Year, on or around the anniversary of the Effective Date, for the purpose of finalizing the research activities to be undertaken in the
forthcoming twelve (12) months; provided further, the JPT will meet in person six (6) months prior to the expiration of the Research Term to permit Agensys to prioritize any ongoing research activities to be performed by Ambrx and to facilitate
successful completion of the Research Program.

  

		(b)	The JPT shall be responsible for directing the Research Program and the research activities under each MTA(s) and making decisions and determinations in connection therewith, including (i) to review and approve the annual (or more frequent)
updates and/or amendments to the Research Plan, (ii) to review and approve the research activities under each MTA, (iii) to review and coordinate the Parties’ activities under the Research Program or any MTA, (iv) to confer regarding the
status of the Research Program and the progress under the Research Program, (v) to review relevant data under the Research Program, (vi) to consider and advise on any technical issues that arise under the Research Program, (vii) to consider issues
of priority of activities under the Research Program and any MTA, (viii) to discuss intellectual property strategy and other intellectual property

 
 

-
22
 - 

   

  

matters under the Research Program, and to discuss matters related to Agensys Background Know-How, Agensys Patent Rights, Ambrx Background Know-How and Ambrx Patent
Rights, which a Party proposed to make available or has made available for use in connection with performance of activities under the Research Program, and to discuss other relevant Third Party intellectual property rights, (ix) to review and advise
on any budgetary, economic, and business matters relating to the Research Program (including to allocate resources across the projects and to determine the number of FTEs needed to conduct the Research Program activities), and (x) ratifying prior
JPT minutes.
  

		2.4.3	Project Leaders. Agensys and Ambrx each shall appoint a person (a “Project Leader”) from the JPT to coordinate its part of the Research Program and activities under any MTA. The Project Leaders shall be the primary
contact between the Parties with respect to the Research Program and the MTAs. Each Party shall notify the other within thirty (30) days of the Effective Date of the appointment of its Project Leader and shall notify the other Party as soon as
practicable upon changing this appointment. The Parties further agree that Project Leaders may be substituted from time to time upon written notice to the other Party.

 

		2.4.4	Limitations on Authority of the JPT. The JPT will have solely the roles and responsibilities assigned to it in this Section 2.4. The JPT will have no authority to amend, modify or waive compliance with this Agreement (provided that for
clarity, the JPT shall have the right to amend or modify the Research Plan as set forth in this Section 2.4). For clarity, once Agensys has paid the Research Milestone for a particular Target, the JPT shall no longer have authority with respect to
further pre-clinical or clinical development activities related to such Target.

  

		2.4.5	Disbandment of JPT. Following the Research Term, the JPT shall have no further authority with respect to the Compounds Discovered under the Research Program. The JPT shall be disbanded and the JPT shall have no further authority with
respect to the activities hereunder, and all further research and development of Compounds hereunder shall be in accordance with Section 3.5.

 

		2.5	Exchange of Information 

  

		2.5.1	Ambrx Background Know-How. Within a reasonable time period following execution of this Agreement (but in all cases within thirty (30) days after the Effective Date), and promptly on an ongoing basis during the Research Term, Ambrx shall
disclose to Agensys in English (and deliver in writing or in an electronic format) Ambrx Background Know-How related to the effects of the non-native amino acid format on process, protein folding, stability, pharmacokinetics and safety not
previously disclosed in writing to Agensys.

  

		2.5.2	EuCODETM Modification or ReCODETM Modification during Research Term. Unless otherwise agreed by the Parties in writing, Ambrx shall be solely

 
 

-
23
 - 

   

  

responsible for all EuCODETM Modification activities and ReCODETM Modification activities involving the use or application of EuCODETM Technology or
ReCODETM Technology under the Research Plan during the Research Term.
  

		2.6	Records and Reports 

  

		2.6.1	Records. Ambrx shall maintain complete and accurate records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in
the performance of the Research Program by Ambrx, as well as the number of FTEs utilized by Ambrx for the performance of the Research Program. Agensys shall maintain complete and accurate records, in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by Agensys. Upon request by a Party during the Term, the other Party shall provide
copies of the records described in Section 2.6.1 above (provided, however, that Ambrx shall only have the right to receive copies of such records with respect to Collaboration Information and Inventions over which Ambrx has prosecution control as
set forth in Article 7).

  

		2.6.2	Copies and Inspection of Records. During the Term, Agensys shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of Ambrx referred to in Section 2.6.1 in order to verify the
number of FTEs utilized by Ambrx in the performance of the Research Program. Agensys shall have the right to arrange for its employees and/or consultants involved in the activities contemplated hereunder to visit the offices and laboratories of
Ambrx and any of its Third Party contractors during normal business hours and upon reasonable notice, and to discuss the Research Program work and its results in detail with the technical personnel and consultants of Ambrx.

 

		2.6.3	Quarterly Reports. Within thirty (30) days following the end of each Calendar Quarter during the Research Term, each Party shall provide to other Party a written progress report in English which shall describe the work performed during
such Calendar Quarter on the Research Program, evaluate the work performed in relation to the goals of the Research Program for such Calendar Quarter and provide such other information as may be required for the Research Program or reasonably
requested by such other Party relating to the progress of the goals or performance of the Research Program.

  

		2.6.4	Data Integrity. Each Party acknowledges the importance of ensuring that the Research Program is undertaken in accordance with the following good data management practices: (i) data is being generated using sound scientific techniques and
processes; (ii) data is being accurately and reasonably contemporaneously recorded in accordance with good scientific practices by Persons conducting research hereunder; (iii) data is being analyzed appropriately

 
 

-
24
 - 

   

  

without bias in accordance with good scientific practices; and (iv) all data and results are being stored securely and can be easily retrieved. Each
Party agrees that it shall carry out the Research Program so as to collect and record any data generated therefrom in a manner consistent with the foregoing requirements.

 

		2.7	Research Collaboration Information and Inventions 

  

		2.7.1	Ownership. Inventorship of Collaboration Information and Inventions and Patent Rights directed thereto shall be determined in accordance with United States patent laws (regardless of where the applicable activities occurred).
Notwithstanding the foregoing, all right, title and interest in and to any and all Collaboration Information and Inventions and Patent Rights directed thereto shall be determined in accordance with the following terms and conditions, such that the
entire right, title and interest in:

  

		(a)	Ambrx Collaboration Information and Inventions and Patent Rights directed thereto shall be owned solely by Ambrx; provided, however, that notwithstanding the foregoing; (i) any Ambrx Collaboration Information and Invention and Patent Rights
directed thereto that constitutes an improvement to Agensys Background Know-How shall be owned solely by Agensys (and shall be considered an Improvement to Agensys Background Technology), (ii) any Ambrx Collaboration Information and Invention and
Patent Rights directed thereto that constitutes any Payload Technology (other than an Improvement to Ambrx Payload Technology Solely Developed by Ambrx) shall be owned jointly by Ambrx and Agensys (and shall be considered Joint Collaboration
Information and Inventions) and (iii) any Patent Rights that claim or cover Collaboration Information and Inventions related to (A) Antibodies Controlled by Ambrx, including Antibodies controlled by Ambrx with EuCODE Modifications or ReCODE
Modifications, or (B)  Compounds or Products incorporating Ambrx Antibodies and Ambrx Payload Technology shall be solely owned by Ambrx;

  

		(b)	Agensys Collaboration Information and Inventions and Patent Rights directed thereto shall be owned solely by Agensys; provided, however, that notwithstanding the foregoing, (i) any Agensys Collaboration Information and Invention and Patent
Rights directed thereto that constitutes an improvement to Ambrx Background Know-How shall be owned solely by Ambrx (and shall be considered an Improvement to Ambrx Background Technology) and (ii) any Patent Rights that claim or cover Collaboration
Information and Inventions related to (A) Agensys Antibodies, including Agensys Antibodies with EuCODE Modifications or ReCODE Modifications, or (B) Compounds or Products incorporating Agensys Payload Technology, shall be solely owned by Agensys,
and (c) any Patent Rights that claim or cover Collaboration Information and

  
 

-
25
 - 

   

  

Inventions that relate to an Improvement to Agensys Payload Technology, shall be solely owned by Agensys; and

 

		(c)	Joint Collaboration Information and Inventions and Patent Rights directed thereto shall be owned jointly by Ambrx and Agensys; provided, however, that notwithstanding the foregoing, any Joint Collaboration Information and Invention and Patent
Rights directed thereto that constitutes (i) an Improvement to Agensys Background Technology shall be owned solely by Agensys (and shall be considered Agensys Collaboration Information and Inventions) or (ii) an Improvement to Ambrx Background
Technology shall be owned solely by Ambrx (and shall be considered Ambrx Collaboration Information and Inventions) and (iii) any Patent Rights that claim or cover Collaboration Information and Inventions related to Compounds or Products comprising
Antibody Drug Conjugates incorporating Agensys Antibodies with Ambrx Payload Technology shall be jointly owned.

  

		2.7.2	Disclosure. Each Party shall promptly disclose to the other Party in writing the development, making, conception or reduction to practice of Collaboration Information and Inventions (including any Compounds within such Collaboration
Information and Inventions). including any Joint Collaboration Information and Inventions.

  

		2.7.3	Assignment of Interests to Effectuate Ownership. With respect to any Collaboration Information and Invention, each of Ambrx and Agensys shall, and hereby do, on behalf of themselves and each of their respective Affiliates, employees and
contractors hereunder, assign to one another ownership of rights, title and interest in and to such Collaboration Information and Inventions and Patent Rights directed thereto to effect the ownership of such Collaboration Information and Inventions
and Patent Rights directed thereto as set forth in Section 2.7.1, subject to any licenses expressly granted under this Agreement. In furtherance of the foregoing, each Party shall, upon request by the other, promptly undertake and perform (and/or
cause its Affiliates and its and their respect employees and/or agents to promptly undertake and perform) such further actions as are reasonably necessary for Ambrx and Agensys, as between the Parties, to each perfect its title in any such
Collaboration Information and Inventions and Patent Rights directed thereto as set forth in Section 2.7.1, as applicable, including by causing the execution of any assignments or other legal documentation, and/or providing the other Party or its
patent counsel with reasonable access to any employees or agents who may be inventors of such Collaboration Information and Inventions and Patent Rights directed thereto.

 

		2.7.4	Joint Collaboration Information and Inventions. Except as otherwise set forth in Section 2.7.1(c), Ambrx and Agensys shall co-own any and all Joint Collaboration Information and Inventions and Patent Rights
directed thereto with the unfettered ability to use and license such Joint Collaboration Information and

  

-
26
 - 

   

  

Inventions and Patent Rights directed thereto for any and all purposes without the need to account to the other (subject, in all cases, to any other applicable terms of
this Agreement, including 2.10, 3.1.1 and ARTICLE 5, in each case, to the extent applicable); provided, however, that for clarity, the foregoing joint ownership rights with respect to Joint Collaboration Information and Inventions and Patent Rights
directed thereto shall not be construed as granting, conveying or creating any license or other rights to the other Party’s intellectual property, unless otherwise expressly set forth in this Agreement; provided further, that Agensys shall not
be permitted to use and/or sublicense Joint Collaboration Information and Inventions and Patent Rights directed thereto in conjunction with any Target which has been an Active Selected Target at any point during the Research Term. For the sake of
clarity, the intention of the Parties is to preclude Agensys from utilizing Joint Collaboration Information and Inventions and Patent Rights directed thereto on any Antibody which binds a Target that was previously an Active Selected Target during
the Research Term.
  

		2.8	Research Term 

  

		2.8.1	Term. Except as otherwise provided herein, the term of the Research Program shall commence on the Effective Date and continue throughout the Research Term, subject to early termination as set forth in Section 2.8.2 or extension as set
forth in Section 2.8.4.

  

		2.8.2	Early Discontinuance of Research Program. Notwithstanding the provisions of Section 2.8.1, Agensys shall have the right, in its discretion, to discontinue the Research Program at any time prior to the scheduled end of the Research Term at
any time after the first anniversary of the Effective Date by providing no less than ninety (90) days prior written notice of such discontinuance to Ambrx. Upon delivery of such Research Program discontinuance notice by Agensys to Ambrx (in
accordance with Section 10.4), the Research Term shall automatically end on the date set forth in the discontinuance notice (but in any event no sooner than ninety (90) days following the delivery of such discontinuance notice). Agensys is
responsible for making all payments required under Section 5.2 during such ninety (90)-day period, unless the Parties agree otherwise.

 

		2.8.3	Discontinuance of Research Program Activities. Upon expiration of the Research Term or early discontinuance of the Research Program, all further Research Program activities shall terminate, but the other rights and obligations under this
Agreement shall not otherwise be affected and shall remain in full force and effect (including the rights of Agensys to further research and develop Compounds and Products in accordance with this Agreement). Immediately upon the expiration of the
Research Term or early discontinuance of the Research Program, (a) each Party shall disclose to the other Party those Collaboration Information and Inventions as set forth in Section 2.7.2, and (b) Ambrx shall reimburse Agensys for any overpayments
made by Agensys under the Research Program, and/or Agensys shall make any payments required under the Research Program (but

 
 

-
27
 - 

   

  

solely to the extent such amounts were incurred and/or constitute an irrevocable obligation to pay prior to the expiration or termination of the Research Program and are
required to be paid by Agensys in accordance with this Agreement), as the case may be. In addition, each Party shall return or cause to be returned to the other Party all Materials provided by the other Party under the Research Program (provided,
however, that each Party may retain any Materials as are reasonably necessary for such Party’s continued practice under any licenses which survive the termination of the Research Term).

 

		2.8.4	Extension of Research Term. The Parties may mutually agree in writing to further extend the Research Program for one (1) or more additional years on terms and conditions to be mutually agreed.

 

		2.9	Materials 

  

Each Party shall provide the other with sufficient quantities of its research materials to conduct the activities under the Research Program as set forth in the Research
Plan or as otherwise determined by the JPT (“Materials”, provided that for clarity, Compounds shall not be considered “Materials”), which Materials shall be used solely for the purpose of enabling the Parties to
perform their respective activities under the Research Program in accordance with the terms of this Agreement. The Materials are not to be used in humans, nor shall any of the Materials, or any derivatives, analogs, modifications or components
thereof, be transferred, delivered or disclosed to any Third Party (other than to permitted subcontractors hereunder in accordance with Section 2.2.3) without the prior written approval of the delivering Party. Any unused Materials and any
derivatives, analogs, modifications or components thereof shall be, at the delivering Party’s option, either returned or destroyed in accordance with instructions given by the delivering Party. All such destruction shall be in accordance with
Applicable Laws. Further, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR
ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.
  

		2.10	Exclusive Efforts. 

  

		2.10.1	(a) During the Research Term, on a Target-by-Target basis, Ambrx shall work exclusively with Agensys in the use of ReCode Technology or EuCode Technology to discover, research, identify and/or optimize Antibody(ies) conjugated to Payload
Technology for each of the Active Selected Targets for therapeutic use in humans.

  

		(b) During the Research Term, on a Target-by-Target basis, Agensys shall work exclusively with Ambrx to discover, research, identify and/or optimize Antibody(ies) conjugated to Payload Technology for each of the Active
Selected Targets for therapeutic use in humans; provided that Agensys may pursue such

  
 

-
28
 - 

   

  

activities with respect to any program which is in existence as of the date on which a Target is nominated as a Research Stage Target.

 

		2.10.2	For the avoidance of doubt, Section 2.10.1 shall not prohibit or otherwise limit Agensys from discovering, researching, developing, identifying, optimizing, commercializing or otherwise exploiting any compounds or products other than Antibody
Drug Conjugates which utilize Ambrx Background Know-How for a specific Target. In addition, Section 2.10.1 shall not apply with respect to Antibodies (under an MTA). Finally, Section 2.10.1 shall not prohibit or otherwise limit Agensys from
evaluating alternative Antibody Drug Conjugates or related Antibody Drug Conjugate know-how or other intellectual property rights for research purposes only.

 

		2.10.3	Section 2.10.1 shall not prohibit a Third Party which becomes an Affiliate of a Party after the Effective Date due to a Change of Control involving such Party and such Third Party from discovering, researching, developing, identifying or
optimizing any Antibody conjugated to Payload Technology for an Active Selected Target or Commercial Target that was owned or otherwise controlled by such Third Party as of the time of such Change of Control; provided that (y) such Affiliate does
not engage in Research Program activities under this Agreement and (z) no Ambrx Know-How or Ambrx Patent Rights licensed to Agensys hereunder are utilized in connection with such Antibody.

 
 Notwithstanding the foregoing, in the event that
this Agreement expires or is terminated with respect to all Products for a particular Target in accordance with ARTICLE 8, then Section 2.10.1 shall not apply with respect to such Target.

 

		2.11	Compliance with Law and Ethical Business Practices 

  

		2.11.1	Neither Party shall make any payment, either directly or indirectly, of money or other assets, including but not limited to the compensation such Party derives from this Agreement (hereinafter collectively referred as a
“Payment”), to government or political party officials, officials of international public organizations, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing
(hereinafter collectively referred as “Officials”) where such Payment would constitute violation of any law. In addition regardless of legality, neither Party shall make any Payment either directly or indirectly to Officials if
such Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement or any other aspect of such Party’s or the other Party’s business.

 

		2.11.2	Each Party acknowledges that no employee of the other Party or its Affiliates shall have authority to give any direction, either written or oral, relating to the making of any commitment by such Party or its agents to any Third Party in
violation of terms of this Section 2.11.

  
 

-
29
 - 

   

  

		2.11.3	Each Party certifies to the other Party that as of the date of this Agreement its officers and directors have not been in Violation. After the execution of this Agreement, each Party shall notify the other Party in writing immediately if any
such Violation occurs or comes to its attention.

  

		2.11.4	Each Party shall indemnify and hold the other Party and any of its Affiliates harmless from and against any and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that may
arise by reason of the acts or omissions of it or its agents or other Third Parties acting on its behalf which would constitute a violation of this Section 2.11.

 

		2.12	Regulatory Matters. In the event that Agensys determines that any regulatory filings for any Compounds or Products are required for any activities hereunder (including any activities under the Research Program), including INDs,
BLAs / NDAs, Drug Master Files (DMFs), and other Marketing Authorizations or foreign equivalents (as applicable), then as between the Parties, Agensys shall have the sole right, in its discretion, to obtain such regulatory filings (in a Related
Party’s name) and as between the Parties, the Related Party shall be the owner of all such regulatory filings; provided that Ambrx may be responsible at the direction of Agensys, in its sole discretion, for preparing certain subsections of the
IND and related technical reports and other documentation in support of the IND for certain Compounds and/or Products. As between the Parties, Agensys or the Related Party shall have the sole right to communicate and otherwise interact with
Regulatory Authorities with respect to the Compounds and/or Products (including during the Research Term). For clarity, Ambrx shall have no right to, and shall not, make any regulatory filings related to any Compounds or Products or otherwise
interact with any Regulatory Authorities with respect to the Compounds or Products. Notwithstanding the foregoing, Agensys shall provide Ambrx with copies those sections of all filings with Regulatory Authorities that reference Ambrx Know-How or
Ambrx Patent Rights, and copies of all material communications to or from Regulatory Authorities that reference Ambrx Know-How or Ambrx Patent Rights, in each case as soon as practicable, but in any event, within twenty (20) Business Days prior to
filing or within twenty (20) Business Days of receipt by Agensys. Agensys shall consult with Ambrx with respect to Ambrx Know-How or Ambrx-Patent Rights incorporated into any filings with Regulatory Authorities and shall incorporate comments from
Ambrx in its reasonable discretion.

  

		2.13	Primary Activity of Compounds; Identification of Compounds and Back-up Compounds.

 

		(a)	The Parties agree that, with respect to a Compound made under the Research Program, such Compound shall be presumed to have Primary Activity against an Active Selected Target in the Field under the Research Program
unless, during the Research Term, the JPT unanimously agrees in writing that such Compound does not have Primary Activity against any such Target in the Field.

 

		(b)	After achieving and following payment of the Research Milestone with respect to

  

-
30
 - 

   

  

a Compound, during the Research Term, Agensys may, by written notice to Ambrx, nominate Back-up Compounds directed to the same Target to be pursued in the event that the
lead Compound does not merit continued development. Any research activities conducted by Agensys pursuant to the identification of Back-up Compounds shall not be deemed activities directed to an Active Selected Target. If Agensys does not nominate
one or more Back-up Compounds during the Research Term, no such Back-up Compounds may be nominated or pursued pursuant to the licenses granted hereunder thereafter.

 

		(c)	At the end of the Research Term, the Parties shall set forth in writing a listing of all Compounds and Back-up Compounds and the Target against which they have Primary Activity.

 

		2.14	UC Berkeley Technology. During the Research Term, Agensys shall have the option, in its sole discretion, to take a sublicense of the UC Berkeley Technology by providing written notice to Ambrx of its desire to use the UC Berkeley
Technology against one or more of the Active Selected Targets under the Research Program (such sublicense, the “UC Berkeley Sublicense”). In the event that Agensys delivers such notice (on behalf of itself or one or more of its
Affiliates), the Parties (or such Affiliate(s)) shall promptly work together to execute an agreement for the UC Berkeley Sublicense and shall use commercially reasonable efforts to enter into such agreement for the UC Berkeley Sublicense; provided
however, that in all cases, such agreement: (i) shall indicate whether the applicable Compound or Product is the “first Licensed Product” as set forth in the UC Berkeley License, (ii) shall indicate that Ambrx shall be solely responsible
for all obligations under the UC Berkeley License, provided that Agensys shall be responsible for reimbursing Ambrx for [***] of the royalty obligations and milestone obligations, if applicable, due on said “Licensed Product” as defined
in the UC Berkeley License, (iii) shall indicate that any royalty due to Ambrx under the UC Berkeley Sublicense shall include the applicable royalty offset as set forth in Section 5.4.7(b) of this Agreement, and (iv) shall indicate that Agensys
shall have no other financial obligations to Ambrx with respect to the UC Berkeley License. Notwithstanding the provisions of Section 3.1.1, unless and until Agensys delivers such written notice, Ambrx shall not use any UC Berkeley Technology in the
conduct of the Research Program, and following the delivery of such notice, Ambrx shall only use the UC Berkeley Technology in the conduct of the Research Program pursuant to the UC Berkeley Sublicense.

 

		2.15	Open Terminated Compounds/Products; Open Terminated Targets 

  

		(a)	Ambrx shall have the right to conduct research, development and/or commercialization only on Open Terminated Compounds (and related Terminated Products) or Open Terminated Targets. No such rights shall exist with respect to Agensys Terminated
Compounds or Agensys Terminated Targets.

  

***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

-
31
 - 

   

  

		(b)	Agensys shall return or cause to be returned to Ambrx all Confidential Information and all substances or compositions of Ambrx delivered or provided by Ambrx, as well as any other material (including Materials) provided by Ambrx in any medium
under the Research Program and related to the Open Terminated Target, Open Terminated Compound(s) and/or Open Terminated Product(s) (provided, however, that Agensys may keep one copy of such Confidential Information of Ambrx in its confidential
files for record purposes).

  

ARTICLE 3

LICENSE; DEVELOPMENT AND COMMERCIALIZATION

 

		3.1	License Grant 

  

		3.1.1	By Ambrx.

  

Research Program Licenses
  

		(a)	Subject to the rights retained by Ambrx in Section 3.1.1(c) and the terms and conditions of this Agreement, Ambrx hereby grants to Agensys an exclusive license (even as to Ambrx) to carry out the activities in the Research Program during the
Research Term in the Territory in the Field under Ambrx Patent Rights, with the right to sublicense as set forth in Section 3.4.1.

 

		(b)	Subject to the rights retained by Ambrx in Section 3.1.1(c) and the terms and conditions of this Agreement, Ambrx hereby grants to Agensys an exclusive license (even as to Ambrx) to carry out the activities in the Research Program during the
Research Term in the Territory in the Field under Ambrx Know-How, with the right to sublicense as set forth in Section 3.4.1.

 

		(c)	Ambrx shall retain non-exclusive rights under the foregoing licenses in clauses (a) and (b) solely as are necessary to perform its activities under the Research Program to research, make and use Compounds as set forth in the Research Plan in
accordance with this Agreement.

  

Development, Manufacturing and Commercialization Licenses
  

		(d)	Subject to the rights retained by Ambrx in Section 3.1.1(f) and the terms and conditions of this Agreement, Ambrx hereby grants to Agensys an exclusive license (even as to Ambrx) in the Territory under the Ambrx Patent Rights, with the right to
sublicense as set forth in Section 3.4.1, to research, develop, make, have made, use, offer to sell, sell, export and/or import Compounds and Products for any and all diagnostic, preventative and therapeutic uses in humans. For clarity, if the
Research Milestone for the applicable Target is not paid to Ambrx prior to the end of the Research Term, the license granted under this Section 3.1.1(d) shall terminate as to all Compounds and Products with Primary Activity against such
Target.

  
 

-
32
 - 

   

  

		(e)	Subject to the rights retained by Ambrx in Section 3.1.1(f) and the terms and conditions of this Agreement, Ambrx hereby grants to Agensys an exclusive license (even as to Ambrx) in the Territory under the Ambrx Know-How, with the right to
sublicense as set forth in Section 3.4.1, to research, develop, make, have made, use, offer to sell, sell, export and/or import Compounds and Products directed to Active Selected Targets and Commercial Targets for any and all diagnostic,
preventative and therapeutic uses in humans. For clarity, if the Research Milestone for the applicable Target is not paid to Ambrx prior to the end of the Research Term, the license granted under this Section 3.1.1(e) shall terminate as to all
Compounds and Products with Primary Activity against such Target.

  

		(f)	Ambrx shall retain non-exclusive rights under the foregoing licenses in clauses (d) and (e) solely as are necessary to perform its activities under the Research Program to research, make and use Compounds as set forth in the Research Plan in
accordance with this Agreement.

  

		3.1.2	By Agensys.

  
 Research
Program Licenses
  

		(a)	If Agensys requests Ambrx to perform activities under the Research Program that require a license under any Agensys Patent Rights or Agensys Know-How, Agensys hereby grants a non-exclusive, non-transferable, non-sublicensable, royalty free,
license to Ambrx under such Agensys Patent Rights or Agensys Know-How, as applicable, solely as are necessary to perform such activities under the Research Program.

 

		3.2	No Grant of Inconsistent Rights by Ambrx.

  

During the Term, Ambrx shall not assign, transfer, convey or otherwise grant to any Person, or otherwise encumber (including through lien, charge, security interest,
mortgage, encumbrance or otherwise), any rights to any Ambrx Know-How or Ambrx Patent Rights (or any rights to any intellectual property that would otherwise be included in the Ambrx Know-How or Ambrx Patent Rights) in any manner that is
inconsistent with or would interfere with the exercise of the rights or licenses granted to Agensys hereunder.
  

		3.3	No Implied Licenses 

  

Except as specifically and expressly set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or
otherwise, in any Confidential Information disclosed to it under this Agreement, know how or under any patents or patent applications owned or Controlled by the other Party or its Affiliates.

 
 

-
33
 - 

   

  

		3.4	Sublicensing.

  

		3.4.1	By Agensys. Except as expressly provided in Section 10.18, prior to the end of the Research Term, Agensys may not sublicense any of the licenses granted under Section 3.1.1(a) or 3.1.1(b) for the conduct of activities under the Research
Program without the prior written consent of Ambrx (such consent not to be unreasonably withheld); provided that Agensys shall have the right to sublicense (through multiple tiers) such licenses without the consent of Ambrx, (a) to a Third Party
contract manufacturer to make or have made Compound and Product in the Field in the Territory on behalf of Agensys, or (b) to a Third Party for the limited purpose of conducting one or more aspects of the research or development contemplated under
the Research Program under this Agreement, or (c) to any Affiliate. With respect to the licenses granted under Section 3.1.1(d) and 3.1.1(e), Agensys shall have the right to sublicense (through multiple tiers) any or all of the rights granted to
Agensys thereunder following the end of the Research Term (and, for clarity, then without the prior written consent of Ambrx). Notwithstanding the foregoing, nothing in this Section shall limit or otherwise restrict any rights of Agensys as set
forth in Section 10.18.

  
 With
respect to any sublicense to a Third Party, the following shall apply: (i) Agensys shall ensure that each of its Third Party sublicensees is bound by a written agreement that is consistent with, and subject to the applicable terms and conditions of,
this Agreement, (ii) Agensys shall be responsible for ensuring that the performance by any of its Third Party sublicensees that are exercising rights under a sublicense of the licenses granted by Ambrx to Agensys under this Agreement is in
accordance with the applicable terms of this Agreement with respect to the applicable activities to be performed by such sublicensee, and the grant of any such sublicense shall not relieve Agensys of its obligations under this Agreement, except to
the extent they are performed by any such sublicensee(s) in accordance with this Agreement and (iii) promptly following the execution of each sublicense with a Third Party as provided in this Section 3.4.1, Agensys shall provide Ambrx with a copy of
such sublicense agreement; provided that the financial terms of any such sublicense agreement may be redacted.
  

		3.4.2	By Ambrx. Ambrx shall have the right to sublicense any or all of the licenses granted under Section 3.1.2 provided that, in connection with any sublicense, (i) Ambrx shall ensure that each of its sublicensees is bound by a written
agreement that is consistent with, and subject to the applicable terms and conditions of, this Agreement, (ii) Ambrx shall be responsible for ensuring that the performance by any of its sublicensees that are exercising rights under a sublicense of
the licenses granted by Agensys to Ambrx under this Agreement is in accordance with the applicable terms of this Agreement with respect to the applicable activities to be performed by such sublicensee, and the grant of any such sublicense shall not
relieve Ambrx of its obligations under this Agreement, except to the extent they are performed by any such sublicensee(s) in accordance with this Agreement and (iii) promptly following the execution of each sublicense as provided in
this

  
 

-
34
 - 

   

  

Section 3.4.2, Ambrx shall provide Agensys with a copy of such sublicense agreement; provided that the financial terms of any such sublicense agreement may be
redacted.
  

		3.5	Development, Manufacture and Commercialization 

  

		3.5.1	Development by Agensys following Achievement of the Research Milestone. Notwithstanding Section 3.5.2, no Related Party may initiate an IND-Enabling Pharmacology and Toxicology Study unless the Research Milestone
for such Target has previously been paid by Agensys.

  

		3.5.2	Compounds and Products By Agensys. Subject to the terms and conditions of this Agreement, Agensys (and its Affiliates), either itself or together with Third Parties, shall have the sole right, at its expense, to research, develop
(including pre-clinical and clinical development), manufacture, register and commercialize Compounds and Products containing such Compounds against any and all Commercial Targets, and Ambrx (and its Affiliates) shall have no right to do so. Agensys
shall use Commercially Reasonable Efforts to develop and commercialize at least one Product in the Field in each of the Major Markets. All other development and commercialization efforts with respect to the Compounds and Products shall be at the
discretion of Agensys.

  
 Upon
expiration of the Research Term, and once per year thereafter until the First Commercial Sale of a Product, Agensys shall provide Ambrx with a written report that summarizes the development progress and plans for such Product and the related
Compound.
  

		3.5.3	Open Terminated Compounds and Open Terminated Products. Each of Ambrx and Agensys (together with their respective Affiliates), either itself or together with Third Parties, shall have the right, at its expense, to develop (including
pre-clinical and clinical development), manufacture, register and commercialize any Open Terminated Compounds (if any) and Open Terminated Products (if any) and to pursue such activities against any Open Terminated Target. For clarity, (a) all
rights or licenses granted to Agensys by Ambrx in any Ambrx Know-How, Ambrx Patent Rights or any other intellectual property of Ambrx shall terminate as to Open Terminated Compounds, Open Terminated Products and/or Open Terminated Targets once such
Compounds, Products and/or Targets become Open Terminated Compounds, Open Terminated Products and/or Open Terminated Targets and (b) Agensys is not granting any rights or licenses to Ambrx in any Agensys Know-How, Agensys Patent Rights or any other
intellectual property of Agensys or any of its Affiliates for use with such Open Terminated Compounds, Open Terminated Products and/or Open Terminated Targets.

 

		3.6	Excused Performance 

  

In addition to the provisions of ARTICLE 6 hereof, the obligations of Agensys with respect to any Product under Section 3.5.1 are expressly conditioned
upon the continuing
  
 

-
35
 - 

   

  

absence of any adverse condition or event relating to the safety or efficacy of the Product, and the obligation of Agensys to develop or commercialize any such Product may
be delayed or suspended so long as in Agensys’ reasonable, good-faith opinion any such condition or event exists.
  

ARTICLE 4

CONFIDENTIALITY AND PUBLICATION

 

		4.1	Nondisclosure Obligation 

  

All Confidential Information disclosed by one Party to the other Party hereunder shall be maintained in confidence by the receiving Party and shall not
be disclosed to any Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent that such Confidential Information:

 

		(a)	is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s competent business records;

 

		(b)	is in the public domain by use and/or publication before its receipt from the disclosing Party, or thereafter enters the public domain through no fault of the receiving Party;

 

		(c)	is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party;

 

		(d)	is developed by the receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party’s competent business records;

 

		(e)	is disclosed to governmental or other regulatory agencies in order to obtain patents or to gain or maintain approval to conduct clinical trials or to market Product, but such disclosure may be only to the extent reasonably necessary to obtain
patents or authorizations;

  

		(f)	is deemed necessary by Agensys to be disclosed to Related Parties, agents, consultants, and/or other Third Parties for any and all purposes Agensys and its Affiliates deem necessary or advisable in the ordinary course of business in accordance
with this Agreement (including the exercise of licenses granted to Agensys hereunder) on the condition that such Third Parties agree to be bound by confidentiality and non-use obligations that substantially are no less stringent than those
confidentiality and nonuse provisions contained in this Agreement; provided, however, that the term of confidentiality for such Third Parties shall be no less than five (5) years; or

 
 

-
36
 - 

   

  

		(g)	is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys, independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial advisors
to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and financial advisors agree to be bound by the confidentiality and non-use obligations no less protective than those set forth in this
Agreement; provided, however, that the term of confidentiality for such attorneys, independent accountants and financial advisors shall be no less than five (5) years.

 

		(h)	in connection with a financing, merger, or acquisition, each Party shall have the further right to disclose the material terms of this Agreement under a confidentiality obligation no less protective than those set forth in this
Agreement.

  

		(i)	the Parties shall agree in advance with each other on the terms of this Agreement to be redacted in any Securities and Exchange Commission filings or any foreign equivalent regulatory filings.

 
 Any combination of features or disclosures shall not
be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are
published or available to the general public or in the rightful possession of the receiving Party.
  

If a Party is required by judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of this Section 4.1,
such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or
administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 4.1, and the Party disclosing Confidential Information pursuant to Applicable Law or court order shall take all steps reasonably
necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information.
  

		4.2	Publication 

  

Agensys and Ambrx each acknowledge the other Party’s interest in publishing the results of its research in order to obtain recognition within the scientific
community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures
permitted pursuant to Section 4.1, either Party, its employees or consultants wishing to make a publication with respect to the research under the Research Program hereunder shall deliver to the other Party a copy of the proposed written publication
or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall have the right (a) to propose modifications to the publication or presentation for patent reasons,

 
 

-
37
 - 

   

  
 trade secret
reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a
period of one hundred and twenty (120) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with ARTICLE 7 below. Upon expiration of such one hundred and twenty (120) days, the
publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure of trade secret
or proprietary business information prior to submission of the publication or presentation.
  

		4.3	Publicity/Use of Names 

  

No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and neither Party shall use the name, trademark, trade name or logo of the
other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be
required by Applicable Law or as permitted pursuant to Section 4.1; provided that in the event disclosure is required by Applicable Law, the disclosing Party shall use good-faith efforts to give the non-disclosing Party an opportunity, with
reasonable advance notice, to review and comment on any proposed disclosure. Notwithstanding the foregoing, Ambrx shall have the right to issue a press release regarding the execution of this Agreement, which press release shall be in a form agreed
to by the Parties in writing in advance of the issuance of such press release. Disclosure of Confidential Information for which consent has previously been obtained will not require advance approval.

 

		4.4	Clinical Trial Register 

  

Notwithstanding the foregoing, Agensys shall have the right to publish the results or summaries of results of any clinical trials conducted hereunder
with respect to a Product on Agensys’ clinical trial register, if applicable.
  

		4.5	Remedies 

  

Each Party shall be entitled to seek, in addition to any other right or remedy it may have, at law or in equity, a temporary injunction, without the posting of any bond or
other security, enjoining or restraining the other Party from any violation or threatened violation of this ARTICLE 4.
  

ARTICLE 5

PAYMENTS; ROYALTIES AND REPORTS

 

		5.1	Upfront Payment and Initial Year of Research Program Funding 

  

In consideration for Ambrx’s performance of its obligations under the Research Program, the licenses granted herein under the Ambrx Patent Rights
and Ambrx Know-How and
  
 

-
38
 - 

   

  

the provision by Ambrx of availability of at least four (4) FTEs for the first twelve (12) months of the Research Term, upon the terms and conditions contained herein,
Agensys shall pay to Ambrx, within fifteen (15) days following the Effective Date, an upfront payment in the amount of Fifteen Million Dollars ($15,000,000), which shall be non-refundable and non-creditable.

 

		5.2	FTE Funding under the Research Program 

  

		5.2.1	General.

  

		(a)	In consideration for Ambrx’s provision of FTEs for the performance of its obligations under the Research Program, upon the terms and conditions contained herein, Agensys (i) shall pay Ambrx the applicable FTE Rate per year for any FTEs in
excess of four (4) FTEs provided by Ambrx in the first year of the Research Term and the applicable FTE Rate per year during the second, third and fourth years of the Research Term for each FTE provided by Ambrx, in each case in accordance with this
Section 5.2 (it being acknowledged that Agensys has pre-paid the applicable FTE Rate for four (4) FTEs for the initial year pursuant to Section 5.1) and (ii) shall reimburse Ambrx for its direct, out-of-pocket research costs incurred by Ambrx for a
Third Party contractor during the entire Research Term solely to perform research activities under the Research Program pursuant to the Research Plan (“Third Party Research Costs”) in accordance with this Section
5.2.

  

		(b)	The number of FTEs to be provided by Ambrx for the performance of the Research Program per year shall be set forth in the applicable Research Plan; provided, however, that the JPT shall have the right to revise the number of FTEs in accordance
with Section 2.1.5. Such FTE funding shall be payable in advance in quarterly installments due on the first day of the applicable Calendar Quarter; provided, however, that the payments for the first Calendar Quarter and the last Calendar Quarter of
the Research Term shall be made on a pro rata basis.

  

		(c)	The amount of any Third Party Research Costs which will be reimbursed by Agensys shall be expressly set forth in the Research Plan (and the Research Plan shall also identify whether a Third Party contractor will perform the applicable activities
under the Research Plan and the activities to be performed by any such Third Party contractor). At the end of each Calendar Quarter during the Research Term, Ambrx shall invoice Agensys for the Third Party Research Costs incurred during such
Calendar Quarter to the extent that such Third Party Research Costs were expressly set forth in the Research Plan. Agensys shall pay such invoiced amounts within thirty (30) days of receipt of the invoice. Notwithstanding the foregoing, Agensys
shall only be obligated to reimburse Ambrx for those Third Party Research Costs which are expressly agreed to by the Parties and set forth in the Research Plan (including with respect to the amount of such Third Party Research Costs and with respect
to the activities to be performed by the applicable Third Party contractor) and Ambrx shall be solely responsible for (and

 
 

-
39
 - 

   

  

shall not be entitled to reimbursement for) any other costs, including any costs in excess of such agreed upon amount or any costs not directly related to the performance
of activities under the Research Plan or any costs not approved by the JPT.
  

		5.2.2	Funding under MTAs. In consideration for Ambrx’s provision of FTEs for the performance of its obligations under an MTA, upon the terms and conditions contained herein, Agensys (i) shall pay Ambrx the applicable FTE Rate per year for
each FTE provided by Ambrx under such MTA which exceeds the FTEs already being allocated under the Research Program and (ii) shall reimburse Ambrx for its direct, out-of-pocket research costs incurred by Ambrx for a Third Party contractor as agreed
by the JPT in connection with such MTA (“Third Party MTA Research Costs”). The number of FTEs to be provided by Ambrx under an MTA shall be set forth in the applicable MTA but shall be subject to Section 2.1.6. Such FTE funding
shall be payable in advance in quarterly installments due on the first day of the applicable Calendar Quarter; provided, however, that the payments for the first Calendar Quarter and the last Calendar Quarter of the applicable MTA shall be made on a
pro rata basis.

  
 The amount of any
Third Party MTA Research Costs which will be reimbursed by Agensys shall be agreed by the JPT. At the end of each Calendar Quarter during the Research Term, Ambrx shall invoice Agensys for the Third Party MTA Research Costs incurred during such
Calendar Quarter. Agensys shall pay such invoiced amounts within thirty (30) days of receipt of the invoice. For clarity, Ambrx shall be solely responsible for (and shall not be entitled to reimbursement for) any Third Party costs in connection with
the MTA not agreed by the JPT.
  

		5.2.3	Reporting and Reconciliation. Ambrx shall, within forty-five (45) days following the end of each Calendar Quarter during the Research Term, deliver to Agensys a written report detailing the number of FTEs actually utilized in such
Calendar Quarter for the performance of Research Program activities and MTA activities, including a description of the activities performed (and Agensys shall have the right to audit Ambrx’s records in connection therewith in accordance with
Section 5.6, mutatis mutandis). In the event that the number of FTEs actually utilized in such Calendar Quarter is less than the number of FTEs for which Agensys made payment in advance pursuant to Section 5.1, 5.2.1, or 5.2.2, then at
Agensys’ option, Ambrx shall either refund or credit Agensys for the difference between the payment made by Agensys and the actual payment due for such FTEs (provided that if Agensys opts for a refund, such refund shall be made by Ambrx within
thirty (30) days following notice by Agensys thereof and if Agensys opts for a credit, Agensys shall be entitled to a credit against any future FTE amounts payable by Agensys pursuant to this Section 5.2). For clarity, in no event shall Ambrx be
entitled to receive payment for (and Ambrx shall be solely responsible for) any and all FTEs in a given Calendar Quarter which are in excess of the number of FTEs authorized to be utilized to conduct the Research Program activities in such Calendar
Quarter as set forth in the Research Plan, an MTA or

  
 

-
40
 - 

   

  

as otherwise expressly approved in writing by the JPT. In all events Ambrx shall be entitled to receive payment for at least two (2) FTEs in a given Calendar Quarter.

 

		5.2.4	Elimination of FTEs. Notwithstanding anything to the contrary in this Section 5.2, in the event that the Parties or the JPT determines to reduce the number of FTEs for the conduct of Research Program and MTA
activities from those set forth in the Research Plan to no less than two (2) FTEs (each, an “Eliminated FTE”), then Agensys shall only be required to fund such reduced number of FTEs in accordance with the provisions of this
Section 5.2; provided, however, that to the extent that Ambrx is unable to reassign (after using Commercially Reasonable Efforts) such Eliminated FTEs to other activities under the Research Program hereunder or to other activities at Ambrx, then,
for a period not to exceed one hundred twenty (120) days, Agensys shall continue to fund such Eliminated FTEs in accordance with this Section 5.2 (provided that for clarity, after such one hundred twenty (120)-day period, Agensys shall no longer be
required to fund such Eliminated FTEs).

  

		5.3	Milestone Payments 

  

		5.3.1	Research Milestone. In consideration of the licenses granted herein under the Ambrx Patent Rights and the Ambrx Know-How and subject to the terms and conditions contained herein, Agensys shall pay to Ambrx [***], which shall be
non-refundable and shall be non-creditable, with respect to each Active Selected Target for which Ambrx [***] (the “Research Milestone”). For clarity, the Research Milestone shall be payable only one (1) time for a given Active
Selected Target upon the initial achievement of the Research Milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such Research Milestone for such Active Selected Target (e.g., achievement of the same
Research Milestone for separate Compounds would not trigger separate Research Milestone payments).

  

		5.3.2	Development and Commercialization Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and the Ambrx Know-How and subject to the terms and conditions contained herein, Agensys shall pay to Ambrx the
following amounts, which shall be non-refundable and shall be non-creditable, with respect to each Commercial Target for which Agensys achieves the following milestone event during the Term (the “Development/Commercial
Milestones”):

  

	 	Payment
	Event	Amount
	[***]	[***]
	[***]	[***]

  

***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

-
41
 - 

   

  

	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

  

[***] For clarity, each of the foregoing Development/Commercial Milestones in this Section 5.3.2 shall be payable only one (1) time for a given Commercial Target
upon the initial achievement of the applicable Development/Commercial Milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such Development/Commercial Milestone for such Commercial Target (e.g.,
achievement of the same Development/Commercial Milestones for separate Compounds or Products for such Commercial Target would not trigger separate Development/Commercial Milestone payments). In addition, in the event that a prior Research Milestone
or Development Milestone has not been paid for a given Commercial Target, and a subsequent Development Milestone is achieved for such Commercial Target, then all such unpaid prior Research Milestones and Development Milestones for such Commercial
Target shall be paid simultaneously with the payment of such subsequent Development/Commercial Milestone which is achieved (by way of example, (i) if Development Milestone 2 is achieved for a given Target and the Research Milestone or Development
Milestone 1 has not been paid with respect to such Target, then such Research Milestone and Development Milestone 1 shall be paid simultaneously with the payment of Development Milestone 2, and (ii) if [***], and so on with respect to each of the
Development/Commercial Milestones of a given Target); provided, however, that in all cases, the Research Milestones and all Development/Commercialization Milestones shall be payable only one (1) time for a given Commercial Target.

 

		5.3.3	Sales Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How and subject to the terms and conditions contained herein, Agensys shall pay to Ambrx the following amounts, which shall be
non-refundable and shall be non-creditable, with respect to each Commercial Target for which Agensys achieves the following milestone event during the Term:

 

	 	Payment
	Event	Amount
	First achievement of aggregate Net Sales in the Territory of all Products in the Territory for use against the
applicable Target in a given Calendar Year exceeding [***] for such Calendar Year	[***]

  

***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

-
42
 - 

   

  

	First achievement of aggregate Net Sales in the Territory of all Products for use against the applicable
Target in a given Calendar Year exceeding [***] for such Calendar Year	[***]

  

For clarity, each of the foregoing milestones in this Section 5.3.3 shall be payable only one (1) time for each such Commercial Target upon the initial achievement of the
applicable milestone and no amounts shall be due hereunder for subsequent or repeated achievement of such milestone.
  

		5.3.4	Reporting and Payment. Agensys shall notify Ambrx in writing within thirty (30) days following the achievement of each milestone as set forth in Section 5.3.1, 5.3.2 or 5.3.3, as applicable, and shall make the appropriate milestone
payment within thirty (30) days after the achievement of such milestone.

  

		5.4	Royalties 

  

		5.4.1	Royalties Payable By Agensys. Subject to the terms and conditions of this Agreement, Agensys shall pay Ambrx royalties as set forth in this Section 5.4.

 

		5.4.2	Patent Royalties. Agensys shall pay Ambrx royalties in an amount equal to the following percentage of Net Sales of Royalty Products sold by the Related Parties in countries within the Territory where the manufacture, use, or sale of a
Royalty Product by Agensys or its Related Party would infringe a Valid Patent Claim:

  

		(a)	[***] of such Net Sales in the Territory in each Calendar Year up to and including Net Sales of [***];

 

		(b)	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***] up to and including [***]; and

 

		(c)	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***].

 
 The foregoing royalty tiers shall be determined on a
Target-by-Target basis. As a result, for purposes of determining the foregoing royalty tiers under this Section 5.4.2, Net Sales of all Royalty Products for a given Target shall be aggregated, subject to Section 5.4.6. If a given Product could be
used for more than one Target, then Net Sales of such Product shall only be used to determine royalties for one (1) Target as determined by Agensys. For clarity, (x) only Net Sales of those Royalty Products for a given Target for which a royalty is
payable in a given country in a given Calendar Year under this Section 5.4.2 or Section 5.4.3, as applicable shall be included in determining such tiers and (y) Net Sales of Royalty Products for a given Target will not be combined with Net Sales
of
  
 ***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
43
 - 

   

  
 Royalty Products
for any other Target for purposes of determining the foregoing royalty tiers.
  

		5.4.3	Know-How Royalty. Notwithstanding the provisions of Section 5.4.2 above, in countries in the Territory where the manufacture, use or sale of a Royalty Product by Agensys or its Related Parties would not infringe a Valid Patent Claim, the
Net Sales of such Royalty Product(s) in such countries shall be halved in determining the applicable royalty rate according to Section 5.4.2.

 

		5.4.4	Royalty Term; Additional Conditions. Royalties on a given Royalty Product at the rates set forth above shall commence with the First Commercial Sale of the Royalty Product and continue on a country-by-country basis until the expiration of
the later of: (i) the last-to-expire Valid Patent Claim that would be infringed by the manufacture, use or sale of such Royalty Product in such country; or (ii) the period of ten (10) years following the First Commercial Sale of such Royalty Product
in such country (the “Royalty Term”). Notwithstanding anything to the contrary contained herein, all royalties are subject to the following conditions:

 

		(i)	that only one royalty shall be due with respect to the same unit of Royalty Product;

 

		(ii)	that no royalties shall be due upon the sale or other transfer among the Related Parties, but in such cases royalties shall be due and calculated upon Agensys’ or its Related Party’s Net Sales to the first independent Third
Party;

  

		(iii)	that no royalties shall accrue on the sale or other disposition of Product by the Related Parties for use in a Clinical Trial;

 

		(iv)	that no royalties shall accrue on the disposition of Royalty Product in reasonable quantities by Agensys or its Related Parties as samples (promotion or otherwise) or as donations (for example, to non-profit institutions or government agencies
for a non commercial purpose);

  

		(v)	that the determination of whether a royalty will be calculated under Section 5.4.2 or 5.4.3 shall be determined on a Royalty Product-by-Royalty Product and country-by-country basis, provided that for clarity, with respect to a given Royalty
Product, the Net Sales of such Royalty Product under Section 5.4.2 and 5.4.3 shall be aggregated for purposes of determining the applicable royalty tiers under Section 5.4.2 or 5.4.3, as applicable; and

  

		(vi)	that no royalties shall be payable by Agensys on any Products other than Royalty Products.

 

		(vii)	that once a Biosimilar for a particular Product is launched in a country within the Territory, then the royalty rate paid on Net Sales in such

 
 

-
44
 - 

   

  

country as provided in Section 5.4.2 or 5.4.3, as applicable, shall be reduced by [***]. For purposes of this Section 5.4.4, “Biosimilar” shall mean an
antibody drug conjugate with primary activity to the same Target as the applicable Product that has a payload technology that uses the same mechanism of action and is conjugated to the Antibody in a site specific fashion to a non-natural amino
acid.
  

		5.4.5	Royalties for Bulk Compound. In those cases in which Agensys sells bulk Compound rather than Product in packaged form to an independent Third Party, the royalty obligations of this Section 5.4 shall be applicable to the bulk Compound (but
solely to the extent that a royalty would otherwise be payable on the Product incorporating such Compound).

  

		5.4.6	Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to Royalty Product in any country in the Territory with a royalty rate lower than the royalty rate provided by Section 5.4.2 or 5.4.3, as applicable,
then the royalty rate to be paid by Agensys on Net Sales in that country under Section 5.4.2 or 5.4.3, as applicable, shall be reduced to the rate paid by the compulsory licensee. In such case, the Net Sales which is subject to the royalty reduction
as stipulated in this section 5.4.6 shall be excluded from the calculation of the royalty rate in Section 5.4.2.

  

		5.4.7	Third Party Licenses.

  

		(a)	In the event that Agensys determines that one or more licenses under any Patent Rights or know-how Controlled by Regeneron Pharmaceuticals, Inc. (“Regeneron”) are required by Agensys or its Related Parties in order to make,
have made, use, offer to sell, sell, export or import an Antibody (hereinafter “Regeneron Licenses”), then [***] of the royalty consideration (excluding, without limitation, upfront payments, license fees and milestone payments)
actually paid under such Regeneron Licenses by Agensys or its Related Parties for the manufacture, use or sale, as applicable, of such Antibody in a country for a given Calendar Quarter shall be creditable against the royalty payments due Ambrx by
Agensys with respect to the sale of Compound or Products containing such Antibody in such country.

  

		(b)	In the event that Agensys determines that one or more licenses under any Patent Rights or know-how from Third Parties (other than Regeneron) are reasonably required by Agensys or its Related Parties in order to make, have made, use, offer to
sell, sell, export or import Compound or Product(s) (hereinafter, together with the UC Berkeley License, “Additional Third Party Licenses”), then [***] of the consideration (including upfront payments, licenses fees and
royalties, but excluding

  
 ***Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.

 
 

-
45
 - 

   

  
 milestone
payments) actually paid under such Additional Third Party Licenses by Agensys or its Related Parties for the manufacture, use or sale, as applicable, of such Compound or Product in a country for a given Calendar Quarter shall be creditable against
the royalty payments due Ambrx by Agensys with respect to the sale of such Compound or Products in such country; provided, however, that patent or know-how licenses relating to (i) formulation technology, (ii) delivery device technology or (iii)
manufacturing process used in the manufacture of the Compounds and/or Products (in each case, of (i), (ii) and/or (iii), as applicable, not related to any Ambrx Know-How or Ambrx Patent Rights) shall not constitute Additional Third Party Licenses
for purposes of this Section 5.4.7.
  

		(c)	In no event shall the royalties owed by Agensys to Ambrx for any Calendar Quarter in any country be reduced by more than [***] pursuant to this Section 5.4.7; provided, however, that if Agensys is not able to fully recover the amounts paid by
Agensys or its Related Parties under Regeneron Licenses and Additional Third Party Licenses as a result of the foregoing restriction, then Agensys shall be entitled to carry forward such right of off-set to future Calendar Quarters with respect to
such excess amount.

  

		5.5	Reports; Payment of Royalty 

  

During the Term following the First Commercial Sale of a Product, Agensys shall furnish to Ambrx a quarterly written report for the Calendar Quarter showing the Net Sales
of all Royalty Products subject to royalty payments sold by the Related Parties in the Territory during the reporting period and the royalties payable under this Agreement. Reports shall be due on the forty-fifth (45th) day following the close of
each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. the Related Parties shall keep complete and accurate records in sufficient detail to enable the royalties
payable hereunder to be determined.
  

		5.6	Audits 

  

		(a)	Upon the written request of Ambrx and not more than once in each Calendar Year, Agensys shall permit an independent certified public accounting firm of nationally recognized standing selected by Ambrx and reasonably acceptable to Agensys, at
Ambrx’s expense, to have access during normal business hours to such of the records of the Related Parties as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than thirty
six (36) months prior to the date of such request. The accounting firm shall disclose to Ambrx only whether the royalty reports are

 
 ***Certain information on this page has been omitted
and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
46
 - 

   

  
 correct or
incorrect and the amount of any discrepancy. No other information shall be provided to Ambrx.
  

		(b)	If such accounting firm identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy within thirty (30) days of the date Ambrx delivers to Agensys such accounting firm’s
written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by Ambrx; provided, however, that if such audit uncovers an underpayment of royalties by Agensys that exceeds [***] of
the total royalties owed for the period in question, the fees of such accounting firm shall be paid by Agensys.

  

		(c)	Agensys shall include in each sublicense granted by it pursuant to this Agreement a provision requiring the sublicensee to make reports to Agensys, to keep and maintain records of sales made pursuant to such sublicense and to grant access to
such records by Ambrx’s independent accountant to the same extent required of Agensys under this Agreement.

 

		(d)	Upon the expiration of thirty six (36) months following the end of any Calendar Year, the calculation of royalties payable with respect to such Calendar Year shall be binding and conclusive upon Ambrx, and Agensys and its Related Parties shall
be released from any liability or accountability with respect to royalties for such Calendar Year.

  

		(e)	Ambrx shall treat all financial information subject to review under this Section 5.6 or under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter
into an acceptable confidentiality agreement with Agensys and/or its Related Parties obligating it to retain all such information in confidence pursuant to such confidentiality agreement.

 

		5.7	Payment Exchange Rate 

  

All payments to be made by Agensys to Ambrx under this Agreement shall be made in United States dollars and may be paid by bank wire transfer in immediately available
funds to such bank account in the United States as may be designated in writing by Ambrx from time to time. In the case of sales outside the United States, the rate of exchange to be used in computing the monthly amount of currency equivalent in
United States dollars due Ambrx shall be made at the average T.T.M. rate published by the Bank of Tokyo Mitsubishi UFJ, Ltd. in Japan for the first and last Business Day of the applicable reporting period for the payment due, consistent with
Agensys’ normal practices.
  
 ***Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

-
47
 - 

   

  

		5.8	Tax Withholding 

  

Ambrx shall be liable for all income and/or other taxes (including interest) imposed upon any payments (“Payments”) made by Agensys to Ambrx under this
ARTICLE 5 (“Taxes”). In the event Applicable Laws require withholding of Taxes, Agensys shall make such withholding payments and shall subtract the amount thereof from the Payments. Agensys shall submit appropriate proof of
payment of the withheld Taxes to Ambrx and shall provide Ambrx with the official receipts within a reasonable period of time. Agensys shall provide Ambrx reasonable assistance necessary to establish that Ambrx is entitled to retain the full amount
of any Payments under the Agreement.
  

		5.9	Ambrx Third Party Licenses 

  

Notwithstanding the provisions of Section 5.4.7, and except as otherwise agreed by the Parties in writing, Ambrx shall be solely responsible for obtaining and satisfying
all licenses, costs and payments of any kind (including all upfront fees, annual payments, milestone payments and royalty payments) (i) arising under any license or other grant of rights from a Third Party to Ambrx, including under the Scripps
License, which payments arise as a result of any activities hereunder and/or (ii) otherwise arising as a result of the use of Ambrx’s proprietary platform technology (including ReCODETM Technology and/or EuCODETM Technology and/or
Ambrx Payload Technology) as contemplated hereunder.
  

ARTICLE 6

REPRESENTATIONS AND WARRANTIES; COVENANTS

 

		6.1	Mutual Representations and Warranties 

  

Each Party represents and warrants to the other Party the following as of the Effective Date:

 

		(a)	Corporate Power. Such Party is duly organized and validly existing under the laws of the state of its organization and has full corporate power and authority to enter into this Agreement and to perform its obligations
hereunder.

  

		(b)	Due Authorization and Execution. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been
duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that
enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors.

 

		(c)	Non-Contravention. The execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated

 
 

-
48
 - 

   

  

hereunder will not (i) in any material respect violate any statute, regulation, judgment, order, decree or other restriction of any governmental authority to which such
Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or (iii) constitute a material violation or breach by such Party of any provision of any material contract, agreement or
instrument to which such Party is a party or to which such Party may be subject although not a party (including, with respect to Ambrx, the Scripps License).

 

		6.2	Ambrx Representations and Warranties 

  

Ambrx represents and warrants to Agensys the following as of the Effective Date:

 

		(a)	to the best of Ambrx’s knowledge, the Ambrx Patent Rights and Ambrx Know-How exist and are not invalid or unenforceable, in whole or in part;

 

		(b)	it has the full right, power and authority, including the full right, power and authority to enter into this Agreement, to perform the Research Program and to grant the licenses granted under ARTICLE 3 hereof;

 

		(c)	It has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or interest in Ambrx Patent Rights or Ambrx Know-How, or (ii) granted any rights to any Third Parties, in either case that would conflict with
the rights granted to Agensys hereunder;

  

		(d)	to the best of Ambrx’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee (pursuant to the Scripps License) of the Ambrx Patent Rights and Ambrx Know-How, all of which are (and shall be) free and clear of any
liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever with respect to the Ambrx Patent Rights and/or Ambrx Know-How
except pursuant to the Scripps License;

  

		(e)	to the best of Ambrx’s knowledge, the exercise of the license granted to Agensys under the Ambrx Patent Rights and Ambrx Know-How, including the research, development, manufacture, use, sale, export and import of Compounds, Products, and
Ambrx Payload Technology, do not interfere with or infringe any intellectual property rights owned or possessed by any Third Party;

 

		(f)	there are no claims, judgments or settlements against or owed by Ambrx and, to the best of Ambrx’s knowledge, no pending or threatened claims or litigation relating to the Ambrx Patent Rights and/or Ambrx Know-How including but not limited
to Ambrx Payload Technology;

  

		(g)	the Scripps License is the only agreement (including any licenses), written or oral, granting any licenses or other rights to Ambrx (or any of its Affiliates) relating to the Ambrx Know-How, Ambrx Patent Rights or Ambrx Payload
Technology;

  
 

-
49
 - 

   

  

		(h)	with respect to the Scripps License, (i) it is in full force and effect; (ii) Ambrx is not in breach; (iii) Ambrx has not received any notice of breach or notice of threatened breach; and (iv) Ambrx has not received any notice from the
counterparty to the Scripps License of intent to reduce the scope of the field or the licenses thereunder or render any of the licenses thereunder non-exclusive, and no event, act or omission has occurred which would reasonably be expected to give
rise to the right of the counterparty to the Scripps License to reduce the scope of the field or the licenses thereunder or render any of the licenses thereunder non-exclusive;

 

		(i)	Ambrx has disclosed to Agensys all reasonably relevant information regarding (i) the Active Selected Targets, and, to the best of Ambrx’s knowledge, relating to the Compounds or Products for use against such Active Selected Target, and/or
(ii) the Ambrx Patent Rights and Ambrx Know-How licensed under this Agreement;

  

		(j)	Ambrx has obtained all necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance of this
Agreement;

  

		(k)	Ambrx has disclosed all material information and data and all material correspondences to/from any Regulatory Authority controlled by Ambrx (or any of its Affiliates) or to which it (or any of its Affiliates) has access, in each case related to
(i) the Research Program regardless of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific or strategic value or attractiveness of the Research Program or (ii) the Active
Selected Targets regardless of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific or strategic value or attractiveness of the Active Selected Targets; and

 

		(l)	Ambrx has not employed or otherwise used in any capacity the services of any Person debarred under United States law, including to Section 21 USC 335a, with respect to the Compounds or Products for use against the Active
Selected Targets.

  

		6.3	Ambrx Further Representations, Warranties and Covenants 

  

		6.3.1	Scripps License. Ambrx represents and warrants to Agensys that it has provided to Agensys in writing prior to the Effective Date a true, correct and complete copy of the Scripps License, and such copy includes any and all amendments,
restatements, side letters, or other modifications thereto, as the Scripps License is in effect as of the Effective Date. Ambrx further covenants and agrees that during the Term of this Agreement, (a) it will satisfy all of its material obligations
(including all payment obligations) under, and take all steps necessary to maintain in full force and effect, the Scripps License, including taking all steps to ensure that all licenses granted thereunder remain in full force and effect (on an
exclusive basis) and that the scope of such licenses (including with respect to all licensed

  
 

-
50
 - 

   

  

intellectual property (including all Patent Rights) and all fields) are not reduced or limited in any manner that would adversely affect Agensys’ rights under this
Agreement; (b) it will not assign (except an assignment to a party to which this Agreement has been assigned as permitted under Section 10.2), amend, restate, amend and restate, terminate in whole or in part, or otherwise modify the Scripps License
in any manner that would adversely affect Agensys’ rights or obligations hereunder without the prior written consent of Agensys; and (c) it will provide Agensys with prompt notice of any claim of a material breach under the Scripps License or
notice of termination of the Scripps License, made by either Ambrx or the counterparty to the Scripps License (or any party acting on behalf of such counterparty) which would reasonably be expected to have an adverse effect on Agensys’ rights
or obligations hereunder. For the purposes of clarity, Ambrx (and not Agensys) shall be responsible for all of the financial and other obligations of Ambrx (and/or any of its Affiliates) to the counterparty under the Scripps License, including any
and all financial obligations to such counterparty with respect to Net Sales of Agensys and its Related Parties.
  

		6.3.2	UC Berkeley License. Ambrx represents and warrants to Agensys that (a) it has provided to Agensys in writing prior to the Effective Date a true, correct and complete copy of the UC Berkeley License; (b) such copy includes any and all
amendments, restatements, side letters, or other modifications thereto, as the UC Berkeley License is in effect as of the Effective Date; and (c) with respect to the UC Berkeley License, (i) it is in full force and effect; (ii) Ambrx is not in
breach; (iii) Ambrx has not received any notice of breach or notice of threatened breach; and (iv) Ambrx has not received any notice from the counterparty to the UC Berkeley License of intent to reduce the scope of the field or the licenses
thereunder or render any of the licenses thereunder non-exclusive, and no event, act or omission has occurred which would reasonably be expected to give rise to the right of the counterparty to the UC Berkeley License to reduce the scope of the
field or the licenses thereunder or render any of the licenses thereunder non-exclusive. Ambrx further covenants and agrees that during the Term, (a) it will satisfy all of its material obligations (including all payment obligations) under, and take
all steps necessary to maintain in full force and effect, the UC Berkeley License, including taking all steps to ensure that all licenses granted thereunder remain in full force and effect (on an exclusive basis) and that the scope of such licenses
(including with respect to all licensed intellectual property (including all Patent Rights) and all fields) are not reduced or limited in any manner that would adversely affect Agensys’ rights under this Agreement; (b) it will not assign
(except an assignment to a party to which this Agreement has been assigned as permitted under Section 10.2), amend, restate, amend and restate, terminate in whole or in part, or otherwise modify the UC Berkeley License in any manner that would
adversely affect Agensys’ rights or obligations hereunder without the prior written consent of Agensys; and (c) it will provide Agensys with prompt notice of any claim of a material breach under the UC Berkeley License or notice of termination
of the UC Berkeley License, made by either Ambrx or the counterparty to the UC Berkeley License (or any party acting on behalf of such

 
 

-
51
 - 

   

  

counterparty) which would reasonably be expected to have an adverse effect on Agensys’ rights or obligations hereunder.

 

		6.4	Disclaimer 

  

EACH PARTY HEREBY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREIN NOT EXPRESSLY MADE IN THIS AGREEMENT TO THE
MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAWS, INCLUDING WITH RESPECT TO THE COMPOUNDS, PRODUCTS, OR ANY TECHNOLOGY OR OTHER INTELLECTUAL PROPERTY LICENSED OR GRANTED UNDER THIS AGREEMENT, INCLUDING ANY WARRANTY OF NON-INFRINGEMENT, QUALITY,
PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE. FOR THE AVOIDANCE OF DOUBT, NOTHING CONTAINED IN THIS SECTION 6.4 SHALL OPERATE TO LIMIT OR INVALIDATE ANY EXPRESS WARRANTY CONTAINED HEREIN OR ANY IMPLIED WARRANTY OF GOOD
FAITH AND/OR FAIR DEALING.
  
 ARTICLE 7

PATENT PROVISIONS
  

		7.1	Filing, Prosecution and Maintenance of Patents for Collaboration Information and Inventions 

 

		7.1.1	Joint Collaboration Information and Inventions. Agensys shall have the first right to file patent applications for Joint Collaboration Information and Inventions (in the name of both Agensys and Ambrx) and thereafter prosecute and
maintain Patent Rights for such Joint Collaboration Information and Inventions. In the event that Agensys files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Collaboration Information and Inventions,
Ambrx shall execute such documents and perform such ministerial acts, at Agensys’ expense, as may be reasonably necessary for Agensys to continue such prosecution or maintenance of Patent Rights claiming such Joint Collaboration Information
and Invention. Agensys shall, in its sole discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Collaboration Information and Inventions; provided that Agensys’ choice of counsel will
not present a conflict of interest for Ambrx. With respect to a given Joint Collaboration Information and Invention, Agensys may elect not to file or may elect not to file in a particular country and if so, Agensys shall notify Ambrx and Ambrx shall
have the right to file such patent applications for such Joint Collaboration Information and Invention (in the name of both Agensys and Ambrx) and thereafter prosecute and maintain Patent Rights for such Joint Collaboration Information and
Invention. In the event that Ambrx files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Collaboration Information and Inventions, Agensys shall execute such documents and perform such ministerial acts,
at Ambrx’s expense, as may be

  
 

-
52
 - 

   

  

reasonably necessary for Ambrx to continue such prosecution or maintenance of Patent Rights claiming such Joint Collaboration Information and Invention. Ambrx shall, in
its sole discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Collaboration Information and Inventions; provided that Ambrx’s choice of counsel will not present a conflict of interest
for Agensys.
  

		7.1.2	Ambrx Collaboration Information and Inventions. Ambrx shall have the first right, at its sole cost and expense, to file patent applications for Ambrx Collaboration Information and Inventions and thereafter prosecute and maintain Patent
Rights for such Ambrx Collaboration Information and Inventions. With respect to a given Ambrx Collaboration Information and Inventions, Ambrx may elect not to file or may elect not to file in a particular country and if so, Ambrx shall notify
Agensys and Agensys shall have the right to file such patent applications for such Ambrx Collaboration Information and Invention and thereafter prosecute and maintain Patent Rights for such Ambrx Collaboration Information and Invention, at its sole
cost and expense. In such event, Ambrx shall execute such documents and perform such ministerial acts, at Agensys’ expense, as may be reasonably necessary for Agensys to continue such prosecution or maintenance of Patent Rights claiming such
Ambrx Collaboration Information and Invention.

  

		7.1.3	Review and Consultation. In each case in connection with the foregoing with respect to Joint Collaboration Information and Inventions and Ambrx Collaboration Information and Inventions, as applicable, the filing Party (a) shall keep the
non-filing Party advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall provide advance copies of any papers related to the filing, prosecution and maintenance of such patent
filings; (c) shall give the non-filing Party an opportunity to review the text of the application before filing and shall consult with the non-filing Party with respect thereto; (d) shall give the non-filing Party an opportunity to review and
comment on any documents relating to such patent filings that will be filed in any patent office at least twenty (20) days before such filing and give due consideration to such substantive, non-cumulative comments; (e) shall supply the non-filing
Party with a copy of the application as-filed, together with notice of its filing date and serial number; and (f) shall promptly give notice to the non-filing Party of the grant, lapse, revocation, surrender, invalidation or abandonment of any Joint
Patent Rights (or Patent Rights claiming Ambrx Collaboration Information and Inventions, as applicable) for which it is responsible for the filing, prosecution or maintenance hereunder (provided that the filing Party shall give at least thirty (30)
days prior written notice to the non-filing Party of any desire to cease prosecution and/or maintenance of such Patent Rights on a country by country basis in the Territory).

 

		7.1.4	Costs. The Parties shall equally split the costs of filing patent applications and procuring and maintaining Patent Rights in the United States, Japan, China,

 
 

-
53
 - 

   

  

Brazil, and with the European Patent Office (including but not limited to all National Phase filing costs and fees) for such Joint Collaboration Information and
Inventions; Agensys shall be responsible for the costs of filing patent applications and procuring and maintaining Patent Rights for such Joint Collaboration Information and Inventions in all other jurisdictions in the Territory. In light of the
foregoing, if, pursuant to Section 7.1.1, Agensys elects not to file or elects not to file in a particular country and Ambrx elects to file and maintain Patent Rights on such Joint Collaboration Information and Inventions, then Ambrx shall solely
pay 100% of the costs to file and maintain said Patent Rights in the elected country(ies).
  

		7.1.5	Agensys Collaboration Information and Inventions. Agensys shall have the sole right, at its sole cost and expense, to file patent applications for Agensys Collaboration Information and Inventions and thereafter prosecute and maintain
Patent Rights for such Agensys Collaboration Information and Inventions, and Ambrx shall have no rights in connection therewith.

 

		7.1.6	Interpretation of Article 7. The Parties hereby acknowledge and agree that any Patent Rights with respect to Joint Collaboration Information and Inventions filed by Agensys in accordance with the foregoing Section 7.1.1 shall be
considered “Agensys Patent Rights” for purposes of the remaining provisions of this ARTICLE 7 and any Patent Rights with respect to Joint Collaboration Information and Inventions filed by Ambrx in accordance with the foregoing Section
7.1.1 shall be considered “Ambrx Patent Rights” for purposes of the remaining provisions of this ARTICLE 7, in each case, as applicable.

 

		7.2	Filing, Prosecution and Maintenance of Ambrx Patent Rights (other than Patent Rights for Collaboration Information and Inventions) and Agensys Patent Rights (other than Patent Rights for Collaboration Information and Inventions)

  

		7.2.1	Ambrx Patent Rights (other than Patent Rights for Collaboration Information and Inventions). Ambrx shall use Commercially Reasonable Efforts to file, prosecute and maintain in the Territory the Ambrx Patent Rights (other than Patent
Rights for Collaboration Information and Inventions, which shall be covered by Section 7.1), in each case, at Ambrx’s sole cost and expense.

 

		7.2.2	Agensys Patent Rights. Agensys shall have the sole right, in its discretion, to file, prosecute and maintain the Agensys Patent Rights (other than Patent Rights for Agensys Collaboration Information and Inventions, which shall be covered
by Section 7.1.5), at Agensys’ sole cost and expense, and Ambrx shall have no rights in connection therewith.

 

		7.3	Interference, Opposition, Invalidation, Reexamination, Reissue, Biosimilar, and Post-Grant Proceedings 

 

		(a)	Ambrx shall, within ten (10) days of learning of such event, inform Agensys of any request for, or filing or declaration of, any interference, opposition,

 
 

-
54
 - 

   

  

invalidation, reissue, derivation, cancellation, revocation, nullification, post-grant review, reexamination or any other official proceeding (each, a “Post Grant
Proceeding”) relating to any Ambrx Patent Rights claiming any Ambrx Collaboration Information and Invention or any Joint Collaboration Information and Invention for which Ambrx is the filing party pursuant to Section 7.1. Agensys and Ambrx
shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding and Agensys shall have the right to review and approve any submission to be made in connection with such proceeding.

 

		(b)	Ambrx shall not initiate any Post Grant Proceedings relating to any Ambrx Patent Rights referenced in the foregoing clause (a) without the prior written consent of Agensys, which consent shall not be unreasonably
withheld.

  

		(c)	In connection with any Post Grant Proceedings relating to any Ambrx Patent Rights referenced in the foregoing clause (a), Agensys and Ambrx will provide reasonable assistance that either may reasonably request. Ambrx shall keep Agensys informed
of developments in any such action or proceeding, including, to the extent permissible by law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto.

 

		(d)	As between the Parties, Ambrx shall bear the expense of any Post Grant Proceedings relating to any Ambrx Patent Rights referenced in the foregoing clause (a).

 

		(e)	Agensys shall have the sole right, in its discretion, to handle any Post Grant Proceedings relating to Agensys Patent Rights (including any Patent Rights claiming any Agensys Collaboration Information and Inventions or any Joint Collaboration
Information and Invention for which Agensys is the filing party pursuant to Section 7.1), and Ambrx shall have no rights in connection therewith; provided, however, that at the request of Agensys, Ambrx will provide Agensys with reasonable
assistance that Agensys may reasonably request (and in the event that Agensys is unable to handle such action solely in its own name, Ambrx will join such action voluntarily and will execute and cause its Affiliates to execute all documents
necessary for Agensys to handle and maintain such action).

  

		7.4	Enforcement and Defense 

  

		(a)	Each Party shall promptly notify the other Party of any infringement or possible infringement by a third party of any rights licensed to Agensys under this Agreement. Further, Ambrx shall give Agensys, and Agensys shall give Ambrx, notice of any
infringement of (i) any Ambrx Patent Rights claiming any Ambrx Collaboration Information and Invention or any Joint Collaboration Information and Invention for which Ambrx is the filing party pursuant to Section 7.1, or any misappropriation or
misuse of Ambrx Collaboration Information and Inventions, that may come to Ambrx’s or Agensys’ attention. Agensys and Ambrx shall thereafter consult and cooperate fully to determine a course of action, including

 
 

-
55
 - 

   

  

but not limited to, the commencement of legal action by either or both Agensys and Ambrx, to terminate any infringement of such Ambrx Patent Rights or any misappropriation
or misuse of such Ambrx Collaboration Information and Invention, as applicable. However, Ambrx, upon notice to Agensys, shall have the first right to initiate and prosecute such legal action at its own expense and in the name of Ambrx, or to control
the defense of any declaratory judgment action relating to such Ambrx Patent Rights or such Ambrx Collaboration Information and Inventions, as applicable, and Agensys, upon notice to Ambrx, shall have the first right to initiate and prosecute such
legal action at its own expense and in the name of Agensys, or to control the defense of any declaratory judgment action relating to such Ambrx Patent Rights or such Ambrx Collaboration Information and Inventions, as applicable. To the extent
permissible by Applicable Law, the non-controlling Party shall have the right to join and participate in such action. Each Party shall promptly inform the other Party if it elects not to exercise such first right and the other Party shall thereafter
have the right to either initiate and prosecute such action or to control the defense of such declaratory judgment action in its name and, if necessary, the name of the first Party. Each Party shall have the right to be represented by counsel of its
own choice.
  

		(b)	In the event that Ambrx elects not to initiate and prosecute an action as provided in paragraph (a), and Agensys elects to do so, the costs of any agreed-upon course of action to terminate infringement of Ambrx Patent Rights referenced in the
foregoing clause (a) or misappropriation or misuse of Ambrx Collaboration Information and Inventions, as applicable, by a Third Party, including without limitation the costs of any legal action commenced or the defense of any declaratory judgment,
shall be shared equally by Ambrx and Agensys.

  

		(c)	For any action to terminate any infringement of Ambrx Patent Rights referenced in the foregoing clause (a) or any misappropriation or misuse of Ambrx Collaboration Information and Inventions, as applicable, by a Third Party, in the event that
Agensys is unable to initiate or prosecute such action solely in its own name, Ambrx will join such action voluntarily and will execute all documents necessary for Agensys to initiate litigation to prosecute and maintain such action. In connection
with any such action, Agensys and Ambrx will provide reasonable assistance that either may reasonably request. Each Party shall keep the other informed of developments in any action or proceeding, including, to the extent permissible by Applicable
Law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto.

 

		(d)	Any recovery obtained by either or both Agensys and Ambrx in connection with or as a result of any action contemplated by the foregoing provisions of this Section 7.4 with respect to any Ambrx Patent Rights referenced in the foregoing clause (a)
or Ambrx Collaboration Information and Inventions, whether by settlement or otherwise, shall be shared in order as follows:

 

		(i)	the Party which initiated and prosecuted the action shall recoup all of its

  

-
56
 - 

   

  

costs and expenses incurred in connection with the action;
  

		(ii)	the other Party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and

 

		(iii)	the amount of any recovery remaining shall then be shared equally between the Parties.

 

		(e)	Agensys shall have the initial right to control any proceedings and initiate a legal action against Third Party with respect to a biosimilar application filed under §351(k) by an unlicensed Third Party at Agensys’ sole cost and
expense. Ambrx shall join in such action as a party at Agensys reasonable request and at Agensys’ sole cost and expense in the event that an adverse party asserts, the court rules or other Laws provide, or Agensys determines in good faith,
that a court would lack jurisdiction based on Ambrx’s absence as a party in such suit. Ambrx may also at any time join in such action and may be represented by counsel of its choice, at Ambrx expense; but in any event control of such action
shall remain with Agensys. At Agensys’ reasonable request and at Agensys’ sole cost and expense, Ambrx shall provide reasonable assistance to Agensys in connection with such action. Without the prior written consent of Ambrx, Agensys
shall not enter into any settlement with such unlicensed Third Party admitting the invalidity of, or otherwise impairing Ambrx rights in, any of the Ambrx Patent Rights or Joint Patent Rights.

 

		(f)	Agensys shall have the sole right, in its discretion, to handle any action with respect to any infringement of Agensys Patent Rights (including any Patent Rights claiming any Agensys Collaboration Information and Inventions and any Joint
Collaboration Information and Inventions for which Agensys is the filing party pursuant to Section 7.1) or any misappropriation or misuse of any Agensys Background Know-How (or any Agensys Collaboration Information and Inventions or any Joint
Collaboration Information and Inventions), and Ambrx shall have no rights in connection therewith. For any action with respect to any infringement of Agensys Patent Rights or any misappropriation or misuse of Agensys Background Know-How (or any
Agensys Collaboration Information and Inventions or any Joint Collaboration Information and Inventions, as applicable) by a Third Party, in the event that Agensys is unable to initiate or prosecute such action solely in its own name, Ambrx will, to
the extent required by Applicable Law to enable the initiation or prosecution of such action by Agensys, join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for Agensys to initiate litigation to
prosecute and maintain such action at Agensys’ expense. In connection with any such action pursuant to this Section 7.4(f), at the request of Agensys, Ambrx will provide Agensys with reasonable assistance that Agensys may reasonably request at
Agensys’ expense. As between the Parties, any recovery obtained in connection with or as a result of any action contemplated by this Section 7.4 (f), whether by settlement or otherwise, shall be shall be retained solely by Agensys. Agensys
shall also have

  
 

-
57
 - 

   

  

the sole right, in its discretion, to handle any certification matter regarding any Agensys Patent Rights pursuant to either 21 U.S.C.
§§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions, or any similar provisions in a country in the Territory, and Ambrx shall have no rights in connection therewith.

 

		7.5	Cooperation; Patent Term Restoration 

  

The Parties agree to cooperate and to take reasonable actions to maximize the protections available under the safe harbor provisions of 35 U.S.C. 103(c) for U.S.
patents/patent applications with respect to any patents/patent applications claiming any Collaboration Information and Invention. The Parties hereto shall provide reasonable assistance that either may reasonably request in obtaining patent term
restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to (i) Compound Patent Rights or (ii) other Ambrx Patent Rights claiming Collaboration Information and Inventions. In the event
that elections with respect to obtaining such patent term restoration are to be made, Agensys shall have the right to make the election and Ambrx agrees to abide by such election.

 
 ARTICLE 8

TERM AND TERMINATION
  

		8.1	Term and Expiration 

  

This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 8.2 below, this Agreement shall continue in full force and
effect on a Product-by-Product and country-by-country basis until expiration of all Agensys royalty obligations hereunder with respect to such Product in such country. The period from the Effective Date until the date of expiration or earlier
termination of this Agreement in its entirety, or as the case may be, until the date of the expiration or earlier termination of this Agreement in part with respect to a given Product on a country-by-country basis, shall be referred to herein as the
“Term”.
  

		8.2	Agensys Termination for Convenience. Agensys shall have the right to terminate this Agreement at any time and from time to time in its sole discretion either in its entirety or on a Target-by-Target and/or country-by-country basis
for any reason. Any termination under this Section 8.2 shall be accomplished by Agensys giving ninety (90) days’ advance written notice to Ambrx. In the event that this Agreement is terminated only with respect to a given Target and/or a given
country pursuant to this Section 8.2, then the effects of termination as set forth in Section 8.4 shall only apply with respect to all Compounds and Products related to such Target and/or such country, as applicable. For clarity, expiration of the
Research Term and early discontinuance of the Research Program under Section 2.8.2 shall not be considered a termination of this Agreement pursuant to this Section 8.2.

 

		8.3	Termination for Cause. This Agreement may be terminated in its entirety or on a Product-by-Product and country-by-country basis at any time during the Term:

 
 

-
58
 - 

   

  

		(a)	upon written notice by either Party if the other Party is in breach of its material obligations hereunder, and has not cured such breach within ninety (90) days after notice requesting cure of the breach; provided, however, that in the event of
a good faith dispute with respect to the existence of a material breach, the ninety (90) day cure period shall be tolled until such time as the dispute is resolved pursuant to Section 10.6 hereof; provided further, however, that notwithstanding the
foregoing, it is agreed that termination pursuant to this Section 8.3(a) shall be on a Product-by-Product and country-by-country basis to which the material breach relates, as applicable, and that the non-breaching Party cannot terminate this
Agreement under this Section 8.3(a) with respect to non-affected Products and non-affected countries (and the effects of termination as set forth in Section 8.4 shall only apply with respect to such terminated Product and such terminated country, as
applicable); or

  

		(b)	by Ambrx, at any time, immediately upon written notice to Agensys in the event that Agensys or any of its Affiliates challenges in a court of competent jurisdiction, the validity, scope or enforceability of, or otherwise opposes, any Ambrx
Patent Rights. If a sublicensee of Agensys or its Affiliate challenges the validity, scope or enforceability of or otherwise opposes any Ambrx Patent Right under which such sublicensee is sublicensed, then Agensys or its Affiliate, as applicable,
shall, upon written notice from Ambrx, terminate such sublicense. Agensys and each of its Affiliates shall include without limitation provisions in all agreements under which a Third Party obtains a license under any Ambrx Patent Right providing
that, if the sublicensee challenges the validity or enforceability of or otherwise opposes any such Ambrx Patent Right under which the sublicensee is sublicensed, then Agensys may terminate such sublicense agreement with such sublicensee, and
Agensys shall, upon request by Ambrx, enforce such right if such sublicensee breaches such restriction; or

  

		(c)	by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing
thereof.

  

		8.4	Effect of Termination 

  

		(a)	If Agensys terminates this Agreement under Section 8.3(a): (i) Agensys’ licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) shall become perpetual, irrevocable licenses (provided, however, that Agensys shall continue to be obligated to pay
the milestone and royalty amounts under Sections 5.3 and 5.4 that would otherwise have been payable under the terms of this Agreement during its Term on the Products or country(ies) subject to the termination), (ii) except with respect to the
milestones and royalties as provided in the foregoing clause (i), no further

  
 

-
59
 - 

   

  

payments or other fees, costs or payments of any kind shall be owed to Ambrx on account of Products or country(ies) for which this Agreement was terminated, except as
mutually agreed by the Parties in writing, and (iii) Ambrx shall, within thirty (30) days after the effective date of such termination, to return or cause to be returned to Agensys all Confidential Information and all Agensys substances or Agensys
compositions delivered or provided by Agensys, as well as any other Agensys material provided by Agensys in any medium (provided, however, that Ambrx may retain any such Confidential Information, substances, compositions and/or material, as
applicable, as are reasonably necessary for Ambrx’s continued practice under any licenses which survive such termination and Ambrx may keep one copy of Confidential Information received from Agensys in its confidential files for record
purposes).
  

		(b)	If Agensys terminates this Agreement under Section 8.2 or if Ambrx terminates this Agreement under Section 8.3(a) or 8.3(b), then (i) Agensys’ licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) shall terminate,
and (ii) each Party shall, within thirty (30) days after the effective date of such termination, return or cause to be returned to the other Party all Confidential Information of the other Party and all substances or compositions owned by the other
Party delivered or provided by such other Party, as well as any other material owned by such other Party provided by such other Party in any medium (provided, however, that receiving Party may retain any such Confidential Information, substances,
compositions and/or material, as applicable, as are reasonably necessary for such other Party’s continued practice under any licenses(s) which survive such termination and the receiving Party may keep one copy of Confidential Information
received from the other Party in its confidential files for record purposes).

  

		(c)	Notwithstanding the foregoing, upon termination of this Agreement by Ambrx pursuant to Section 8.3(a), the applicable licenses set forth in Sections 3.1.1(d) and 3.1.1(e) shall survive for a period of eighteen (18) months in order for Agensys
and its Affiliates, sublicensees and distributors, at their discretion, during such eighteen (18) month period immediately following the effective date of termination, to finish any Product related manufacturing work-in-progress and to sell any
Products or Compound remaining in inventory, in accordance with the terms of this Agreement, in each case, utilizing such licenses (subject to the payment obligations of Agensys as set forth in Section 5).

 

		(d)	If this Agreement is terminated by Agensys pursuant to Section 8.3(c), then the provisions of Section 8.4(a) shall apply, and in addition, if such termination would be due to a rejection of this Agreement by or on behalf of Ambrx under Section
365 of the United States Bankruptcy Code (the “Code”), all licenses and rights to licenses granted under or pursuant to this Agreement by Ambrx to Agensys are, and shall otherwise be deemed to be, for purposes of Section 365(n) of
the Code, licenses of rights to “intellectual property” as defined under Section 101 (35A) of the Code and not executory contracts. The Parties agree that Agensys, as a licensee of such rights under this Agreement, shall retain and
may

  
 

-
60
 - 

   

  

fully exercise all of its rights and elections under the Code. The foregoing provisions of Section 8.4(d) are without prejudice to any rights Agensys may have arising
under the Code or other Applicable Law.
  

		(e)	For clarity, if this Agreement is terminated only with respect to a given Product(s) and/or a given country(ies, then the foregoing provisions of this Section 8.4 shall only apply with respect to such Product and/or such country, as
applicable.

  

		8.5	Effect of Expiration or Termination; Survival 

  

		(a)	Upon expiration of the Term, Agensys’ licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) shall become fully paid-up, perpetual, irrevocable licenses.

 

		(b)	Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Each Party shall pay all amounts then due and owing as of the expiration or termination date (and Ambrx
shall reimburse Agensys for any uncredited fees paid by Agensys pursuant to the Research Program). Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under
this Agreement prior to expiration or termination, including the obligation to pay royalties for Product(s) or Compound sold prior to such expiration or termination.

 

		(c)	The provisions of ARTICLE 4 shall survive the expiration or termination of this Agreement and shall continue in effect for ten (10) years. In addition, the provisions of Articles 1 (as necessary for the interpretation of other surviving
provisions), 7 and 10, and Sections 2.6.1, 2.6.4, 2.7, 2.9 (other than the first sentence thereof), 2.11.4, 5.2.2, 5.2.3, 5.6, 6.4, 8.4, 9.1 through 9.4, and this 8.5 shall survive any expiration or termination of this Agreement.

 
 ARTICLE 9

INDEMNIFICATION; LIMITATION ON LIABILITY

 

		9.3	Indemnification by Agensys 

  

Agensys hereby agrees to indemnify, hold harmless and defend Ambrx, its Affiliates and their respective officers, directors, agents, employees, successors and assigns
(collectively, the “Ambrx Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether
governmental or private, arising out of or relating to (i) the research, development, manufacture, use, sale or other disposition of Compounds and Products by Agensys or its Affiliates or sublicensees under this Agreement, (ii) the breach of any of
Agensys’ covenants, representations or warranties under this Agreement, or (iii) the willful misconduct by Agensys, its Affiliates or their respective officers, directors, agents or employees, in performing any obligations under this
Agreement; provided, however, that Agensys shall not be required to indemnify, hold harmless or defend any Ambrx Indemnified Party against any claim to the extent that

 
 

-
61
 - 

   

  

Ambrx has an obligation to indemnify the Agensys Indemnified Parties under clauses (ii) or (iii) of Section 9.2.

 

		9.2	Indemnification by Ambrx 

  

Ambrx agrees to indemnify, hold harmless and defend Agensys, its Affiliates and their respective officers, directors, agents, employees, successors and assigns
(collectively, the “Agensys Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether
governmental or private, arising out of or relating to (i) the research, development, manufacture, use or other disposition of Compounds and/or Products by Ambrx or its sublicensees under this Agreement, (ii) the breach of any of Ambrx’s
covenants, representations or warranties under this Agreement, or (iii) the willful misconduct by Ambrx or its officers, directors, agents or employees, in performing any obligations under this Agreement; provided, however, that Ambrx shall not be
required to indemnify, hold harmless or defend any Agensys Indemnified Party against any claim to the extent that Agensys has an obligation to indemnify the Ambrx Indemnified Parties under clauses (ii) or (iii) of Section 9.1.

 

		9.3	Procedure 

  

If either Party is seeking indemnification under Section 9.1 or 9.2 (the “Indemnified Party”), it shall inform the other Party (the
“Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable after receiving notice of the claim (provided, however, any delay or failure to provide such
notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable, Section 9.1 or 9.2, except to the extent that such delay or failure materially prejudices the
Indemnifying Party’s ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall
cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at
its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any claim without the prior written consent of the Indemnified Party, not to
be unreasonably withheld. The Indemnified Party shall not settle or compromise any such claim without the prior written consent of the Indemnifying Party, which it may provide in its sole discretion. If the Parties cannot agree as to the application
of Section 9.1 or 9.2 to any claim, pending resolution of the dispute pursuant to Section 10.6, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance
with Section 9.1 or 9.2 upon resolution of the underlying claim.
  
 

-
62
 - 

   

  

		9.4	Limitation of Liability 

  

NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES (INCLUDING LOST PROFITS) ARISING FROM OR RELATING TO
THIS AGREEMENT (INCLUDING BREACH OF THIS AGREEMENT) OR THE EXERCISE OF ITS RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.4 IS INTENDED TO OR SHALL LIMIT OR
RESTRICT (1) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 9.1 OR 9.2, OR (2) DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 4.

 

		9.5	Insurance 

  

Each Party shall procure and maintain insurance, including product liability insurance (or self-insure), adequate to cover its obligations hereunder and which is
consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Reversion Product, as applicable, is being clinically tested with human subjects or commercially distributed or sold by such
Party. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this ARTICLE 9 or otherwise. Each Party shall provide the other Party with
written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, non renewal or material change in such insurance or self insurance which materially
adversely affects the rights of the other Party hereunder.
  

ARTICLE 10

MISCELLANEOUS
  

		10.1	Force Majeure 

  

Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation
under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of
terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall
notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances.

 
 

-
63
 - 

   

  

		10.2	Assignment/Change of Control 

  

Except as provided in this Section 10.2, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred,
by either Party without the consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to (i) an Affiliate
or (ii) in connection with a Change of Control; provided, however, that Ambrx must notify Agensys at least twenty (20) days prior to completion of any such Change of Control, and Agensys shall have the right (in its discretion), at any time after
receipt of such notice, to elect any one or more of the following options: (i) terminate the Research Program in compliance with Section 2.8.2 (and Ambrx shall reimburse Agensys for any uncredited fees paid by Agensys pursuant to the Research
Program), (ii) require Ambrx, including its acquiring party, to adopt reasonable procedures to be agreed upon in writing with Agensys to prevent the disclosure of all Confidential Information of Agensys and its Affiliates and other information with
respect to the development and commercialization of Compounds or Products (the “Sensitive Information”) beyond Ambrx personnel having access to and knowledge of Sensitive Information prior to the Ambrx Change of Control, and to
control the dissemination of Sensitive Information disclosed after the Ambrx Change of Control, which procedures shall include reasonable restrictions on the scope of any Sensitive Information to be provided by Agensys; (iii) terminate Ambrx’s
involvement on the JPT; and/or (iv) terminate the Agreement in its entirety pursuant to Section 8.2. Any permitted assignee shall assume all obligations of its assignor under this Agreement. This Agreement is binding upon the permitted successors
and assigns of the Parties. Any attempted assignment not in accordance with this Section 10.2 shall be void.
  

		10.3	Severability 

  

If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their
good faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

 

		10.4	Notices 

  

All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal
delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

	If to Ambrx, to:	Ambrx, Inc.
	 	10975 North Torrey Pines Road
	 	La Jolla, CA 92037

  
 

-
64
 - 

   

  

	 	Attn: Office of General Counsel
	 	Facsimile No.: (858) 453-9511
	 	 
	With a copy to:	Latham & Watkins, LLP
	 	12636 High Bluff Drive, Suite 400
	 	San Diego, CA 92130
	 	Attention: Faye H. Russell, Esq.
	 	Facsimile No.: (858) 523-5450
	 	 
	If to Agensys, to:	Agensys, Inc.
	 	1800 Stewart St.
	 	Santa Monica, CA 90404
	 	Attn: V.P., Head of Research
	 	Facsimile No.: 310-382-2888
	 	 
	With a copy to:	Agensys, Inc.
	 	Legal Department
	 	1800 Stewart St,
	 	Santa Monica, CA 90404
	 	ATTN: Shane M. Popp, Esq.
	 	Facsimile No.: 310-382-2888
	 	e-mail: spopp@agensys.com

  
 or to such other address(es) as the
Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or
if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch, if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by
mail.
  

		10.5	Applicable Law 

  

This Agreement shall be governed by and construed in accordance with the laws of the State of California and the patent laws of the United States,
without reference to any rules of conflict of laws or renvoi.
  

		10.6	Dispute Resolution 

  

		10.6.1	The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof. If the Parties do not fully settle, and a Party wishes to pursue
the matter, each such dispute, controversy or claim that is not an “Excluded Claim” shall be finally resolved by binding arbitration in accordance with the

 
 

-
65
 - 

   

  

Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (“AAA”),
and judgment on the arbitration award may be entered in any court having jurisdiction thereof.
  

		10.6.2	The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business: within thirty (30) days after initiation of arbitration, each Party shall select one person to act as arbitrator; and the two
Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the
AAA. The place of arbitration shall be Los Angeles, California, and all proceedings and communications shall be in English.

 

		10.6.3	Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court
having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by
a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration.

 

		10.6.4	Except to the extent necessary to confirm an award or as may be required by Applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In
no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable California statute of limitations.

 

		10.6.5	The Parties agree that, in the event of a good faith dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial
determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due.

 

		10.6.6	As used in this Section, the term “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright; or (b) any antitrust,
anti-monopoly or competition law or regulation, whether or not statutory.

  

		10.7	Entire Agreement; Amendments 

  

This Agreement together with the Schedules hereto contains the entire understanding of the Parties with respect to the subject matter hereof, including
the Research Program and
  
 

-
66
 - 

   

  

the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with regard to
the subject matter hereof, including the Research Program and/or the licenses granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by reference and shall be deemed a part of this
Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto.

 

		10.8	Headings and Interpretation 

  

The captions to the several Articles and Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading
the several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or
Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”,
“hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any
provision of this Agreement uses the term “including” (or “includes” or words of similar import), such term shall not be limiting and such term shall be deemed to mean “including without limitation” (or
“includes without limitation”), (e) the word “or” shall not be construed as exclusive, and (f) references to any Articles or Sections include Sections and subsections that are part of the reference Article or section (e.g., a
section numbered “Section 2.2.1” would be part of “Section 2.2.”, and references to “Article 2” or “Section 2.2.” would refer to material contained in the subsection described as “Section
2.2.2”).
  

		10.9	Independent Contractors 

  

It is expressly agreed that Ambrx and Agensys shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint
venture or agency. Neither Ambrx nor Agensys shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the
other Party.
  
 

-
67
 - 

   

  

		10.10	Waiver 

  

The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not
be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise.

 

		10.11	Cumulative Remedies 

  

No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this
Agreement or otherwise available under law.
  

		10.12	Waiver of Rule of Construction 

  

Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction
that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.
  

		10.13	Business Day Requirements 

  

In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a business day then
such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day.
  

		10.14	Counterparts 

  

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original.
  

		10.15	Further Actions 

  

Each Party will execute, acknowledge and deliver such further instruments, and to do all such other ministerial, administrative or similar acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.
  

		10.16	No Third Party Rights 

  

The provisions of this Agreement are for the exclusive benefit of the Parties, and no other person or entity shall have any right or claim against any
Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.
  
 

-
68
 - 

   

  

		10.17	Expenses 

  

Except as otherwise specifically provided in this Agreement, each Party (and its Affiliates) shall bear its own costs and expenses in connection with
entering into this Agreement and the consummation of the transactions and performance of its obligations contemplated hereby.
  

		10.18	Extension to Affiliates 

  

Agensys shall have the right to extend the rights, licenses, immunities and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms
and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Agensys. Agensys shall remain fully liable for any acts or omissions of such
Affiliates.
  
 [Remainder of this page is left
intentionally blank]
  
 

-
69
 - 

   

  

IN WITNESS WHEREOF, the Parties have executed this Research Collaboration and Exclusive License Agreement as of the date first set forth above.

 

	AGENSYS, INC.	 
	 	 
	By:	/s/ Sef Kurstjens	 
	Name:	Dr. Sef Kurstjens	 
	Title:	President and CEO	 
	 	 	 
	AMBRX, INC.	 
	 	 
	By:	/s/ Simon Allen	 
	Name:	Simon Allen	 
	Title:	Chief Business Officer	 

  

SIGNATURE PAGE TO RESEARCH COLLABORATION

AND EXCLUSIVE LICENSE AGREEMENT

 
 

 
 

   

  

SCHEDULE 1.79

 
 Workplan for
Agensys/Ambrx Collaboration FY2013
  
 At the beginning of each year, a workplan
for the year will be generated and agreed upon between Agensys and Ambrx. This Appendix 1 describes the workplan for FY2013 (April 2013 – March 2014).
  

		[***]	An overview of the workplan timeline is depicted in Table 1 and specifics are described hereon.

 

		1.	[***]

  

		2.	[***]

  

		3.	[***]

  

		4.	[***]

  

		a.	[***]

  

		i.	[***]

  

		ii.	[***]

  

		b.	[***]

  

		i.	[***]

  

		ii.	[***]

  

		5.	[***]

  

		a.	[***]

  

		b.	[***]

  

		c.	[***]

  

		d.	[***]

  

		6.	[***]

  

		7.	[***]

  

		a.	[***]

  

		b.	[***]

  

		8.	[***]

  

		a.	[***]

  

		b.	[***]

  

		9.	[***]

  

		10.	[***]

  

		a.	[***]

  

		b.	[***]

  

***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

   

   

  

	Experimental flow	 	 	 	 	 
	 	Activity	 	Description	Performed by	 
	[***]	[***]	 	[***] [***]	[***]	 
	[***]	[***]	 	[***]	[***]	 
	[***]	[***]	 	[***]	[***]	 
	[***]	[***]	 	[***]	[***]	 
	[***]	[***]	 	[***]	[***]	 
	[***]	[***]	 	[***][***][***][***]	[***]	 
	[***]	[***]	 	[***]	[***]	 

  
 ***Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

   

   

  
 Additional
Material Transfer to Support the Program:
  

	 	[***]	[***]
	[***]	[***]	 
	[***]	[***]	[***] [***]
	[***]	[***]	 
	[***]	[***]	 
	[***]	[***]	[***] [***]
	[***]	[***]	 

  
 ***Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

   

   

  

SCHEDULE 1.85

 
 SELECTED
TARGETS
 (as of the Effective Date)

 
 TARGET 1:

 
 [***][***][***][***][***][***]

 
 [***][***][***][***]

 
 TARGET 2:

 
 [***]

 
 TARGET 3:

 
 [***]

 
 ***Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.6

   
 

Exhibit 10.6

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
  
 CO-DEVELOPMENT AND LICENSE AGREEMENT
  
 Between
  
 Zhejiang Medical Corporation
  
 and
  
 AMBRX, INC.
  
 Dated as of June 14, 2013 
  
 

 

   

 
CO-DEVELOPMENT AND LICENSE AGREEMENT

 

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this
“Agreement”), effective as of June 14, 2013 (the “Effective Date”), is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and
on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal
business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a
“Party” or, collectively, as the “Parties.”
  
 RECITALS
  
 WHEREAS, Ambrx owns and/or controls Ambrx Background Technology (as hereinafter defined) and has rights to Licensed Intellectual Property Rights as hereinafter defined) with
respect to αHer2-ADC Program (as hereinafter defined);
  
 WHEREAS, ZMC is a pharmaceutical company engaged in research, development, and commercialization of pharmaceutical products, including the human therapeutic products in the
Territory (as hereinafter defined);

 

WHEREAS, ZMC desires to obtain an exclusive
license under the Ambrx Existing Patent Rights in the Territory upon the terms and conditions set forth herein, and Ambrx desires to grant such a license, in order for ZMC to develop, make, use, sell, offer for sale the Licensed Products (as
hereinafter defined) for the prevention or treatment of human diseases and human conditions in the Territory;
  
 WHEREAS, ZMC desires to obtain assistance from AMBRX and AMBRX desires to offer such assistance to ZMC to develop αHer2-ADC Program to the Licensed Products in the
Territory under the world-class standards and complete phase I human clinical trials outside the Territory and build a cGMP manufacturing facility to produce the Licensed Product for commercialization in the Territory and/or αHer2-ADC API or
αHer2-ADC Product (as hereinafter defined) outside the Territory.
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows:

 

ARTICLE 1 

DEFINITIONS

 

As used in this Agreement, the following terms
shall have those meanings set forth in this Article 1 unless the context dictates otherwise.
  
 
 

2
 

   

 
 

		1.1	“Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control
with such Person. A Person shall be deemed to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, , whether through the ownership of fifty percent (50%)
or more of the voting securities of such Person by voting agreement, by contract or otherwise.

  

		1.2	“Her2” shall mean v-erb-b2 erythroblastic leukemia viral oncogene homolog having a Genbank ID number of 2064 and a protein
sequence as shown in Exhibit 1.

  

		1.3	“αHer2-Antibody” shall mean an Antibody that primarily binds to Her2. 

 

		1.4	“αHer2-ADC” shall mean an Antibody Drug Conjugate (ADC) which is capable of binding primarily to Her2 and being conjugated to one cytotoxic
payload. For clarity, αHer2-ADC includes ADC that has been conjugated to one cytotoxic payload. 

  

		1.5	“αHer2-ADC API” shall mean αHer2-ADC in compliance with regulatory requirements by CFDA in the Territory, the FDA in the United States and
other such appropriate Regulatory Authority and suitable as an active pharmaceutical ingredient for pharmaceutical or biological preparation. 

 

		1.6	“αHer2-ADC Candidate(s)” shall mean αHer2-ADC controlled and provided by AMBRX to ZMC for further evaluation under the αHer2-ADC
Program to determine suitability for continued development for regulatory approval and commercialization. 

  

		1.7	“αHer2-ADC Program” shall mean development, preclincal and clinical activities directed by the joint Steering Committee
and undertaken by ZMC to develop an αHer2-ADC API and/or αHer2-ADC Product from αHer2-ADC Candidate(s). 

  

		1.8	“αHer2-ADC Product” shall mean any pharmaceutical or biological preparation in final form containing αHer2-ADC API.
For clarity, different formulations or dosage strengths of a given αHer2-ADC API shall be considered the same αHer2-ADC Product for purposes of this Agreement. 

 

		1.9	“AMBRX Background Technology” shall mean Know How and AMBRX Patent Rights, including inventions, discoveries, improvements, processes, methods,
protocols, formulas, compositions, data, inventions, know-how and/or trade secrets, patentable or otherwise, which are owned and/or Controlled by AMBRX or any of its Affiliates as of the Effective Date or during the Term of this
Agreement.

  

		1.10	“AMBRX Existing Patent Rights” shall mean all Patent Rights owned or

 

 

 
3
 

   

   

Controlled by or licensed to Ambrx as of the Effective Date which
is related to αHer2-ADC as shown in Exhibit X.

 

		1.11	“AMBRX Improvements” shall mean all Patent Rights and Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have
utility by one or more employees or Third Parties working on behalf of AMBRX, in connection with the development of Licensed Products or in the course of engaging in αHer2-ADC Program during the Term of this Agreement without involvement of
any employees from ZMC.

  

		1.12	“AMBRX Know-How” shall mean all Confidential Information & Materials, technical knowledge, materials, cells or cell lines, software, trade secrets,
Know How, process technology and other knowledge, information, or technology in possession of AMBRX and its Affiliate, as of the Effective Date and during the Royalty Term, concerning subject matter relating to Licensed Products, or which otherwise
are useful for the development, manufacture, use or sale of Licensed Products.

  

		1.13	“AMBRX Patent Rights” shall mean any Patent Rights Controlled or owned by AMBRX as of the Effective Date or during the Term of
this Agreement. For clarity, AMBRX Patent Rights excludes AMBRX Existing Patent Rights.

  

		1.14	“Antibody(ies)” shall mean a full length antibody which is a “Y”-shaped protein consisting of four polypeptide
chains: two identical heavy chains and two identical light chains connected by disulfide bonds, capable of binding to an antigen, whether polyclonal, monoclonal, human, humanized, chimeric, murine, synthetic or from any other
source.

  

		1.15	“Antibody Drug Conjugate” or “ADC” shall mean an Antibody which 1) has undergone modification through the incorporation, substitution
or addition of one or more non-naturally encoded amino acids (i.e., amino acids other than the 20 naturally-encoded amino acids), 2) provides one or more specific site(s) in the amino acid sequence of the Antibody suitable for conjugation, and 3) is
suitable and capable of being conjugated, linked or attached to one or more cytotoxic payload(s) via one or more specific site(s). For clarity, ADC includes an Antibody that has been conjugated, linked or attached to one or more cytotoxic payload(s)
via one or more specific site(s).

  

		1.16	“Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in
carrying out activities hereunder or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject by law or by agreement, and shall include all statutes, enactments, acts of legislature, laws,
ordinances, rules, regulations, notifications, guidelines, policies, directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority or other governmental entity in such
jurisdictions.

  

 

 
4
 

   

   

		1.17	“Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March
31, June 30, September 30 and December 31.

 

		1.18	“Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on
December 31.

  

		1.19	“CFDA” shall mean China Food and Drug Administration in the People’s Republic of China, or any
successor thereto.

  

		1.20	“cGMP” or “Current Good Manufacturing Practice” shall mean the applicable then-current standards for
manufacturing of pharmaceuticals or biologicals, as set forth in the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C §§ 301, as amended from time to time, together with any similar standards of good manufacturing practice as
required by CDA and other relevant Regulatory Authority.

  

		1.21	“Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with
respect to any objective, reasonable, diligent, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the
research, discovery, development or commercialization of any Licensed Product (or αHer2-ADC, αHer2-ADC Candidate, αHer2-ADC API, αHer2-ADC Product, as applicable) by either Party, such efforts shall be substantially
equivalent to those efforts and resources commonly used by such Party for a product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account
efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval, the profitability and commercial potential of the
product to the applicable Party (including the amounts payable to licensors of patent or other intellectual property rights), alternative products and other relevant factors.

  

		1.22	“Confidential Information & Material” shall mean any and all proprietary and/or confidential information, materials, and
data, including all scientific, pre-clinical, clinical, regulatory, process, formulation, manufacturing, marketing, financial and commercial information or data, compounds, cells, cell lines, whether communicated in writing or orally or by any other
method, which are provided by one Party to the other Party prior to or during the Term of this Agreement.

  

		1.23	“Control”, “Controls” or “Controlled by” shall mean with respect to any Existing Patent
Rights, Patent Rights, Know-How, Confidential Information & Materials, or other intellectual property assets or other items or rights, as applicable, the possession of (whether by ownership or license or other right, other than pursuant to a
license under this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, such item or right as provided for

 

 

 
5
 

   

   

herein without violating the terms of any agreement or other
arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense.

 

		1.24	“Covered By” shall mean, with respect to Patent Rights: materials, products and services developed, manufactured, used, sold or
provided by ZMC, which but for the License, would infringe a Valid Claim of such Patent Rights in the Territory in which such products or services are developed, used, manufactured, sold or provided by ZMC, respectively.

 

		1.25	“Effective Date” shall mean the date first set forth above.

 

		1.26	“FDA” shall mean the United States Food and Drug Administration, or any successor thereto.

 

		1.27	“Field” shall mean the field of αHer2-ADC including all human indications and uses, such as diagnosis, prevention, and treatment of human diseases
and conditions associated with αHer2. For clarity, Field is for human use only and excludes all non-human indications and uses. 

  

		1.28	“First Commercial Sale” shall mean, with respect to Licensed Product, the first sale to the general public of such Licensed Product in the Territory
after all required marketing and pricing approvals have been granted, or otherwise permitted, by the governing health authority of Territory such as CFDA. “First Commercial Sale” shall not include the provision of any Licensed Product
for use in clinical trials or for compassionate use prior to the receipt of necessary Marketing Authorization.

  

		1.29	“Full Time Equivalent” or “FTE” shall mean a dedicated full-time employee or contractor of Ambrx, as the case may be, or in the case
of less than a full-time dedicated person, a full-time, equivalent person year, each based upon the total of one thousand six hundred eighty (1680) hours per year of work on activities hereunder.

 

		1.30	“FTE Rate” means the yearly rate at which ZMC will fund Ambrx FTEs.

 

		1.31	“China GAAP” shall mean Generally Accepted Accounting Principles for the People’s Republic of
China.

  

		1.32	“Generic Competition” shall mean the sale of products containing αHer2-ADC in the Territory by a Third Party.

  

		1.33	“Joint Development Committee” shall mean the entity organized and acting pursuant to Section 3.

 

		1.34	“Joint Development Technology” or “Joint Improvements” shall mean all Inventions and Know-How first (i)
conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by, on one hand, one or more employees or

  
 
 

 
6
 

   

   

Third Parties working on behalf of ZMC, on the
one hand, with one or more employees or Third Parties working on behalf of AMBRX, on the other hand, in connection with the development of Licensed Products or in the course of engaging in αHer2-ADC Program, as well as any and all Patents
covering the same.
  

		1.35	“Know-How” shall mean unpatented technical and other information or materials which are not in the public domain including information comprising or
relating to discoveries, inventions, data, designs, formulae, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development or
αHer2-ADC Program), cells or cell lines (including cells or cell lines producing αHer2 Antibody or αHer2 ADC), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical,
pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries and information contained in submissions to and information from ethical committees and regulatory
authorities. Know-How includes rights protecting Know-How. The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, and/or a development relating to the item, is (and remains)
not known to the public.

  

		1.36	“License” shall mean all of the rights granted by Ambrx to ZMC by this Agreement under the Licensed Intellectual Property
Rights pursuant to Sections 2.1.1 and 2.1.2.

 

		1.37	“Licensed Intellectual Property Rights” shall mean (a) AMBRX Know How; and (b) AMBRX Existing Patent
Rights.

  

		1.38	“Licensed Products” shall mean any aHER2-ADC product related to αHer2-ADC products, that meets any of the following criteria: (i) the development,
use, manufacture or sale of any such aHER2-ADC product is or will be Covered By a Valid Claim of any Existing Patents and/or AMBRX Patent Rights; or (ii) such product (a) is not described in clause (i) above and (b) is developed, manufactured, sold
or provided using AMBRX Know-How. For the avoidance of doubt, Licensed Products include αHer2-ADC, αHer2-ADC Candidate, αHer2-ADC API, and αHer2-ADC Product.

 

		1.39	“Marketing Authorization” shall mean all approvals from CFDA necessary to market and sell a Licensed Product in the Territory
or a Regulatory Authority in a corresponding jurisdiction outside Territory.

  

		1.40	“Net Sales” shall mean (I) to AMBRX, the revenue AMBRX received from a Third Party by transferring, assigning or licensing Phase I Clinical Data to such
Third Party, or from the commercialization of an αHer2-ADC Product outside Territory whereas the Market Authorization of such αHer2-ADC Product is

 

 

 
7
 

   

   

based on Phase I Clinical Data, excluding FTEs, reimbursements
and deductions as defined in 1.40(II)(a)-(i); and

 

(II) to ZMC, the gross invoice price (not
including value added taxes, sales taxes, or similar taxes) of Licensed Product sold by ZMC or its Affiliate to the first Third Party in which ZMC has no equity interest after deducting, if not previously deducted, from the amount invoiced or
received:
  

		(a)	trade and quantity discounts actually given other than early payment cash discounts;

 

		(b)	returns, rebates, charge backs and other similar fees and allowances actually taken;

 

		(c)	retroactive price reductions that are actually allowed or granted;

 

		(d)	deductions to gross invoice price of Licensed Product imposed by Regulatory Authorities or other governmental entities;

 

		(e)	sales commissions, distribution fees and other similar fees paid to Third Party distributors and/or selling agents actually
paid;

  

		(f)	early payment cash discounts, transportation and insurance, and custom duties actually taken; and

 

		(g)	the standard inventory cost of devices or delivery systems used for dispensing or administering or delivering Product;

 

		(h)	interest charge, late payment penalty and other similar fees; and

 

		(i)	uncollectable unpaid invoices.

  
 Any individual items that are estimated and deducted in calculating Net Sales shall be periodically (but at least on a calendar quarter basis) trued up and adjusted by ZMC
consistent with its customary practices and in accordance with China GAAP. Any deductions subsequently reversed shall be included in Net Sales for the royalty period in which such deductions are reversed. The calculation of Net Sales hereunder shall
be in accordance with China GAAP and ZMC’ and/or its Affiliates’ customary accounting policies, applied consistently across periods, and

 

(a)  Transfer or sale
of a Licensed Product within ZMC, between ZMC and an Affiliate, or between ZMC and a non-Affiliate Third Party in which ZMC has equity interest shall not be considered a sale, commercial use or disposition for the purpose of the foregoing
paragraphs;

 

(b)  in the event that
ZMC has to transfer or sell any Licensed Product to a non-Affiliate Third Party in which ZMC has equity interest, ZMC and AMBRX shall

 

 
8
 

   

   

jointly discuss and determine the value of Net Sales;
and
  

(c) in the event that ZMC receives consideration for any Licensed
Products in the case of transactions not at arm’s length with a non-Affiliate of ZMC, Net Sales will be calculated based on the fair market value of such consideration or transaction, assuming an arm’s length transaction made in the
ordinary course of business.
  

		1.41	“Party” shall mean AMBRX or ZMC and, when used in the plural, shall mean AMBRX and ZMC.

 

		1.42	“Patent Rights” shall mean any and all rights under any of the following, whether existing now or in the future, and whether or not filed: (i) a United
States, international or foreign patent, utility model, design registration, certificate of invention, patent of addition or substitution, or other governmental grant for the protection of inventions or industrial designs anywhere in the world,
including any reissue, renewal, re-examination or extension thereof; and (ii) any application for any of the foregoing, including any international, provisional, divisional, continuation, continuation-in-part, or continued prosecution
application.

  

		1.43	“Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company,
partnership or other business entity, or any government or any agency or political subdivision thereof.

  

		1.44	“Phase I Clinical Data” shall mean data, information, or regulatory filings related to Phase I Clinical Trial in a country that
would satisfy the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent thereof.

  

		1.45	“Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR
312.21(a), as may be amended, or the foreign equivalent thereof.

  

		1.46	“Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR
312.21(b), as may be amended, or the foreign equivalent thereof.

  

		1.47	“Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR
312.21(c), as may be amended, or the foreign equivalent thereof.

  

		1.48	“Regulatory Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing,
reimbursement and/or pricing of an αHer2-ADC API or αHer2-ADC Product in the Territory or outside Territory, including, in the Territory, CFDA, and in the United States, the United States Food and Drug Administration and any successor
governmental authority having substantially the same function

 

		1.49	“Royalty Term” shall mean the period commencing with the First Commercial

 

 

 
9
 

   

   

Sale of the Licensed Product and continue until the expiration of
the later of: (i) the last-to-expire Valid Patent Claim that would be infringed by the manufacture, use or sale of Licensed Product in the Territory; or (ii) the period of twenty (20) years following the First Commercial Sale of such Licensed
Product in Territory.
  

		1.50	“Territory” shall mean all cities, zones, provinces, territories and other divisions or regions in and throughout the
People’s Republic of China.

  

		1.51	“Third Party” shall mean a person or entity other than Ambrx, ZMC or their Affiliates.

 

		1.52	“Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent Rights that has not been (i) held permanently revoked,
unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (ii) rendered unenforceable through disclaimer or otherwise, (iii)
abandoned or (iv) permanently lost through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending patent application within the Patent Rights that (i) has been asserted and continues to be
prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling.

  

		1.53	“ZMC Improvements” shall mean all Patent Rights and Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have
utility by one or more employees or Third Parties working on behalf of ZMC, in connection with the development of Licensed Products or in the course of engaging in αHer2-ADC Program without any involvement with employee(s) of
AMBRX.

  

		1.54	“ZMC Manufacturing Facility” shall mean a manufacturing facility to be built or acquired and operated by ZMC or on behalf of ZCM, which 1) meets the
regulatory requirement under CFDA for Marketing Authorization of the Licensed Product in the Territory, and 2) meets the cGMP requirements under United State FDA to manufacture αHer2-ADC API or αHer2-ADC Product and passes the inspection
from FDA.

  

ARTICLE 2 

LICENSE; DEVELOPMENT AND COMMERCIALIZATION

 

		2.1	EXCLUSIVE LICENSE GRANT BY AMBRX.

 

		2.1.1	Subject to the rights retained by AMBRX in Sections 2.1.3 & 2.1.4, AMBRX hereby grants to ZMC an exclusive right and license in the Field throughout the Territory,
with the right to grant sublicenses subject to Section 2.7.1, under AMBRX Existing Patents to develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products.

 

		2.1.2	Subject to the rights retained by AMBRX in Sections 2.1.3 & 2.1.4,

 

 

 
10
 

   

   

AMBRX hereby grants to ZMC an exclusive right and
license in the Field throughout the Territory, with the right to grant sublicenses subject to Section 2.7.1, under AMBRX Know-How to develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensed
Products.
  

		2.1.3	AMBRX shall retain non-exclusive and sublicensable rights under the foregoing Licenses in Section 2.1.1 and 2.1.2 solely as are necessary to
perform documented research activities in the Territory and AMBRX shall notify ZMC of such activities.

  

		2.1.4	AMBRX shall retain all rights under Licensed Intellectual Property Rights unless otherwise specifically and expressly set forth in this
Agreement.

  

		2.2	NON-EXCLUSIVE LICENSE GRANT BY AMBRX. AMBRX hereby grants to ZMC a non-exclusive right and license in the Field in a mutually approved jurisdiction outside the Territory,
under Licensed Intellectual Property Rights, for the sole purpose of conducting regulatory activities for Phase I Clinical Data in said jurisdiction for the Licensed Products; provided that Australia is deemed as a mutually approved jurisdiction as
of the Effective Date of this Agreement for the purpose of this section and the Joint Steering Committee may amend such jurisdiction from time to time.

 

		2.3	NON-EXCLUSIVE SUBLICENSE GRANT BY AMBRX. In the event that, during the term of this Agreement and after the Effective Date, AMBRX licenses from any Third Party rights in
the Field to any Valid Claim of any issued patent or patent application issued to a Third Party that shall be necessary for ZMC’s exercise of its rights pursuant to Section 2.1 herein (a “AMBRX Third Party License”) in the
Territory, AMBRX shall promptly so notify ZMC of the terms of such AMBRX Third Party License and the rights covered by such license. Upon request by ZMC, and to the extent not prohibited by such AMBRX Third Party License, AMBRX shall grant to ZMC,
and does hereby grant to ZMC, a non-exclusive right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses subject to Section 2.7.1, under the rights granted to AMBRX in the AMBRX Third Party License. AMBRX
shall use reasonable efforts to secure the right to grant the sublicense under this Section in any AMBRX Third Party License. If ZMC is required to pay certain royalty payment to such a Third Party under AMBRX Third Party License, ZMC is entitled to
offset such royalty payment pursuant to the terms in Section 6.6.

  

		2.4	NO ASSERTION BY AMBRX. So long as ZMC is in compliance with the terms and conditions of this Agreement, AMBRX shall not assert against any claims for infringement of any
AMBRX Background Technology owned or Controlled by AMBRX covering ZMC’s permitted exercise of its rights hereunder solely for the purpose of developing, making, having made, using, selling, offering for sale, having sold any Licensed Product
in the Territory or solely for the purpose of engaging permitted regulatory activities for Phase I Clinical Data in Australia or a

  
 

 
11
 

   

   

mutually approved jurisdiction outside the Territory pursuant to
Section 2.2.
  

		2.5	NON-EXCLUSIVE LICENSE GRANT BY AMBRX. AMBRX hereby grants to ZMC a non-exclusive, sub-licensable, royalty-free right and license in the Territory, under AMBRX’s
interest in the AMBRX Improvements, to use, develop and exploit AMBRX Improvements only for Licensed Products.

  

		2.6	EXCLUSIVE LICENSE GRANT BY ZMC. As the consideration to the rights granted by AMBRX under Section 2.3, ZMC hereby grants to AMBRX an exclusive (even as to ZMC),
sub-licensable, royalty-free right and license in the world outside the Territory, under ZMC’s interest in the ZMC Improvements and Joint Improvements, to use, develop and exploit ZMC Improvements and Joint
Improvements.

  

		2.7	NON-EXCLUSIVE LICENSE GRANT BY ZMC. As the consideration to the rights granted by AMBRX under Section 2.5, ZMC hereby grants to AMBRX a
non-exclusive, sub-licensable, royalty-free right and license in the Territory, under ZMC’s interest in the ZMC Improvements, to use, develop and exploit ZMC Improvements.

 

		2.8	TRANSFER OR EXCLUSIVE LICENSE GRANT BY ZMC REGARDING PHASE I CLINICAL DATA. To the extent permissible by Applicable Law, ZMC shall transfer and assign to AMBRX ownership
of all preclinical, clinical, regulatory filings, and Phase I Clinical Data in Australia or a mutually approved jurisdiction outside the Territory, provided however, if such transfer and assignment is not legally permitted, ZMC hereby grants to
AMBRX an exclusive (even as to ZMC), sub-licensable, transferable, perpetual, irrevocable, non-terminable, royalty-bearing right and license in the world outside the Territory, under ZMC’s interest in information including regulatory filings
and Phase I Clinical Data, to use, develop and exploit such information by AMBRX, its Affiliate or a Third Party authorized by AMBRX. ZMC shall make reasonable effort to perfect such transfer, assignment or exclusive license under this
section.

  

		2.9	SUBLICENSES.

  

		2.9.1	Any sublicense by ZMC of the rights granted to ZMC under Sections 2.1 and 2.2 shall obtain written approval from the Joint Steering Committee first, and then AMBRX prior
written consent not unreasonably withhold or delayed, be consistent with the terms of this Agreement, include an obligation for the sublicensee to comply with the applicable obligations of the sublicensing Party set forth in this Agreement. ZMC
shall not grant any sublicense hereunder that would impose obligations on AMBRX greater than those obligations of AMBRX contained in this Agreement. ZMC shall provide to AMBRX a copy of each sublicense hereunder, which shall permit verification by
AMBRX of compliance with the provisions of this Agreement. Parties expressly agree that AMBRX 1) shall reasonably withhold the written consent if ZMC sublicenses its

 

 

 
12
 

   

   

substantially entire rights and interests granted herein to a
Third Party unless Parties negotiate in good faith to reach an agreement prior to such sublicense, and 2) shall not unreasonably withhold such consent if ZMC enters such sublicense for the purpose of distributing or supplying Licensed Products in
the Territory or otherwise expressed approved herein or by the Joint Steering Committee.
  

		2.9.2	With respect to any sublicense by one Party of the rights granted to said Party under Sections 2.5, 2.6 and 2.7, said Party shall not grant any
sublicense hereunder that would impose obligations on the other Party greater than those obligations of the other Party contained in this Agreement.

 

		2.9.3	Both Parties expressly acknowledges and agrees that WUXI AppTec Co. Ltd shall be deemed as an approved sublicensee under Section 2.8.1 solely for the purpose of conducting
preclinical and clinical trials and manufacturing the Licensed Product in Territory prior to the completion and operation of ZMC’s Manufacturing Facility. Parties expressly acknowledges that ZMC shall enter a service agreement with WUXI AppTec
within one month from the Effective Date (“ZMC–WUXI Service Agreement as shown in Exhibit 3) for the purpose of developing, conducting preclinical and clinical trials and manufacturing the Licensed Product in
Territory.

  

		2.10	NO OTHER GRANT OF RIGHTS. Except as expressly provided herein, nothing in this Agreement will be construed to confer any ownership interest, license or other rights upon
Licensee by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of AMBRX, or any other entity, regardless of whether such technology, intellectual property rights, products or
biological materials are dominant, subordinate or otherwise related to any AMBRX Background Technology or Licensed Intellectual Property Rights.

 

ARTICLE 3 

JOINT STEERING COMMITTEE

 

		3.1	MEMBERS. The Parties shall establish a Joint Steering Committee (the “Joint Steering Committee”), which shall comprise six (6)
members, three (3) designated by ZMC and three (3) by AMBRX (or such other number as the Parties may agree in writing). The initial members of the Joint Steering Committee are set forth on Exhibit 5. Any member of the Joint Steering Committee may be
represented at any meeting by a designee who is appointed by the Party designating such member for such meeting and who has authority to act on behalf of such member, as evidenced by written notice from the Party designating such member to the
chairperson of the Joint Steering Committee. The chairperson of the Joint Steering Committee shall be one of the members designated by Ambrx during the first three-year period following the Effective Date and one of the
members

 

 

 

 
13
 

   

 
 

designated by ZMC thereafter. The initial chairperson is
designated on Exhibit 5. Each Party shall be free to replace its representative members with new appointees who have authority to act on behalf of such Party on the Joint Steering Committee, on written notice to the other Party.

 

		3.2	RESPONSIBILITIES. The Joint Steering Committee shall be responsible for (a) approving and providing implementation plans to ZMC that are suitable for WUXI AppTec to
perform the work plans defined in the ZMC-WUXI Service Agreement or sub-agreement thereof and (b) planning, overseeing and directing evaluation and review of αHer2-ADC Candidates, selection of αHer2-ADC API or αHer2-ADC Product
from αHer2-ADC Candidates based on the performance of αHer2-ADC Program, the development and commercialization of, and regulatory filings relating to, Licensed Products (including αHer2-ADC API or αHer2-ADC Product) in
Territory or Phrase I Clinical Trials of Licensed Products outside the Territory, including, without limitation, overseeing all research, development, pre-clinical, and clinical trial activities, coordination of activities in building a manufacture
facility in compliance with cGMP requirements and overseeing early stage manufacture, preclinical, and clinical development activities to be conducted by a Third Party regarding the Licensed Products pursuant to Section 2.8.

 

		3.3	MEETINGS. The Joint Steering Committee shall meet as frequently as the Parties deem appropriate during the first three-year period following the Effective Date but no less
frequently than once a Calendar Quarter (or more frequently, as agreed upon by the Parties) thereafter, on such dates and at such times as the Parties shall agree, on ten (10) days’ written notice to the other Party unless such notice is
waived by the other Party. The Joint Steering Committee may convene or be polled or consulted from time to time by means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate by the Parties. To the extent
that meetings are held in person, they shall alternate between the offices of the Parties unless the Parties otherwise agree. The chairperson shall be responsible for sending notices of meetings to all members.

 

		3.4	DECISIONS.

  

		3.4.1	A quorum for a meeting of the Joint Steering Committee shall require the presence of at least two AMBRX members (or designees) and at least two ZMC members (or designees)
in person or by telephone. All decisions made or actions taken by the Joint Steering Committee shall be made unanimously by its members, with the AMBRX members present at a meeting cumulatively having one vote and the ZMC members present at a
meeting cumulatively having one vote.

  

		3.4.2	In the event that unanimity cannot be reached by the Joint Steering Committee with respect to a matter that is a subject of its decision-making
authority within thirty (30) days after the matter is first brought before the Joint Steering Committee, then the matter shall be decided unanimously

 

 

 
14
 

   

   

by the Chairman of ZMC and the CEO of AMBRX or
by their designated representative. If no such decision is made then the chairperson of the Joint Steering Committee shall make a final decision in good faith, provided however, in the event such decision is relevant to activities outside Territory
or cGMP compliance, such decision shall be made by a member designated by AMBRX.
  

		3.5	MINUTES. Within fifteen (15) days after each Joint Steering Committee meeting, the chairperson of the Joint Steering Committee shall prepare and distribute minutes of the
meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint Steering Committee at such meeting. The chairperson of the Joint
Steering Committee shall be responsible for circulation of all draft and final minutes. Draft minutes shall be circulated to all members of the Joint Steering Committee sufficiently in advance of the next meeting to allow review and comment prior to
the meeting. Minutes shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee.

 

		3.6	TERM. The Joint Steering Committee shall exist until the expiration of the Royalty Term for all Licensed Products.

 

ARTICLE 4 

DEVELOPMENT AND COMMERCIALIZATION

 

		4.1	DEVELOPMENT EFFORT BY ZMC. ZMC shall, either itself or through its Affiliates or Third Parties mutually approved by the Join Steering Committee, at ZMC’s sole
expense, use Commercially Reasonable Efforts to conduct the development and commercialization of Licensed Products within the Territory. ZMC shall exercise in the performance of such development commercially reasonable effort, technical skill and
competence. Such diligent efforts shall include, without limitation, the funding and expenditure by ZMC to perform the work plans as defined in the ZMC-WUXI Service Agreement (“WORK PLAN” as shown in Exhibit 4, which is incorporated
herein in its entirety as a part of the this Agreement and the αHer2-ADC Program and can be revised by the Joint Steering Committee from time to time) and the development and commercialization of Licensed Products. In addition, without
limiting the foregoing, ZMC shall use Commercially Reasonable Efforts to achieve the following objectives (“ZMC MILESTONES”):

 

		4.1.1	ZMC either on its own, on behalf or through WUXI AppTec pursuant to Section 2.8) or any other Third Party approved by the Joint Steering Committee from time to time, shall
use Commercially Reasonable Efforts to engage in the performance of the WORK PLAN and/or the αHer2-ADC

  
 

 
15
 

   

   

Program, under the guidance and supervision of
the Joint Steering Committee, to evaluate αHer2-ADC Candidate(s) provided by AMBRX and select αHer2-ADC API or αHer2-ADC Product therefrom for development and commercialization.

 

		4.1.2	ZMC either on its own, on behalf or through WUXI AppTec (pursuant to Section 2.8) or any other Third Party approved by the Joint Steering Committee from time to time,
shall use Commercially Reasonable Efforts to pursue preclinical and initiate clinical trial evaluations for Licensed Products (including αHer2-ADC API or αHer2-ADC Product) under CFDA or the equivalent regulatory agency required for
Marketing Authorization and thereafter commercialize the Licensed Product in Territory; provided however, should ZMC decide to build or acquire a ZMC Manufacturing Facility in Territory suitable to manufacture Licensed Product, such ZMC
Manufacturing Facility shall be to a world class standard meeting cGMP requirements with the capacity to supply αHer2-ADC API on a world-wide scale, provided further that cGMP standard is determined by a Third Party mutually approved and
selected by both Parties, and thereafter, ZMC shall use Commercially Reasonable Efforts to transfer any information and materials related to the performance of the WORK PLAN and/or the αHer2-ADC Program and/or manufacturing of Licensed
Products from WUXI AppTech or a Third Party herein to such ZMC Manufacturing Facility.

  

		4.1.3	ZMC either on its own, on behalf or through any Third Parties mutually approved by the Joint Steering Committee, shall use Commercially Reasonable Efforts to pursue
preclinical and Phase I Clinical Trial for Licensed Products under a Regulatory Authority in Australia as mutually agreed upon by Parties or a mutually approved country outside Territory from time to time by the Join Steering Committee; thereafter,
ZMC shall promptly provide to the Joint Steering Committee and AMBRX copies of all correspondence related the Licensed Product delivered to or received from the Regulatory Authority and diligently assist AMBRX to further transfer Phase I Clinical
Data to AMBRX or transferees to whom AMBRX transfers in countries outside Territory; provided that regulatory filings outside the Territory shall be owned by AMBRX, to the extent permitted by Applicable Law or otherwise exclusively licensed to AMBRX
pursuant to Section 2.8 of this Agreement. Upon obtaining Phase I Clinical Data, ZMC has the first right, but not obligation, to negotiate with AMBRX on terms and financial obligations for ZMC to engage in Phase II Clinical Trials or Phase III
Clinical Trials outside Territory.

  

provided, however, that, upon request by ZMC,
ZMC shall present to the Joint Steering Committee and AMBRX, revisions to the milestones described in clauses 4.1.1 through 4.1.3 above, or in the designated time periods, with supporting evidence of technical difficulties or delays in financing,
clinical
  

 

 
16
 

   

 
 

studies, or regulatory processes that AMBRX shall deem
appropriate at its sole discretion.
  

ARTICLE 5 

SUPPORT AND ASSISTANCE

 

		5.1	EFFORTS BY AMBRX . AMBRX shall, either itself or through its Affiliates, use commercially reasonable efforts to provide technical and consulting assistance or other
services as requested by ZMC, at ZMC’s expense, which are necessary for ZMC to exercise its rights under this Agreement to achieve ZMC Milestones under Sections 4.1.1 to 4.1.3. In addition, without limiting the foregoing, AMBRX shall use
commercially reasonable efforts to undertake the following responsibilities (“AMBRX RESPONSIBILITIES”):

  

		5.1.1	AMBRX shall assist ZMC to secure arrangement(s) with Third Party contract research organization(s) and/or consultant(s) under Section 4.1, approved by the Joint Steering
Committee, to conduct development, preclinical and clinical development activities for the Licensed Products in the Territory and produce the Licensed Products on behalf of ZMC before the transferring of clinical and/or manufacturing programs and
protocols from said Third Party under Section 4.1 to ZMC Manufacturing Facility.

  

		5.1.2	AMBRX shall assist ZMC to select a Third Party under Section 4.1.3, approved by the Joint Steering Committee, to conduct preclinical and Phase I
Clinical Trials and evaluation of Phase I Clinical Data for Licensed Product outside the Territory.

  

		5.1.3	Should ZMC decide to build or acquire a ZMC Manufacturing Facility in Territory under Section 4.1.2, AMBRX shall assist ZMC, during the construction of or acquiring ZMC
Manufacturing Facility, to communicate with United States FDA and recommend Third Party consultant(s) having experience in FDA inspections on cGMP requirements (or having worked at FDA) at the expenses of ZMC, as necessary for ZMC to prepare for FDA
inspection of ZMC Manufacturing Facility and achieve ZMC Milestones under Section 4.1.

  

		5.2	TECHNICAL ASSISTANCE: Parties agree that AMBRX will dispatch two FTEs during the first three years period following the Effective Date, provided however, the Joint
Steering Committee may request from time to time and ZMC may at its sole discretion approve additional FTEs from AMBRX to provide technical and consulting assistance or other services to ZMC, as necessary for ZMC to achieve ZMC Milestones under
Section 4.1.

  

ARTICLE 6 

MONETARY OBLIGATIONS, REPORTS AND AUDITS

 

		6.1	PAYABLE BY ZMC. Subject to the terms and conditions of this Agreement, ZMC shall pay AMBRX royalties as set forth in Section
6.2.

  

 

 
17
 

   

   

		6.2	PATENT ROYALTIES. ZMC shall pay Ambrx royalties in an amount equal to the following percentage of Net Sales of Licensed Products sold by ZMC or
its Affiliates:

  

		6.2.1	[***] of such Net Sales in the Territory in each Calendar Year up to and including Net Sales of [***];

 

		6.2.2	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding of [***] up to and including of [***];
and

  

		6.2.3	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***].

 

		6.3	KNOW-HOW ROYALTY. Notwithstanding the provisions of Section 6.2 above, in the event that and after the manufacture, use or sale of Licensed Products by ZMC or its
Affiliates would not infringe a Valid Patent Claim, or Existing Patents covering the Licensed Products are deemed invalid or have expired, the Net Sales of such Licensed Products in the Territory shall remain the same during the Royalty Term in
determining the applicable royalty rate according to Section 6.2, provided however, the Net Sales of such Licensed Products shall be [***] if Generic Competition exists.

 

		6.4	ROYALTY TERM. Royalties on Licensed Product at the rates set forth above shall be paid during the Royalty Term, which shall commence with the First Commercial Sale of the
Licensed Product and continue until the expiration of the later of: (i) the last-to-expire Valid Patent Claim of AMBRX Existing Patent Rights that would be infringed by the manufacture, use or sale of Licensed Product in the Territory; or (ii) the
period of twenty (20) years following the First Commercial Sale of such Licensed Product in Territory.

  

		6.5	PAYABLE BY AMBRX. AMBRX shall pay ZMC royalties in an amount equal to the following percentage of Net Sales of Phase I Clinical Data transferred
or licensed by AMBRX to a Third Party:

  

		6.5.1	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data without making additional efforts as defined in
Sections 6.5.2 to 6.5.4;

  

		6.5.2	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data after AMRBX initiates Phase II Clinical Trial
outside Territory;

  

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  

 

 
18
 

   

   

		6.5.3	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data after AMRBX initiates Phase III Clinical Trial
outside Territory; and

  

		6.5.4	[***] of such Net Sales if AMBRX or its Affiliate(s) commercializes and sales a Licensed Product outside Territory, the Market Authorization of
such Licensed Product is based on Phase I Clinical Data.

 

		6.6	THIRD PARTY ROYALTY SET-OFF. If ZMC under AMBRX Third Party License is required to pay royalty as necessary for ZMC’s exercise of its rights hereunder in Territory
pursuant to Section 2.3 or obtain a license from a Third Party due to infringement action under Section 7.4, it may offset any royalty payments actually paid by ZMC to such Third Party due thereunder with respect to sales of Licensed Products
against the royalty payments that are due to AMBRX; provided that in no event shall the royalty payments to AMBRX with respect to such Licensed Products be reduced by more than [***] of the amount otherwise due.

 

		6.7	FUNDING FOR DEVELOPMENT. ZMC shall be responsible and pay the full amounts related to the development efforts made by ZMC as described under Section 4.1, ZMC Milestone as
described under Sections, and assistance provided by AMBRX as described under Section 5.1.

  

		6.8	THIRD PARTY PAYMENTS. ZMC shall be responsible for and at its sole expense shall pay all amounts owing to WUXI APPTEC and any Third Party under Sections 4.1.1 to 4.1.3 and
5.1.1 to 5.1.3 as necessary for ZMC to achieve ZMC Milestones. The invoice from WUXI APPTEC OR OTHER Third Party approved within the WORK PLAN or incurred by AMBRX for a given Calendar Quarter will be sent to ZMC within forty-five (45) days
following the end of such Calendar Quarter. Such invoice reimbursable by ZMC shall be payable within thirty (30) days after ZMC receives such invoice.

 

		6.9	FTE PAYMENTS TO AMBRX. In consideration of technical assistance provided by AMBRX pursuant to Sections 5.2 and 5.3, ZMC shall fund a minimal of two AMBRX FTEs during the
first three years period following the Effective Date at the FTE Rate of [***] per FTE per Calendar Year. ZMC shall pay AMBRX in an amount of [***] for the two AMBRX FTEs at the beginning of each Calendar Quarter during the three years period
following the Effective Date and any additional amount quarterly if more FTEs from AMBRX are requested and approved pursuant to Section 5.2.

 

		6.10	REPORTS. During the Term following the First Commercial Sale of Licensed Product, ZMC shall furnish to Ambrx a quarterly written report for the
Calendar

  

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  

 

 
19
 

   

   

Quarter showing the gross and Net Sales of all Licensed Products
subject to royalty payments sold by ZMC and its Affiliates in the Territory during the reporting period and the royalties payable under this Agreement. Reports shall be due on the forty-fifth (45th) day following the close of each Calendar Quarter.
Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. ZMC and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to
be determined.
  

		6.11	Audits

  

		6.11.1	ACCOUNTING FIRM. Upon the written request of Ambrx and not more than once in each Calendar Year, ZMC shall permit a qualified and reputable independent certified public
accounting firm selected by AMBRX and approved by ZMC not unreasonably withhold, at AMBRX’s expense, to have access during normal business hours to such of the records of ZMC related to the production and sales of Licensed Products as may be
reasonably necessary to verify the accuracy of the royalty reports pursuant to Section 6.10 for any Calendar Year ending not more than thirty six (36) months prior to the date of such request. The accounting firm shall disclose to AMBRX and ZMC
whether the royalty reports are correct or incorrect and the amount of any discrepancy.

  

		6.11.2	ACCESS. In order to fulfill the auditing, the accounting firm so selected shall have the right to access, examine, review and copy all books or accounts of ZMC, relevant
procurement/distribution agreements and other purchase/sales contracts, purchase/sales orders, operation records, tax paid to local government, and itemized tax for the Licensed Products, and to discuss the business, operations and conditions of ZMC
with its respective directors, officers, employees, accounts, auditors, financial advisors, legal counsel and investment bankers, to the extent reasonably deemed by AMBRX as necessary for determining the accuracy of the royalty reports. ZMC shall
not unreasonably restrict the accounting firm’s access to premises of ZMC during normal business hours.

  

		6.11.3	PAYMENT AND FEES. If such accounting firm identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy
within thirty (30) days of the date AMBRX delivers to ZMC such accounting firm’s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by AMBRX, provided however, that
if such audit uncovers an underpayment of royalties by ZMC that exceeds [***] of the total royalties owed for the period in question, the fees of such

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 
 

 
20
 

   

   

accounting firm shall be equally shared by AMBRX and
ZMC.
  

		6.11.4	SUBLICENSEE. ZMC shall include in each sublicensee granted by it pursuant to this Agreement a provision requiring the sublicensee to make reports to ZMC, to keep and
maintain records of sales made pursuant to such sublicense and to grant access to such records by AMBRX’s independent accountant to the same extent required of ZMC under this Agreement.

 

		6.11.5	CONFIDENTIALITY. AMBRX shall treat all financial information subject to review under this Section 6.11 or under any sublicense agreement in accordance with the terms of
Article 8 of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with AMBRX, or with ZMC and/or its Affiliates or sublicensee, obligating it to retain all such information in confidence pursuant
to such confidentiality agreement.

  

		6.12	PAYMENT EXCHANGE RATE. All royalty payments due hereunder shall be paid in United States dollars by wire transfer to a bank account designated by AMBRX. Any payments or
portions thereof due hereunder which are not paid on the date such payments are due under this Agreement shall bear interest at a rate equal to the lesser of prime rate as reported by Citibank, New York, New York (or its successor in interest) or
the maximum rate permitted by law, calculated on the number of days such payment is delinquent. If the royalty payments are paid in United States Dollar, the Parties shall apply the middle exchange rate between RenMinBi and United States Dollar
announced by the People’s Bank of China on the date of occurrence of payment of the royalty during the calendar quarter giving rise to the payment of royalty in United States Dollar.

 

		6.13	TAX WITHHOLDING. AMBRX shall be liable for all income and/or other taxes (including interest) imposed upon any royalty payments made by ZMC to AMBRX under this Agreement
(“Taxes”). In the event Applicable Laws require withholding of Taxes, ZMC shall notify Ambrx in writing number of tax payable in advance, before it makes such withholding payments and subtracts the amount thereof from the payments. ZMC
shall submit appropriate proof of payment of the withheld Taxes to Ambrx and shall provide Ambrx with the official receipts within a reasonable period of time. Notwithstanding the foregoing, to the extent permitted by Applicable Laws and upon
request of Ambrx, ZMC shall Commercially Reasonable Efforts to apply for approvals from competent PRC tax authorities, on behalf of Ambrx, for reduction or exemption of applicable PRC taxes over the payments made by ZMC to AMBRX, before it makes the
withholding payments and subtracts the amount thereof from the payments due to Ambrx.

  

		6.14	PAYMENT PROCEDURES. ZMC shall be responsible for obtaining any and all governmental approval/registration procedures (if legally required) and foreign exchange related
procedures/formalities in connection with repatriation of any

 

 

 
21
 

   

 
 

payments made by ZMC to AMBRX under the Agreement to the bank
accounts designated by AMBRX outside China, and AMBRX will provide reasonable assistance if necessary.
  

ARTICLE 7 

INTELLECTUAL PROPERTY

 

		7.1	OWNERSHIP. ZMC is the sole owner of ZMC Improvement. AMBRX is the sole owner of AMBRX Improvement. Joint Development Technology is co-owned by ZMC and AMBRX. Other than
provided herein, each Party is responsible for filing and prosecuting of patents stemming from its own improvements.

  

		7.2	FILING, PROSECUTION AND MAINTENANCE OF PATENTS FOR JOINT DEVELOPMENT TECHNOLOGY

 

		7.2.1	JOINT DEVELOPMENT TECHNOLOGY. AMBRX shall have the first right to file patent applications for Joint Development Technology (in the name of both ZMC and AMBRX) and
thereafter prosecute and maintain Patent Rights for such Joint Development Technology. In the event that AMBRX files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Development Technology, ZMC shall
execute such documents and perform such ministerial acts, at ZMC’ expense, as may be reasonably necessary for AMBRX to continue such prosecution or maintenance of Patent Rights claiming such Joint Development Technology. AMBRX shall, in its
sole discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Development Technology; provided that AMBRX’ choice of counsel will not present a conflict of interest for ZMC. With respect to
a given Joint Development Technology, AMBRX may elect not to file or may elect not to file in a particular country and if so, AMBRX shall notify ZMC and ZMC shall have the right to file such patent applications for such Joint Development Technology
(in the name of both ZMC and AMBRX) and thereafter prosecute and maintain Patent Rights for such Joint Development Technology. In the event that ZMC files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint
Development Technology, AMBRX shall execute such documents and perform such ministerial acts, at AMBRX’s expense, as may be reasonably necessary for ZMC to continue such prosecution or maintenance of Patent Rights claiming such Joint
Development Technology. ZMC shall, in its sole discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Development Technology; provided that ZMC’s choice of counsel will not present a
conflict of interest for AMBRX.

  

 

 
22
 

   

   

		7.2.2	ZMC IMPROVEMENTS. ZMC shall have the first right, at its sole cost and expense, to file patent applications for ZMC Improvement and thereafter prosecute and maintain
Patent Rights for such ZMC Improvements. With respect to a given ZMC Improvement, ZMC may elect not to file or may elect not to file in a particular country outside the Territory and if so, ZMC shall notify AMBRX and AMBRX shall have the right but
not the obligation to file such patent applications for such ZMC Improvement and thereafter prosecute and maintain Patent Rights for such ZMC Improvement. In such event, ZMC shall execute such documents and perform such ministerial acts, at
AMBRX’ expense, as may be reasonably necessary for AMBRX to continue such prosecution or maintenance of Patent Rights claiming such ZMC Improvements outside the Territory.

 

		7.2.3	REVIEW AND CONSULTATION. In each case in connection with the foregoing with respect to Joint Development Technology and ZMC Improvement, as applicable, the filing Party
(a) shall keep the non-filing Party advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall provide advance copies of any papers related to the filing, prosecution and
maintenance of such patent filings; (c) shall give the non-filing Party an opportunity to review the text of the application before filing and shall consult with the non-filing Party with respect thereto; (d) shall give the non-filing Party an
opportunity to review and comment on any documents relating to such patent filings that will be filed in any patent office at least twenty (20) days before such filing and give due consideration to such substantive, non-cumulative comments; (e)
shall supply the non-filing Party with a copy of the application as-filed, together with notice of its filing date and serial number; and (f) shall promptly give notice to the non-filing Party of the grant, lapse, revocation, surrender, invalidation
or abandonment of any Patent Rights claiming Joint Development Technology and ZMC Improvement, as applicable) for which it is responsible for the filing, prosecution or maintenance hereunder (provided that the filing Party shall give at least thirty
(30) days prior written notice to the non-filing Party of any desire to cease prosecution and/or maintenance of such Patent Rights).

  

		7.2.4	COSTS. The Parties shall equally split the costs of filing patent applications and procuring and maintaining Patent Rights in the United States, Japan, China, Brazil, and
with the European Patent Office (including but not limited to all National Phase filing costs and fees) for such Joint Development Technology; AMBRX shall be responsible for the costs of filing patent applications and procuring and maintaining
Patent Rights for such Joint Development Technology in all other jurisdictions outside the Territory, provided however, if, pursuant to Section 7.2.1, AMBRX elects not to file in a particular country in such other jurisdictions and ZMC elects to
file in such particular country for such Joint Development Technology, then ZMC shall pay 100% of the costs to

  
 

 
23
 

   

   

file and maintain said Patent Rights in said elected country.
Further, if, pursuant to Section 7.2.2, ZMC elects not to file in a particular country outside Territory and Ambrx elects to file and maintain Patent Rights on such ZMC Improvements, then AMBRX shall pay 100% of the costs to file and maintain said
Patent Rights in the elected country(ies). For clarity, AMBRX shall be responsible for prosecuting and maintaining AMBRX Existing Patent Rights and AMBRX Patent Rights in and outside the Territory at its own expense.

 

		7.3	ENFORCEMENT OF PATENT RIGHTS

  

		7.3.1	NOTICE. Each Party shall promptly notify the other Party of any infringement or possible infringement by a third party of any rights licensed to ZMC under this Agreement.
Further, Ambrx shall give ZMC, and ZMC shall give Ambrx, notice of any infringement of (i) any AMBRX Existing Patent Rights in the Territory, or any misappropriation or misuse of Ambrx Know-How, that may come to AMBRX’s or ZMC’
attention. ZMC and Ambrx shall thereafter consult and cooperate fully to determine a course of action, including but not limited to, the commencement of legal action by ZMC and/or Ambrx, to terminate any infringement of such Ambrx Existing Patent
Rights or any misappropriation or misuse of such Ambrx Know-How, as applicable.

  

		7.3.2	SUIT BY ZMC. ZMC shall have the first right, but not obligation, to initiate and prosecute such legal action at its own expense and in the name of ZMC to terminate any
infringement relating to such AMBRX Existing Patent Rights or such Ambrx Know-How in the Territory, as applicable. Should ZMC elect to bring suit against an infringer, ZMC shall keep AMBRX reasonably informed of the progress of the action and shall
give AMBRX a reasonable opportunity in advance to consult with ZMC and offer its views about major decisions affecting the litigation. ZMC shall give careful consideration to Ambrx views, but shall have the right to control the action; provided,
however, that if the validity and/or enforceability of the Existing Patent Rights is raised by the infringer in the action or, or if ZMC’s license to a Valid Claim in the suit terminates, AMBRX may elect to take control of the action pursuant
to Section 7.3.5. Should ZMC elect to bring suit against an infringer and AMBRX is joined as party plaintiff in any such suit, AMBRX shall have the right to approve the counsel selected by ZMC to represent ZMC and AMBRX, such approval not to be
unreasonably withheld. The expenses of such suit or suits that ZMC elects to bring, including any expenses of AMBRX incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by ZMC and ZMC shall
hold AMBRX free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. ZMC shall not compromise or settle such litigation without the prior written consent of AMBRX, which consent shall
not be unreasonably withheld or delayed.

  

 

 
24
 

   

   

In the event ZMC exercises its right to sue pursuant to this
Section 7.3.2, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the
prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then AMBRX shall receive an amount equal to [***] of such funds and the remaining [***] of such funds shall be retained by ZMC.

 

		7.3.3	SUIT BY AMBRX. If ZMC does not take action in the prosecution, prevention, or termination of any Infringement pursuant to Section 7.3.2 above, and has not commenced
negotiations with the infringer for the discontinuance of said infringement, within ninety (90) days after receipt of notice to ZMC by AMBRX of the existence of an Infringement, AMBRX may elect to do so. Should AMBRX elect to bring suit against an
infringer and ZMC is joined as party plaintiff in any such suit, AMBRX shall have the right to select the counsel to represent AMBRX and ZMC unless otherwise conflicted out. The expenses of such suit or suits that AMBRX elects to bring, including
any expenses of ZMC incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by AMBRX. In the event AMBRX exercises its right to sue pursuant to this Section 7.3.3, it shall first reimburse
itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such
reimbursement, any funds shall remain from said recovery, then ZMC shall receive an amount equal to [***] of such funds and the remaining [***] of such funds shall be retained by AMBRX. Notwithstanding the foregoing, AMBRX shall have the right to
initiate and prosecute any legal action(s) relating to Licensed Intellectual Property Rights or AMBRX Background Technology outside Territory at its own expense.

 

		7.3.4	COOPERATION. Each party agrees to cooperate fully in any action under this Article 7 that is controlled by the other party, provided that the controlling party reimburses
the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing such assistance.

 

		7.3.5	DECLARATORY JUDGMENT & INVALIDITY CHALLENGE. If a declaratory judgment action is brought naming ZMC and/or any of its Affiliates as a
defendant, or a claim alleging invalidity or unenforceability of any Valid Claims within the Existing Patent Rights, ZMC shall

  
 ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  

 

 
25
 

   

   

promptly notify AMBRX in writing and AMBRX may elect, upon
written notice to ZMC within thirty (30) days after AMBRX receives notice of the commencement of such action, to take over the defense of the invalidity and/or unenforceability aspect of the action solely.

 

		7.4	INFRINGEMENT ACTIONS BY THIRD PARTIES.

 

		7.4.1	NOTICE. Each Party shall notify the other Party promptly in writing of any claim of, or action for, infringement of any Patents owned or licensed by Third Parties which is
threatened, made or brought against either Party by reason of either Party’s performance of its obligations under this Agreement or development, manufacture, use or sale of any Licensed Products in the Territory.

 

		7.4.2	DEFENSE. In the event that such an action for infringement is commenced by a Third Party solely against a Party or both Parties jointly and/or any of their respective
Affiliates, as the case may be, with respect to a Licensed Product developed and commercialized by ZMC and/or its Affiliate, AMBRX shall defend such action at its own expense, and ZMC hereby agrees to assist and cooperate with AMBRX to the extent
necessary in the defense of such suit. AMBRX shall have the right to settle any such action or consent to an adverse judgment thereto, and ZMC’s consent shall not be required unless such settlement or consent: (i) imposes any material
obligation on ZMC or limits AMBRX’s obligations to ZMC under this Agreement or (ii) materially impairs ZMC’s rights herein. For clarity, any payment including royalty payments to such Third Party as a result of such settlement shall not
require ZMC’s consent.

  

		7.4.3	PAYMENT OBLIGATION. During the pendency of any such action, ZMC shall continue to pay all royalties and other payments due hereunder. AMBRX shall retain any award or
compensation (including the fair market value of non-monetary compensation) received by AMBRX as a result of any such action (i.e., as a result of a counterclaim).

 

ARTICLE 8 

CONFIDENTIALITY & PUBLICATIONS

 

		8.1	NONDISCLOSURE OBLIGATION. EXCEPTIONS. Except to the extent expressly authorized by this Agreement the Parties agree that, during the Term of this Agreement and for ten
(10) years thereafter, each Party and its Affiliates, if any (collectively, a “receiving Party”), shall use their best efforts to keep Confidential Information & Materials completely confidential, shall not publish or otherwise
disclose to any Third Party and shall not use for any purpose other than the performance of this Agreement both the financial terms of this Agreement and any information furnished to it by the other Party or its Affiliates, if any (collectively, a
“disclosing Party”) (and shall ensure that its and its Affiliates’ respective directors, officers, employees or agents do likewise), except to the

 

 

 
26
 

   

   

extent that it can be established by the receiving Party by
competent proof that such information: (i) is, or hereafter becomes, generally available to the public other than by reason of any default by the receiving Party with respect to its confidentiality obligations hereunder; (ii) was already known to
the receiving Party at the time of disclosure by the disclosing Party; (iii) was lawfully disclosed to the receiving Party by a Third Party not in default of any confidentiality obligation to the disclosing Party; or (iv) is independently developed
by or for the receiving Party without reference to or reliance upon the information furnished by the disclosing Party.
  

		8.2	EXCLUSIONS TO CONFIDENTIALITY. The restrictions contained in Section 8.1 shall not apply to any Confidential Information & Materials in the hands of a receiving Party
that (i) is submitted by the receiving Party to governmental authorities to facilitate the issuance of Marketing Authorization for Licensed Products in the Territory, provided that reasonable measures shall be taken to assure confidential treatment
of such information, if practicable, or (ii) is otherwise required to be disclosed in compliance with Applicable Laws (including, without limitation, to comply with any governmental or stock exchange disclosure requirements) or an order by a court
or other regulatory body having competent jurisdiction; provided, however, that if a receiving Party is required to make any such disclosure of the disclosing Party’s Confidential Information & Materials such receiving Party shall, except
where impracticable for necessary disclosures (for example to physicians conducting studies or to health authorities), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the
case of patent applications or otherwise, will use its best efforts to secure confidential treatment of such Confidential Information & Materials required to be disclosed. In addition, any press release or other public announcement permitted by
the terms of Section 8.4 hereof shall be excluded from the provisions of Section 8.1.

  

		8.3	PUBLICATION. ZMC and AMBRX each acknowledge the other Party’s interest in publishing the results of its research in order to obtain recognition within the scientific
community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information. Consequently, except for disclosures
permitted pursuant to Section 8.2, either Party, its employees or consultants wishing to make a publication with respect to the development or clinical results regarding the Licensed Products hereunder shall deliver to the other Party a copy of the
proposed written publication or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall have the right (a) to propose modifications to the publication or presentation
for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay
submission or presentation for a period of one hundred and twenty (120) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with

 

 

 
27
 

   

 
  

Article 7 above. Upon expiration of such one hundred and twenty
(120) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure
of trade secret or proprietary business information prior to submission of the publication or presentation.
  

		8.4	PUBLICITY/USE OF NAMES. No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and neither Party shall use the name, trademark, trade
name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party,
except as may be required by Applicable Law or as permitted pursuant to Section 8.2; provided that in the event disclosure is required by Applicable Law, the disclosing Party shall use good-faith efforts to give the non-disclosing Party an
opportunity, with reasonable advance notice, to review and comment on any proposed disclosure. Notwithstanding Section 8.4 herein, ZMC and AMBRX shall make reasonable effort to issue a mutually agreed joint press releases as shown in Exhibit 6
regarding the execution of this Agreement and the cooperation between both Parties, provided further, any further press release to be issued by one Party mentioning the execution of this Agreement or naming the other Party shall be approved in
advance by the other Party.

  

		8.5	INJUNCTIVE RELIEF. The Parties acknowledge that monetary damages alone may not adequately compensate the disclosing Party in the event of a material breach by the
receiving Party of this Article 8, and that, in addition to all other remedies available to the disclosing Party under this Agreement, at law or in equity, to the extent permitted by Applicable Laws, it shall be entitled to seek injunctive relief
for the enforcement of its rights under this Section 8.

 

ARTICLE 9 

REPRESENTATIONS AND WARRANTIES

 

		9.1	MUTUAL REPRESENTATIONS AND WARRANTIES

 

Each Party represents and warrants to the other
Party the following as of the Effective Date:
  

		(a)	CORPORATE POWER. Such Party is duly organized and validly existing under the laws of the country/state of its organization, and has full legal and corporate power and
authority to enter into this Agreement and to perform its obligations hereunder.

  

		(b)	DUE AUTHORIZATION AND EXECUTION. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have
been duly authorized by the necessary

  

 

 
28
 

   

   

corporate actions of such Party. This Agreement has been duly
executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party enforceable against it in accordance with their respective terms, except to the extent that enforcement
of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors.

 

		(c)	NON-CONTRAVENTION. The execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in
any material respect violate any statute, regulation, judgment, order, decree or other restriction of any governmental authority to which such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational
documents of such Party, or (iii) constitute a material violation or breach by such Party of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a
party.

  

		9.2	REPRESENTATIONS BY AMBRX

  
 AMBRX represents and warrants to ZMC the following as of the Effective Date:

 

		(a)	to AMBRX’s knowledge, the Licensed Intellectual Property Rights exist and are not invalid or unenforceable, in whole or in
part;

  

		(b)	it has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or interest in Licensed Intellectual Property Rights related to
αHer2-ADC in the Territory, or (ii) granted any rights to any Third Parties, in either case that would conflict with the rights granted to ZMC hereunder;

 

		(c)	to AMBRX’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee of Licensed Intellectual Property Rights related to
αHer2-ADC in the Territory,

  

		(d)	to AMBRX’s knowledge, there are no claims, judgments or settlements against or owed by Ambrx and, no pending or threatened claims or
litigation relating to Licensed Intellectual Property Rights in the Territory.

  
 9.3 REPRESENTATIONS BY ZMC. ZMC represents, warrants and covenants to AMBRX that:

 

		9.3.1	All necessary consents, approvals and authorizations of all regulatory authorities and other governmental authorities and other persons or entities required to be obtained
by ZMC in order to enter into this Agreement have been obtained or, with respect to such consents, approvals and

  
 

 
29
 

   

   

authorizations of regulatory authorities or other governmental
authorities that cannot be obtained before the Effective Date, will be obtained within sixty (60) days after the Effective Date.

 

		9.3.2	ZMC, its Affiliates, and its and their respective principals, owners, officers, directors, employees, agents, consultants, and joint venture partners, and any other party
acting on behalf of ZMC (collectively as “ZMC Representatives”), have not and shall not offer, promise, provide, or accept any item of value (broadly meaning any monetary payment, such as fees or commissions, or nonmonetary
benefit, such as employment opportunities, gifts, travel or entertainment), directly or indirectly, to or from any person in exchange for a business advantage;

 

		9.3.3	All ZMC Representatives shall abide by all applicable anti-bribery and corruption laws, including the United States Foreign Corrupt Practices Act
of 1977 and any other international or local laws of a similar nature or having similar effect now existing or to be enacted in the future;

 

		9.3.4	No principal, owner, officer, director, employee or agent of ZMC or its Affiliates is currently a “Government Official,” defined as: (a) an officer, agent or
employee of a government; or (b) a candidate for government or political office.

  

		9.3.5	No Government Official who is closely related to a ZMC Representative has been or will be, directly or indirectly, involved in influencing, obtaining, or retaining
business on behalf of ZMC or fulfilling ZMC’s obligations to AMBRX under this Agreement;

  

		9.3.6	No ZMC Representative (i) is listed on the Office of Foreign Assets Control’s (“OFAC”) “Specially Designated National and Blocked Person
List” (“SDN List”) or otherwise subject to any sanction administered by OFAC (“U.S. Economic Sanctions”); (ii) is owned, controlled by or acting on behalf of, directly or indirectly, any person, entity, or government
listed on the SDN List or otherwise subject to any U.S. Economic Sanction; (iii) has made sales to, contracted with, or otherwise engaged in any dealing or transaction with or for the benefit of any person, entity, or government listed on the SDN
List or otherwise subject to any U.S. Economic Sanction during the previous five years; or (iv) has used, directly or indirectly, any corporate funds to contribute to or finance the activities of any person, entity, or government listed on the SDN
List or otherwise subject to any U.S. Economic Sanction.

 

		9.3.7	ZMC and its Affiliates (i) are in compliance in all material respects with all Applicable Laws relating to anti-money laundering, and (ii) are not and have not been part
of any proceedings (nor is any such proceeding pending or threatened) with respect to any such laws.

  
 

 
30
 

   

   

		9.3.8	Both the AMBRX Existing Patent Rights and the AMBRX Know-How are permitted to be imported into China under PRC law, and none of it falls within the PRC categories for
technologies that are restricted or prohibited from being imported.

  

		9.3.9	ZMC and its Affiliates will use the AMBRX Existing Patent Rights and AMBRX Know-How solely for the purpose of the development, use, manufacture or sale of the Licensed
Products in Territory strictly in accordance with the terms of this Agreement and not for any other purpose.

  

		9.3.10	ZMC and its Affiliates shall invest sufficient resources and funds and use Commercially Reasonable Efforts to achieve ZMC Milestones so as to develop and commercialize
Licensed Product in the Territory and obtain Phase I Clinical Data outside the Territory.

  
 

 
31
 

   

   

ARTICLE 10 

INDEMNIFICATION & INSURANCE

 

		10.1	INDEMNIFICATION BY ZMC. ZMC hereby agrees to indemnify, hold harmless and defend AMBRX, its Affiliates and their respective officers, directors, agents, employees,
successors and assigns (collectively, the “AMBRX Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any
Third Party, whether governmental or private, arising out of or relating to the development, manufacture, use, sale or other disposition of Licensed Products by ZMC or its Affiliates or sublicensees under this Agreement, (ii) ZMC’s failure to
perform its obligations under this Agreement by ZMC, its Affiliates or their respective officers, directors, agents or employees, (iii) the breach of any of ZMC’ covenants, representations or warranties under this Agreement, or (iv) the
negligence or willful misconduct by ZMC, its Affiliates or their respective officers, directors, agents or employees, in performing any obligations under this Agreement.

 

		10.2	INDEMNIFICATION BY AMBRX. AMBRX hereby agrees to indemnify, hold harmless and defend ZMC, its Affiliates and their respective officers, directors, agents, employees,
successors and assigns (collectively, the “ZMC Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any
Third Party, whether governmental or private, arising out of or relating to (i) AMBRX’s failure to perform its obligations under this Agreement by AMBRX, its Affiliates or their respective officers, directors, agents or employees,, (ii) the
breach of any of AMBRX’ covenants, representations or warranties under this Agreement, or (iii) the negligence or willful misconduct by AMBRX, its Affiliates or their respective officers, directors, agents or employees, in performing any
obligations under this Agreement.

  

		10.3	PROCEDURE. If a Party is seeking indemnification under Article 10 (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying
Party”) of the claim giving rise to the obligation to indemnify pursuant to Article 10 as soon as reasonably practicable after receiving notice of the claim (provided, however, any delay or failure to provide such notice shall not
constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable, Article 10 except to the extent that such delay or failure materially prejudices the Indemnifying Party’s
ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the
Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at its own expense and
with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any claim without the prior written

 

 

 
32
 

   

   

consent of the Indemnified Party, which the Indemnifying Party
may provide in its sole discretion. The Indemnified Party shall not settle or compromise any such claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld.

 

		10.4	INSURANCE.

  

		10.4.1	AMOUNT. Beginning the First Commercial Sale of Licensed Product by ZMC or by an Affiliate, ZMC shall, at its sole cost and expense, procure and maintain commercial general
liability insurance in amounts not less than $1,000,000 per incident and $5,000,000 annual aggregate and naming AMBRX as additional insured. During clinical trials of Licensed Product, ZMC shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in such equal or lesser amount as AMBRX shall require, naming AMBRX as additional insured. Such commercial general liability insurance shall provide: (a) product liability coverage and (b) broad form
contractual liability coverage for ZMC’s indemnification obligations under this Agreement.

  

		10.4.2	EVIDENCE. ZMC shall provide AMBRX with written evidence of such insurance upon request of AMBRX. ZMC shall provide ZMBRX with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance.

  

		10.4.3	MAITENENCE. ZMC shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during: (a) the period that any Licensed
Product is being commercially distributed or sold by ZMC or its Affiliate and (b) a reasonable period after the period referred to in (a) above which in no event shall be less than ten (10) years

 

ARTICLE 11

 

TERM & TERMINATION

 

		11.1	TERM. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 11, shall continue in full force and
effect until the expiration of the Royalty Term with respect to Licensed Products in Territory (the “Expiration”).

  

		11.2	Effect of Expiration. Following the expiration of this Agreement with respect to Licensed Product in the Territory pursuant to Section 11.1, ZMC shall have the
royalty-free, perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export such Licensed Product In the Territory.

 

		11.3	TERMINATION BY ZMC. ZMC may terminate this Agreement upon six (6) months prior written notice to AMBRX.

 

 

 
33
 

   

   

		11.4	TERMINATION FOR DEFAULT. Each Party shall have the right to terminate this Agreement, upon notice to the other Party, in the event
that:

  

		11.4.1	Such other Party materially defaults with respect to any of its material obligations under this Agreement or the terms in ZMC-WUXI Service Agreement and does not cure such
default within sixty (60) days after the receipt of a notice from the non-breaching Party specifying the nature of, and requiring the remedy of, such default (or, if such default cannot be cured within such sixty (60)-day period, if the breaching
Party does not commence and diligently continue actions to cure same during such sixty (60)-day period);

  

		11.4.2	The other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any
jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting
the material allegations of a petition filed against or in respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets,

 

(v)  admitted in writing
its inability to pay all or substantially all of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or

 

		11.4.3	An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect
of the other Party, or of its property, under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party
or for all or substantially all of its property, or

 

(iii)  the winding-up or liquidation of
such other Party; and, in each case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for
thirty (30) days.
  

		11.5	EFFECT OF TERMINATION.

  

		11.5.1	TERMINATION OF RIGHTS.

  

		(a)	Upon termination of this Agreement by AMRBX pursuant to Section 11.4 or by ZMC pursuant to Section 11.3, (i) the rights and licenses granted to ZMC under Sections 2.1,
2.2, 2.3, 2.5, shall terminate, all rights therein or under will revert to AMBRX and neither ZMC nor its Affiliates may make, develop, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products in the Territory; (ii) the
rights and licensed granted to AMBRX under Sections 2.6 and 2.7 will revert back to ZMC,

  
 

 
34
 

   

   

provided however, ZMC shall not assert against AMBRX, its
Affiliates or sublicensees any claims for infringement of the reverted rights in the event AMRBX and/or its Affiliate and/or sublicensees continue to make, develop, manufacture, have manufactured, sell, offer for sale and have sold Licensed
Products; and (iii) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense; provided, however, that, for each sublicensee, upon termination of the Sublicense agreement with such sublicensee, if the
sublicensee is not then in breach of its Sublicense agreement with ZMC such that ZMC would have the right to terminate such Sublicense, such sublicensee shall have the right to seek a license from AMBRX at AMBRX’s sole discretion.

 

		(b)	Upon termination of this Agreement by ZMC pursuant to Section 11.4, (i) the rights and licenses granted to ZMC under Sections 2.1, 2.2, 2.3 and 2.5 shall terminate, all
rights therein or under will revert to AMBRX and neither ZMC nor its Affiliates may make any further develop, manufacture, have manufactured, sell, offer for sake and have sold Licensed Products in the Territory; and (ii) rights and licensed granted
to AMBRX under Section 2.6 and 2.7 will revert to ZMC.

 

		11.5.2	NO RELEASE. Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued
to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior
to such termination.

  

		11.5.3	RIGHTS TO SELL STOCK ON HAND. After the date of termination, ZMC and its Affiliates (a) may sell Licensed Products then in stock and may perform Licensed Services then in
process (b) may complete the production of Licensed Products then in the process of production and sell the same; provided that, in the case of both (a) and (b), Licensee shall pay the applicable royalties and payments to AMBRX in accordance with
Article 6.

  

		11.5.4	TRANSFER OF INFORMATION, MATERIALS AND REGULATORY FILINGS AND. Notwithstanding the foregoing, upon termination of this Agreement by either party pursuant to Section 11.4
or by ZMC pursuant to Section 11.3, ZMC shall promptly transfer and assign to AMBRX ownership of all preclinical data, clinical data, regulatory filings and any other information and materials as necessary for AMBRX, its Affiliate or successor to
continue to develop and commercialize αHer2 ADC API or αHer2 ADC Product in Territory, Phase I Clinical Data in a jurisdiction outside Territory to the extent permissible by Applicable Law; if such transfer and assignment is not legally
permitted, ZMC shall provide AMBRX with the right to reference, cross-reference, review, have access

  
 

 
35
 

   

   

to, incorporate and use all documents and other materials filed
by or on behalf of ZMC and its Affiliates with any Regulatory Authority in furtherance of applications for Marketing Authorization in the Territory or outside Territory with respect to Licensed Product. AMBRX shall be entitled to freely and
exclusively use and to grant others the right to use all such materials and documents delivered pursuant to this Section 11.5.4
  

		11.5.5	RETURN CONFIDENTIAL INFORMATION & MATERIALS. Upon any termination of this Agreement, each Party shall promptly return to the other Party all Confidential Information
& Materials or Know How received from the other Party, except as reasonably required to exercise any surviving rights or licenses hereunder.

 

		11.6	SURVIVAL.

  

		11.6.1	Termination or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such
termination or expiration. Such termination or expiration shall not relieve either Party from obligations which are expressly indicated to survive termination or expiration of this Agreement. The rights of the Parties upon termination described in
this Agreement shall not be exclusive of any other rights or claims at law or in equity that either Party may have against the other arising out of this Agreement.

 

		11.6.2	Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to pay all royalties, milestone payments and other monetary
obligations that may have accrued hereunder prior to such termination. All of the Parties’ rights and obligations under Sections 2.8, 7.1, 7.2, 7.3, 7.4, 11.5, and 14.4, Article 1, Article 8, Article 10, Article 12, and Article 13 shall
survive termination, relinquishment or expiration hereof.

 

ARTICLE 12 

LIMITATIONS OF LIABILITY

 

		12.1	EXCLUSION OF DAMAGE. EXCEPT WITH RESPECT TO ARTICLES VIII (CONFIDENTIALITY), IX (REPRESENTATIONS AND WARRANTIES) AND X (INDEMNIFICATION), IN NO EVENT WILL EITHER PARTY BE
LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES INCURRED BY SUCH PARTY ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE TERMINATION HEREOF) INCLUDING, BUT NOT LIMITED TO, THE LOSS OF PROSPECTIVE PROFITS OR
ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OR OTHERWISE,

  
 

 
36
 

   

   

EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF
THE POSSIBILITY OR LIKELIHOOD OF SAME.

 

		12.2	MAXIMUM LIABILITY. EXCEPT FOR ZMC’S PAYMENT OBLIGATIONS HEREUNDER AND EXCEPT WITH RESPECT TO ARTICLES VIII (CONFIDENTIALITY), IX (REPRESENTATIONS AND WARRANTIES) AND
X (INDEMNIFICATION), EACH PARTY’S MAXIMUM LIABILITY TO THE OTHER PARTY FOR ANY KIND OF LOSS, DAMAGE OR LIABILITY ARISING UNDER OR IN CONNECTION WITH ITS PERFORMANCE OR BREACH HEREOF, UNDER ANY THEORY OF LIABILITY, SHALL NOT EXCEED ONE MILLION
UNITED STATES DOLLARS (U.S. $1,000,000).

  

		12.3	FAILURE OF ESSENTIAL PURPOSE. The limitations specified in this Article XII shall survive and apply even if any limited remedy specified in this
Agreement is found to have failed of its essential purpose.

 

ARTICLE 13

 

DISPUTE RESOUTION

 

		13.1	JURISDICTION. The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or
the breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim shall be submitted to the exclusive jurisdiction of the court at the place of the execution of this Agreement
for final resolution.

  

		13.2	EFFECT. The Parties agree that, in the event of a good faith dispute over the nature or quality of performance under this Agreement, neither Party
may terminate this Agreement until final resolution of the dispute by a court decision.

  
 ARTICLE 14 
 MISCELLANEOUS

  

		14.1	FORCE MAJEURE

  
 Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this
Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism,
insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the
other Party of such force majeure circumstances as soon as
  

 

 
37
 

   

 
 

reasonably practical, and shall promptly undertake all reasonable
efforts necessary to cure such force majeure circumstances.
  

		14.2	ASSIGNMENT

  
 Except as provided in this Section 14.2, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either
Party without the consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; provided,
however, that the assigning party must notify the other party at least twenty (20) days prior to completion of any such assignment. Further, each party may assign this Agreement to any assignee of all or substantially all of such Party’s
business or in the event of such Party’s merger, consolidation or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. This Agreement is binding upon the permitted successors and
assigns of the Parties. Any attempted assignment not in accordance with this Section 14.2 shall be void
  

		14.3	SEVERABILITY

  
 If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their good faith
efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

 

		14.4	NOTICES

  
 All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery,
registered or certified mail or overnight courier), sent by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

		If to Ambrx, to:	Ambrx, Inc.
	 	 	10975 North Torrey Pines Road
	 	 	La Jolla, CA 92037
	 	 	Attn: Office of General Counsel
	 	 	Facsimile No.: (858) 453-9511

  
 With a copy to:
  

 

 
38
 

   

 
 

	 	 	If to ZMC, to:

   
 With a copy to:
  
 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to
have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch, if sent by
internationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail.

 

		14.5	APPLICABLE LAW

  
 This Agreement shall be governed by and construed in accordance with the laws of the People’s Republic of China, without reference to any rules of conflict of laws or
renvoi. The United Nations Convention on the Sale of Goods shall not apply to this Agreement.
  

		14.6	ENTIRE AGREEMENT; AMENDMENTS

  
 This Agreement together with the Schedules hereto contains the entire understanding of the Parties with respect to the subject matter hereof, including the research program and the
licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with regard to the subject matter hereof, including the research program and/or the licenses
granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by
a written instrument duly executed by authorized representatives of both Parties hereto.
  

		14.7	HEADINGS AND INTERPRETATION

  
 The captions to the several Articles and Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the
several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Schedule
or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”,
“hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any
provision of this
  

 

 
39
 

   

 
 

Agreement uses the term “including” (or
“includes” or words of similar import), such term shall not be limiting and such term shall be deemed to mean “including without limitation” (or “includes without limitation”), (e) the word “or” shall
not be construed as exclusive, and (f) references to any Articles or Sections include Sections and subsections that are part of the reference Article or section (e.g., a section numbered “Section 2.2.1” would be part of “Section
2.2.”, and references to “Article 2” or “Section 2.2.” would refer to material contained in the subsection described as “Section 2.2.2”).

 

		14.8	INDEPENDENT CONTRACTORS

  
 It is expressly agreed that Ambrx and ZMC shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency.
Neither Ambrx nor ZMC shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

 

		14.9	WAIVER

  
 The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any
other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise.
  

		14.10	CUMULATIVE REMEDIES

  
 No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise
available under law.

 

		14.11	WAIVER OF RULE OF CONSTRUCTION

  
 Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any
ambiguity in this Agreement shall be construed against the drafting Party shall not apply.
  

		14.12	BUSINESS DAY REQUIREMENTS

  
 In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a business day then such notice or other action
or omission shall be deemed to be required to be taken on the next occurring business day.
  

		14.13	COUNTERPARTS

  
 

 
40
 

   

   

This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original.

 

		14.14	PRC REGULATORY MATTERS

  
 ZMC shall be responsible for any and all PRC related regulatory approvals, registrations and/or filings in connection with performance of this Agreement, including without
limitation registering this Agreement with competent commission of commerce and providing registration certificate to Ambrx within sixty (60) days after execution of this Agreement. Before ZMC’s filing or submission of any reports or other
documents with any PRC governmental authority or securities exchange, it shall provide copies of any such reports or documents to be filed or submitted to Ambrx for its prior consents; after regulatory approvals, registrations and/or filings are
completed, ZMC shall provide a copy of relevant certificates to Ambrx immediately.
  

		14.15	EXPORT LAWS

  
 Notwithstanding anything to the contrary contained herein, all obligations of Ambrx and ZMC are subject to prior compliance with the export regulations of the United States and any
other relevant country and such other laws and regulations in effect in the United States and/or any other relevant country as may be applicable, and to obtaining all necessary approvals required by the applicable agencies of the governments of the
United States and any other relevant countries. Ambrx and ZMC shall cooperate with each other and shall provide assistance to the other as reasonably necessary to obtain any required approvals.

 

		14.16	FURTHER ACTIONS

  
 Each Party will execute, acknowledge and deliver such further instruments, and to do all such other ministerial, administrative or similar acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Agreement.
  

		14.17	NO THIRD PARTY RIGHTS

  
 The provisions of this Agreement are for the exclusive benefit of the Parties, and no other person or entity shall have any right or claim against any Party by reason of these
provisions or be entitled to enforce any of these provisions against any Party.
  

		14.18	EXPENSES

  
 Except as otherwise specifically provided in this Agreement, each Party (and its Affiliates) shall bear its own costs and expenses in connection with entering into this Agreement
and the consummation of the transactions and performance of its obligations contemplated hereby.
  

 

 
41
 

   

 
 

		14.19	EXTENSION TO AFFILIATES

  
 ZMC shall have the right to extend the rights, licenses, immunities and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions
of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to ZMC. ZMC shall remain fully liable for any acts or omissions of such Affiliates.

 

		14.20	LANGUAGE

  
 The official text of this Agreement is in the English language as written and spoken in the United States of America. Any text or version of this Agreement in another language, even
if such text or version is made by translation or prepared by or executed by one or both of the Parties for a Party’s convenience shall not be binding and shall have no force or effect. Without limiting the foregoing, in the event of any
conflict or inconsistency between the English text of this Agreement and any text or version of this Agreement in another language, the English text of this Agreement will prevail.

 

[Remainder of this page is left intentionally blank]

 

 

 
42
 

   

 
 

IN WITNESS WHEREOF, the Parties have
executed this Co-development and License Agreement as of the Effective Date in HuangPu District, Shanghai, People’s Republic of China.

 

	Zhejiang Medicine Co., Ltd.	 
	 	 	 
	By:	/s/ Chunbo Li	 
	Name:	Chunbo Li	 
	Title:	Board Chairman	 

 

  
 

	AMBRX, INC.	 
	 	 	 
	By:	/s/ Lawson Macartney	 
	Name:	Lawson Macartney	 
	Title:	CEO	 

  
 
 

 
43
 

   

 
 

 

Exhibit 1

 

Protein Sequence of HER2

 

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

Exhibit 2

 

AMBRX Existing Patent Rights

 

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

 

  

Exhibit 3

 

ZMC-WUXI Service Agreement

 

DEVELOPMENT, MANUFACTURING, AND TESTING TERMS AND
CONDITIONS
  

This Development, Manufacturing and Testing Terms
and Conditions together with any Technology Development Contracts attached hereto is made and entered into as of Jun 14_, 2013 (Effective Date) by and between WuXi AppTec Biopharmaceuticals Co., Ltd., a company organized under the laws of PR.China,
having a principal place of business at 88 West Meiliang Rd, Wuxi City, Jiangsu, PR China and its affiliates. (collectively, “WuXi”) and Zhejiang Medicine Co Ltd, a company organized under the laws of PR China having a principle place of
business at 268 Dengyun Rd Gongshu District, Hangzhou, PR China (“Customer”). Customer and WuXi are referred to herein individually as a “Party” and collectively as the “Parties”.

 

The Parties agree as follows:

 

1. Definitions

 

1.1 Defined Terms. The
following terms (whether or not underscored) when used in this Agreement, shall, except where the context otherwise requires, have the following meanings:

 

1.1.1 “Affiliate” means any
company, partnership or other entity which directly or indirectly controls, is controlled by or is under common control with the relevant Party to this Agreement. “Control” means the ownership of at least fifty per cent (50%) of the
equity of the entity or the legal power to direct the general management and policies of the entity.
  
 1.1.2 “Agreement” means these Terms and Conditions together with an applicable Technology Development

 

Contract.

 

1.1.3 “Batch” means the total
Product obtained from one bioreactor run and associated purification using the Process and carried out in accordance with cGMP or non cGMP if so identified in the Technology Development Contract.

 

1.1.4 “Cell Line” means the
cell line used to produce Product, particulars of which are set out in Technology Development Contracts.
  
 1.1.5 “Certificate of Analysis” means a certificate of analysis as to testing of Specifications of any Product in form and substance agreed to by WuXi and
Customer.
  

1.1.6 “cGMP” means current
Good Manufacturing Practices and General Biologics Products Standards as promulgated under the US Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the Guide to Good Manufacturing Practices for Medicinal Products as
promulgated under European Directive 91/356/EEC and ICH Guidance Q7A (Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. WuXi’s operational quality standards are defined in internal GMP policy documents.

 

1.1.7 “cGMP Product” means
Product which may be required under Technology Development Contracts to be manufactured in accordance with cGMP.

 

1.1.8 “Customer” means Zhejiang Medicine Co Ltd
and its successors and assigns.
 

 
 

1
 

   

   

  

1.1.9 “Customer
Information” means all technical and other information from time to time supplied by Customer to WuXi, which at the time of supply by Customer is not (i) already in the public domain or (ii) already known by WuXi at the time of disclosure
as established by written records.
  
 1.1.10 “Customer Know-How” means all technical and other information relating to the Product or the Process known to Customer from time to time other than WuXi
Know-How and information in the public domain.
  
 1.1.11 “Customer Materials” means the materials supplied by Customer to WuXi and identified as such in Technology Development Contracts hereto.

 

1.1.12 “Customer
Patent Rights” means all patents and patent applications of any kind throughout the world that are necessary or useful in performance of the Services, or related to the Products or the Process, which from time to time Customer is the owner
of or is entitled to use.
  
 1.1.13 “Deliver”, “Delivered” or “Delivery” has the meaning ascribed to it by Section 5.1.

 

1.1.14. “Price” means the price specified in
Technology Development Contracts for the Services.

 

1.1.15 “Process” means the
process for the production of the Product from the Cell Line, including any improvements or modifications thereto from time to time.

 

1.1.16 “Product” means all or
any part of the product manufactured (including any sample thereof), particulars of which are set out in Technology Development Contracts and includes all derivatives thereof.

 

1.1.17 “Quality Agreement” means the
quality agreement between the Parties. The Quality Agreement is attached as Appendix X and hereby incorporated into this Agreement and all related Technology Development Contracts by reference.

 

1.1.18 “Services” means all
or any part of the services that are the subject of the Agreement, particulars including but not limited to specifications, cost, quantity, and delivery dates of which are set out in Technology Development Contracts.

 

1.1.19 “Specification” means
the specification for Product or Services, as applicable, particulars of which are set out in Technology Development Contracts.

 

1.1.20 “Terms of Payment” means the terms of
payment specified in Technology Development Contracts.

 

1.1.21 “Testing Laboratories” means any third
party instructed to carry out tests on the Cell Line or the Product. All proposed third party laboratories (or for that matter, any other Parties to which WuXi subcontracts work on Customer Cell Line or Product) shall be subject to prior review and
approval by Customer.
  

1.1.22 “Technology Development
Contract” means any such appendix to this Agreement specifying Services, as agreed to in writing by the Parties from time to time during the Term of this Agreement. Approved Technology Development Contract(s) shall be attached to this
Agreement and shall, when approved in writing signed by both Parties, be deemed an integral part hereof. Technology Development Contract(s) may be updated from time to time by mutual written agreement of the Parties.

 
 

 
2
 

   

   

  

1.1.23 “WuXi” means WuXi AppTec Biopharmaceutical
Co Ltd, and its successors and assigns.

 

1.1.24 “WuXi Know-How” means all technical and
other information and materials, ideas, concepts, methods, procedures, designs, documents, data, inventions, discoveries and works of authorship (in each case, whether or not patentable) known to WuXi from time to time other than confidential
Customer Information and information in the public domain.

 

1.1.25 “WuXi Patent Rights”
means all patents and patent applications of any kind throughout the world relating to WuXi Know-How or to the Process which from time to time WuXi is the owner of or is entitled to use

 

1.2 Use of Definitions. Unless the context
requires otherwise, words and phrases defined in any other part of the Agreement shall bear the same meanings in these Standard Terms and Conditions, references to the singular number include the plural and vice versa, references to Technology
Development Contracts are references to Technology Development Contracts to the Agreement, and references to Sections are references to sections of these Standard Terms and Conditions.

 

1.3 Conflicting Definitions. In the event
of a conflict between a term in any executed Technology Development Contract or any supplemental or additional term agreed to in writing from time to time between the parties and these Standard Terms and Conditions, any Technology Development
Contract and any supplemental or additional term agreed to in writing after the date hereof shall prevail.
  
 2. Applicability of Terms and Conditions
  
 These Terms and Conditions will not be effective until it (or a counterpart of it) has been signed on behalf of both Parties. Customer and WuXi must complete and execute a
Technology Development Contract before Services are provided. Each Technology Development Contract will include information relating to the specific Services agreed to by the Parties and price for Services. Once signed, a Technology Development
Contract becomes a part of the Agreement, although the terms in a Technology Development Contract will govern only Services described in that Technology Development Contract. A Technology Development Contract will not change any term in the
Agreement. In the event of any inconsistency between the Agreement and any Technology Development Contract, the Agreement will prevail unless the Technology Development Contract Specifies. No variation of or addition to the Agreement or any part
thereof shall be effective unless in writing and signed on behalf of both Parties. Notwithstanding the above, the Parties hereby confirm that amendments to the Specification shall be effective if reduced to writing and signed by the quality and/or
regulatory representative of both Parties, which quality and/or regulatory representative shall be nominated from time to time by each Party. Any such amendments to Specifications must also reflect, in writing, any corresponding changes to the
timing of the Services and any changes to the Pricing detailed in the applicable Technology Development Contract.

 

3. Representations and Warranties

 

		3.1	WuXi Warranties. WuXi represents and warrants that:

 

3.1.1 The Services will be performed in accordance with the Terms
and Conditions of this Agreement;
  

 

 
3
 

   

 
 

  

3.1.2 It will use reasonable endeavors to keep
the Cell Line and/or the Customer Materials and/or the Customer Know-How secure and safe from loss and damage in such manner as WuXi stores its own material of similar nature;

 

3.1.3 It will not part with possession of the
Cell Line and/or the Customer Materials or the Product, save for the purpose of tests at any third party Testing Laboratories that may be required and only with Customer’s written permission; and

 

3.1.4 It will use only Testing Laboratories
bound to obligations of confidence substantially similar to those obligations of confidence imposed on WuXi under these Standard Terms and Conditions.

 

3.1.5 Subject to Section 13, unencumbered title to Product will be
conveyed to Customer upon Delivery;
  

3.1.6 As of the date of this Agreement, to the best of WuXi’s
knowledge without independent investigation, the WuXi Patent Rights and the WuXi Know-How are owned by WuXi or WuXi is otherwise entitled to use them for the purposes of providing Services under this Agreement and during the term of this Agreement
WuXi shall not do or cause anything to be done which would adversely affect their ownership or entitlement to use the same for those purposes. WuXi will notify Customer in writing immediately if it receives or is notified of a claim from a third
party that the use by WuXi of the WuXi Know-How or the WuXi Patents Rights for Services infringes any intellectual property rights vested in such third party;

 

3.1.7 WuXi has the necessary corporate authorizations to enter into
this Agreement;
  

3.1.8 WuXi has all necessary licenses from Life Technologies to use
their host cell/vector system to develop a Cell Line. WuXi has the right to grant Customer a royalty-free sublicense to use the Cell Line for development and commercial production upon payment of [***] to Life Technologies.

 

3.1.9 To the best of WuXi’s knowledge, no
taxes are payable to P.R.China in connection with the Services or production and Delivery of Product.
  
 3.2 DISCLAIMER. SECTION 3.1 IS IN LIEU OF ALL CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT OF THE SERVICES AND/OR THE PRODUCT WHETHER EXPRESSED OR IMPLIED BY STATUTE,
CUSTOM OF THE TRADE OR OTHERWISE (INCLUDING BUT WITHOUT LIMITATION ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF THE PRODUCT, ITS FITNESS OR SUITABILITY FOR A  PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS
WHETHER OR NOT KNOWN TO WUXI APPTEC) AND ANY SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED AND DISCLAIMED.

 

3.3 Representations and Warranties of
Customer. Customer represents and warrants to WuXi that:

 

3.3.1 Customer shall supply to WuXi the Customer
Information, together with full details of any hazards relating to the Cell Line (if applicable) and/or the Customer Materials, their storage and use. Upon review of this Customer Information, the Cell

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  

 

 
4
 

   

   

  

Line and/or the Customer Materials and/or the
Customer Know-How will be provided to WuXi at WuXi’s reasonable request. The Cell Line and/or the Customer Materials and/or the Customer Information and/or the Customer Know-How supplied to WuXi will remain the property of Customer.

 

3.3.2 Customer hereby grants WuXi the
non-exclusive right to use the Cell Line, the Customer Materials, the Customer Know-How and the Customer Information for the purpose of the Agreement. WuXi hereby undertakes not to use the Cell Line, the Customer Materials, the Customer Know-How or
the Customer Information (or any part thereof) for any other purpose.
  
 3.3.3 Customer has the necessary corporate authority to enter into this Agreement;

 

3.3.4 To Customer’s knowledge without independent
investigation, as of the date of this Agreement, Customer has the right to supply the Cell Line (if applicable), the other Customer Materials and the Customer Information to WuXi and the necessary rights to license or permit WuXi to use the same for
the purpose of the Services; and Customer shall not do or cause anything to be done which would adversely affect their ownership or entitlement to use the same for those purposes;

 

3.3.5 To Customer’s knowledge and belief
without independent investigation, as of the date of this Agreement, the use by WuXi of the Cell Line, other Customer Materials, Customer Information and Customer Patent Rights for the Services (including without limitation the manufacture of the
Product) will not infringe in China any intellectual property rights of any third party; and Customer shall not do or cause anything to be done which would adversely affect such use;

 

3.3.6 Customer will promptly notify WuXi in
writing if it receives or is notified of a claim from a third party that the Cell Line, other Customer Materials, Customer Information or the Customer Patent Rights or that the-use by WuXi thereof for the provision of the Services infringes any
intellectual property rights of such third party;
  
 4. Provision of the Services
  
 4.1 Services. WuXi acknowledges and agrees that Customer commissioned WuXi to perform the Services, and all rights, title, interests and benefits in and to the Customer Property,
including all inventions therein, vest absolutely and exclusively in Customer from the moment of their creation or development. WuXi shall carry out the Services as provided in applicable Technology Development Contracts and shall use reasonable
efforts to achieve the estimated time schedule thereto or as agreed to by the Parties. Customer shall have the right to be present during manufacturing of Product, and the right to conduct periodic routine GMP compliance audits or “for
cause” audits of WuXi’s manufacturing facility.
  
 4.2 Specification. Specifications will be agreed to by the Parties prior to initiation of a manufacturing run or other Services, as appropriate.

 

4.3 Time Limitations. Due to the
unpredictable nature of discovery services, technical transfer, Cell Line development, process development, process scale-up, assay development, formulation and other related Services, the time schedule set down for the performance of these Services
is estimated only. Upon completion or near completion of these Services the project teams will work to finalize the pilot and cGMP manufacturing schedules.

 

 

 
5
 

   

 
 

 

4.4 Quality. Responsibility for
quality assurance and quality control of Products shall be allocated between Customer and WuXi as set forth in the Quality Agreement and in WuXi standard operating procedures.

 

5. Delivery, Transportation of
Product
  

5.1 Delivery. Product will be delivered Ex
Works WuXi premises in Wuxi at the address set forth in the first paragraph of this Agreement, which means (a) WuXi places Product at the disposal of Customer at WuXi’s premises not cleared for export and not loaded onto any collecting vehicle
and (b) risk and title to Product pass to Customer upon delivery (“Deliver,” “Delivery,” or “Delivered,” as appropriate). Subject to Section 5.2, WuXi shall deliver to Customer the Certificate of Analysis, the
Certificate of Compliance (with GMP), and BSE/TSE Certification for each Batch of Product not later than the date of Delivery. Transportation of Product, whether or not under any arrangements made by WuXi on behalf of Customer, shall be made at the
sole risk and expense of Customer.

 

5.2 Delivery Without Certificate of
Analysis. At Customer’s request, WuXi will Deliver Product in quarantine prior to delivery of the Certificate of Analysis. Such request shall be accompanied by Customer’s written acknowledgement that the Product has been Delivered
without the transmittal to Customer of a Certificate of Analysis, that accordingly the Product cannot be administered to humans until transmittal of the Certificate of Analysis, and that Customer nevertheless accepts full risk of loss, title and
ownership of the Product. The Delivery of Product in quarantine will be subject to such testing requirements as WuXi may reasonably require, and the forty-five (45) day period referred to in Section 5.8 will run from Delivery in quarantine by
Customer of the Product.

 

5.3 Packaging and Labeling. Unless
otherwise agreed, WuXi shall package and label Product for Delivery in accordance with its standard operating procedures and in accordance with required shipping conditions. It shall be the responsibility of Customer to inform WuXi in writing in
advance of any special packaging and labeling requirements for Product. All additional costs and expenses of whatever nature incurred by WuXi in complying with such special requirements must be agreed to in advance in writing and will be charged to
Customer in addition to the Price.

 

5.4 Insurance. If requested in writing by
Customer, WuXi will (acting as agent for Customer) arrange for insurance of Product while held by WuXi after Delivery (awaiting transportation) for a maximum of fourteen (14) days on terms equivalent to those under which WuXi insures product prior
to Delivery. Third party expenses incurred by WuXi in arranging such insurance must be agreed to in advance in writing and will be charged to Customer in addition to the Price.

 

5.5 Transportation. If requested in
writing by Customer, WuXi will (acting as agent of Customer for such purpose) arrange the transportation of Product from WuXi’s premises to the destination indicated by Customer together with insurance coverage for Product in transit at its
invoiced value. All additional costs and expenses of whatever nature incurred by WuXi in arranging such transportation and insurance must be agreed to in advance in writing and will be charged to Customer in addition to the Price.

 

5.6 Additional Cost. Any
other additional cost and expenses for this project need to be approved in writing by both parties including both the contractor and the contractee.

 

5.7 Acceptance of Delivery. Where WuXi has
made arrangements for the transportation of Product, Customer shall diligently examine the Product as soon as practicable after receipt. Notice of all claims (time being of the essence) arising out of:

 

 

 
6
 

   

 
 

 

 

5.7.1 Visible damage to or total or partial loss
of Product in transit will be given in writing to WuXi and the carrier within five (5) working days of receipt by Customer; or

 

5.7.2 Non-delivery will be given in writing to WuXi within ten (10)
days after the receipt by Customer of WuXi’s dispatch notice.
  
 5.8 Damage Claims. Customer shall make damaged Product and associated packaging materials available for inspection and shall comply with the reasonable requirements of any
insurance policy covering the Product, for which notification has been given by WuXi to Customer. WuXi shall offer Customer all reasonable assistance in pursuing any claims arising out of the transportation of Product.

 

6. Non-Conforming Product or Tests.

 

6.1 Non-Conforming Product. Within thirty
(30) days following Delivery of Product and copies of the relevant production batch records in English, including copies of the CoA, CoC, and BSE/TSE certification provided at Delivery, Customer shall determine whether the Product conforms to the
Specifications and has been manufactured in material accordance with such batch records. If Customer determines that the Product fails to meet Specification, or was not produced in material accordance with the batch records Customer shall give WuXi
written notice within such 30 day period and shall return such Product to WuXi’s premises, at WuXi’s expense, for further analysis. In the absence of such written notice, Product shall be deemed to have been accepted by Customer as
meeting Specification and Customer has waived its right to revoke acceptance. If Customer reasonably demonstrates to WuXi that Product returned to WuXi fails to meet Specification or was not manufactured in material accordance with the batch records
and that such failure is due to the negligence of WuXi and not due in whole or in part to the inherent property of the Product or Process, or acts or omissions of Customer or any third party after Delivery, WuXi shall at its option either refund
that part of the Price that relates to the production of such non-conforming Product, or initiate a manufacturing run within sixty (60) calendar days from the date it was determined that the Product was non-conforming to replace such Product at its
own cost and expense.

 

6.2 Non-Conforming Test. If, within
fourteen (14) calendar days of receiving a result from a test conducted by WuXi, Customer notifies WuXi in writing that the result is unexpected, WuXi will initiate a laboratory investigation of the result. The Customer and WuXi will agree on an
appropriate course of action pending the results of the laboratory investigation. If WuXi observes an Out Of Specification (OOS) result it will notify Customer as soon as reasonable but in any case within two (2) working days of learning of such
result. Customer and WuXi will agree on the appropriate course of action to investigate the OOS result. If WuXi determines that an unexpected, or OOS result is due to the inherent condition of the sample matrix, or to the act, omission, direction,
or negligence of Customer or any third party outside of WuXi’s control, Customer shall be liable to WuXi for the Price of the Services performed, including any additional testing or retests, and materials, reagents, expenses consumed,
employed, or specially obtained during the course of the laboratory investigation. If the unexpected or OOS result was caused by a combination of the inherent property of the sample matrix or the act, omission, direction, or negligence of Customer
or any third party outside of WuXi’s control and WuXi error, or a reasonable determination of cause cannot be ascertained, Customer shall be liable for 50% of the Price of the Services performed, including any additional testing or retests,
and 50% of the cost of any materials or reagents specially obtained by WuXi during the course of the laboratory investigation. Customer is not liable to WuXi for unexpected, or OOS results due to WuXi error and WuXi shall provide a refund of any
payments made by Customer for the Services giving rise to the unexpected or OOS results. Should Customer request a repeat or retest of such non-conforming Services Customer shall be liable for the Price of a successful repeat or retest of such
non-conforming Services.

 

 

 
7
 

   

 
 

 

 

7. Records

 

Records of Services are available for Customer
review at the WuXi facility where the Services were performed. WuXi will retain Batch, laboratory and other technical records (“Records”) of Services for the longer of ten (10) years or for the minimum period required by applicable law
and consistent with FDA, EMA, or other relevant Competent Authority regulations and guidance relating to the manufacture or testing of products intended to support an application for regulatory approval. Technology Development Contracts shall
include copies of protocols, test methods, method qualification/validation reports. To the extent that raw data from Services or descriptions of any of WuXi’s protocols, test methods, or SOPs are not included in the Customer-approved protocol
Technology Development Contract, or Report pertaining to any particular Service and are required by a competent regulatory authority, WuXi will upon written request by Customer provide a copy of such raw data or relevant portions of such protocols,
test methods, or SOPs to be used solely for purposes of such regulatory submission under the provisions of Confidentiality in accordance with Section 10. In the event WuXi proposes to dispose of Records WuXi shall provide Customer written notice
thereof. If within thirty (30) days after such notice Customer requests any Records, WuXi shall provide to Customer at Customer’s expense such Records rather than disposing thereof. WuXi may, however, retain copies of any Records as are
reasonably necessary for regulatory or insurance purposes, subject to WuXi’s obligation of confidentiality.

 

All the original lab notes will be in Chinese to
meet Chinese regulatory requirements. All technical reports and regulatory dossiers will be in both Chinese and English.

 

For the time specified in 5, 6, and 7, one party can ask for extension
once upon written request from the other party. Only a single extension is allowed.
  
 8. Price and Terms of Payment
  
 8.1 Price. Customer shall pay the Price in accordance with the Price detailed in Technology Development Contracts attached hereto.

 

8.2 Payment. Payment will be made in
accordance with Technology Development Contracts attached hereto. Unless otherwise indicated in a Technology Development Contract, all Prices and charges are exclusive of any applicable taxes, levies, duties and fees of whatever nature imposed by or
under the authority of any government or public authority, which shall be paid by Customer (other than taxes on WuXi’s income). Payment must be made within thirty (30) days of receipt by Customer of a correct invoice. Payment shall be made
without deduction, deferment, set-off, lien or counterclaim of any nature. Payment shall be made in RMB by wire transfer to a Chinese bank account designated by WuXi. For uncontrollable reasons such as natural disasters, war, government control and
bank errors that lead to payment delay, the client will notify WuXi and make corrections in a reasonable timeframe.

 

8.3 No Additional Cost. WuXi acknowledges that it
is duly compensated for all actions through being entrusted by Customer with the performance of the Services under this Agreement, and WuXi agrees that it shall not be entitled to any additional fees, costs, reimbursement or other charges, unless
otherwise agreed by the Parties in writing. WuXi represents and warrants to Customer that all its employees, agents, consultants, and contractors who have contributed and will contribute to the Services have been and will be, as the case may be,
properly remunerated, compensated and awarded for their contributions. WuXi agrees that this Agreement does not create an employment relationship between Customer and any of WuXi employees, agents, consultants, or contractors, notwithstanding any
agreements that a WuXi employee, agent, consultant, or contractor may sign with Customer and/or WuXi from time to time. It is WuXi’s sole responsibility to compensate its

 

 

 
8
 

   

 
 

 

 

employees, agents, consultants, and contractors as prescribed by
applicable Chinese laws. Customer shall have no liability or responsibility for compensating any of WuXi employees, agents, consultants, or contractors for any invention.

 

9. Indemnification and Limitation of
Liability
  

9.1 WuXi Indemnity. WuXi shall indemnify
and hold Customer harmless against all claims, actions, costs, expenses (including court costs and reasonable attorney’s fees) or other liabilities (collectively, “Losses”) whatsoever to, from or in favor of third parties, to the
extent such Losses are in respect of WuXi’s material breach of any of the terms and conditions of this Agreement, or the negligence or wrongful action of WuXi or any of its employees or agents in the provision of Services under this
Agreement.
  

9.2 Customer Indemnity. Customer shall
indemnify and hold WuXi harmless against all claims, actions, costs, expenses (including court costs and reasonable attorney’s fees) or other liabilities whatsoever to, from or in favor of third parties, in respect of

 

9.2.1 Customer’s storage, research,
development, manufacture, distribution, use, sales or other disposition by Customer, or any distributor, collaborator, customer, sublicense, representative or agent of Customer, of the Product or other test materials or any other substances upon
which the Services of WuXi were performed; or
  
 9.2.2 any claim that the use, sale, marketing, or distribution of the Product by Customer or WuXi’s use of Customer-supplied information or materials violates any third
party’s intellectual property or proprietary rights; or
  
 9.2.3 any negligent or willful act, omission, or breach of Customer in connection with this Agreement.

 

9.3 Limitation. Except for the above
indemnification obligations, neither Party shall be liable for any penalties, liquidated, special, consequential, incidental or indirect damages arising out of or in connection with this Agreement (or the termination hereof), including, without
limitation, loss of profits or anticipated sales to the fullest extent permitted by law, and the total liability, in the aggregate, of either Party and its agents to the other Party and anyone claiming by or through the other Party, for any and all
claims, losses, costs or damages, including without limitation, attorneys’ fees and costs and expert-witness fees and costs of any nature whatsoever or claims expenses resulting from or in any way related to this Agreement from any cause or
causes shall not exceed the fees paid or owed under this Agreement for the portion of the Services under which such liability arises. Except as otherwise provided, it is intended that this limitation apply to any and all liability or cause of action
however alleged or arising, including without limitation, negligence, professional errors and omissions, breach of contract, unless otherwise prohibited by law. For the avoidance of doubt, the foregoing shall not limit either Party’s ability
to obtain equitable relief of any type.

 

9.4 Further Limitation. The obligation of
WuXi under Section 9.1 and Customer under Section 9.2 is limited to one-hundred thousand dollars ($100,000) per event, except that this limitation will not apply with respect to any indemnifiable claim arising out of or relating to gross negligence,
fraud or willful misconduct by the indemnifying Party under this Agreement. Except for claims arising under indemnities contained herein, any claim must be brought by either Party within one (1) year from the completion of Services under which such
claim arises or such claim will be forever barred.
  
 
 

 
9
 

   

 
 

 

 

9.5 Limitation Exception. Nothing
contained in these Standard Terms and Conditions shall purport to exclude or restrict any liability for death or personal injury resulting directly from gross negligence by a Party in carrying out their obligations in breach of the terms of this
Agreement.
  

9.6 Waiver of Claims. WuXi represents only
that it will use reasonable care in the provision of Services. WuXi makes no representation or warranty, and Customer expressly waives all claims against WuXi and its Affiliates, and any of its respective agents or employees, arising out of or in
connection with any claims relating to the stability, efficacy, safety, or toxicity of the Product developed, formulated, packaged, or manufactured in accordance with the agreed upon Services.

 

9.7 For each party that is
involved in legal or administrative procedures due to this agreement, the other party shall provide reasonable support.

 

9.8 Survival. The
obligations of WuXi and Customer and under this Section 9 shall survive the termination or expiration of this Agreement.

 

10. Confidentiality

 

10.1 Confidential Information. The Parties
will exchange proprietary and confidential information during the term of this Agreement, including without limitation, the existence and terms of this Agreement. The Parties will identify, in writing, such information as confidential and/or
proprietary. Notwithstanding the foregoing, Customer Confidential Information will also include Customer Information, Customer Materials, and Customer Know-How, and WuXi Confidential Information will include WuXi Know-How, study designs, pricing
information, and test protocols. Customer acknowledges that WuXi Confidential Information and WuXi AppTec acknowledges that Customer Confidential Information, with which it is supplied by the other pursuant to the Agreement is supplied subject to
Sections 10.5 and 10.6 in circumstances imparting an obligation of confidence. Each Party agrees to keep the other Party’s confidential information secret and confidential and to respect the other’s proprietary rights therein and not at
any time for any reason whatsoever to disclose or permit the other party’s confidential information to be disclosed to any third party save as expressly provided herein. Processes, formulations, SOPs, assays and test results developed by WuXi
AppTec in the course of providing the Services and specific to Customer Process and Product is the Confidential Information of Customer.

 

10.2 Obligations of Confidentiality.
Customer and WuXi AppTec shall each cause all their respective employees, consultants, contractors and persons for whom it is responsible having access to WuXi AppTec Confidential Information or Customer Confidential Information to be subject to the
same obligations of confidence as Customer and WuXi pursuant to Sections 10.1 and 10.3 and shall be bound by confidentiality agreements in support of such obligations. WuXi and Customer each undertake not to disclose or permit to be disclosed to any
third party, or otherwise make use of or permit to be made use of (a) any trade secrets or confidential information relating to the technology, business affairs or finances of the other, any subsidiary, holding company or subsidiary or any such
holding company of the other, or of any suppliers, agents, distributors, licensees or other customers of the other which comes into its possession under this Agreement, or (b) the commercial terms of this Agreement; except to the extent that the
same is required to be disclosed pursuant to subpoena, court order, judicial process or otherwise by law, provided the receiving party provides prompt notice to the disclosing Party of such requirement in order to give the disclosing party an
opportunity to timely seek a protective order or other appropriate judicial relief. In the event the disclosing Party is unable to obtain a protective order or other appropriate judicial relief, the receiving party shall disclose only that portion
of the disclosing Party’s confidential information which is legally required to be disclosed, and that the disclosing party shall be given an opportunity to review the confidential information prior to its disclosure.

 

 

 
10
 

   

 
 

 

 

10.3 Limitations. The obligations of confidentiality
referred to in this Section 10 shall not extend to any information which:
  
 10.3.1 Is or becomes generally available to the public otherwise than by reason of a breach by the recipient Party of the provisions of this Section 10;

 

10.3.2 Is known to the receiving Party and is at
its free disposal prior to its receipt from the disclosing Party, as established by written records;
  
 10.3.3 Is subsequently disclosed to the receiving Party without being made subject to an obligation of confidence by a third party, as established by written records;

 

10.3.4 Is required to be disclosed by WuXi or
Customer under any statutory, regulatory or similar legislative requirement, or is incorporated into a regulatory submission, subject to the imposition of obligations of confidentiality wherever possible in that relation; or

 

10.3.5 Is developed by any servant or agent of
the recipient Party without access to or use or knowledge of the information by the disclosing party, as established by written records.

 

10.4 Remedies. Without prejudice to any
other rights and remedies that the Parties may have, the Parties agree that the confidential information is valuable and that damages may not be an adequate remedy for any breach of the provisions of Sections 10.1, 10.2, or 10.3. The Parties agree
that the relevant party will be entitled to seek the remedies of an injunction and other equitable relief for any actual or threatened breach by the other Party.

 

10.5 WuXi Confidential Information.
Customer acknowledges that Customer shall not at any time have any right, title, license or interest in or to WuXi Confidential Information the WuXi Patent Rights or any other intellectual property rights relating to the Services which are vested in
WuXi or to which WuXi is otherwise entitled.
  
 10.6 Customer Confidential Information. WuXi acknowledges that save as provided herein WuXi shall not at any time have any right, title, license or interest in or to the
Customer Confidential Information, Customer Patent Rights, Customer Know-How, or any other intellectual property rights vested in Customer or to which Customer is entitled.

 

10.7 Survival. The
obligations of WuXi and Customer under this Section 10 shall survive the termination or expiration of this Agreement.

 

11. Term and Termination

 

11.1 Term. This Agreement will expire on
the later of (a) two (2) years from the Effective Date or (b) the completion of all Services under the last Technology Development Contract executed by the Parties prior to the second anniversary of the Effective Date. The Agreement may be extended
by mutual agreement of the Parties or earlier terminated in accordance with Section 11.2. or 11.3.
  
 11.2 Termination without Cause.
  
 11.2.1 Customer may in its sole discretion terminate this Agreement at any time for any reason or no reason by giving not less than thirty (30) days notice in writing to WuXi. In
the event of termination pursuant to this Section 10.2.1 Customer shall pay WuXi for Services performed up to the date of termination. In addition, Customer shall reimburse WuXi for expenses incurred or irrevocably committed to third parties in
accordance with this Agreement

 

 

 
11
 

   

 
 

 

 

and the Price for any cell banks, toxicology studies, or manufacturing
Batches that are in-progress or that has an initiation date scheduled within forty-five (45) days of the receipt of notice of termination.

 

11.2.2 WuXi may in its sole discretion terminate
this Agreement or any Technology Development Contract at any time for any reason or no reason by giving not less than one hundred eighty (180) days notice in writing to Customer. During such notice period, WuXi shall continue and complete all work
in progress and both Parties shall remain liable to each other for their respective obligations under this Agreement. In the event of termination pursuant to this Section 11.2.2 Customer shall pay WuXi for Services performed and for expenses
incurred or irrevocably committed to third parties.
  
 11.3 Termination for Cause. WuXi and Customer may each terminate the Agreement forthwith by notice in writing to the other upon the occurrence of any of the following
events:
  

11.3.1 If the other commits a material breach of
the Agreement which in the case of a breach capable of remedy is not remedied to the reasonable satisfaction of the non-breaching Party within forty-five (45) days of the receipt by the other of written notice identifying the breach and requiring
its remedy; or
  

11.3.2 Any party may terminate this Agreement at
any time by giving notice in writing to the other Party, if the other Party files a petition of any type as to its bankruptcy, is declared bankrupt, becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or
receivership, otherwise loses legal control of its business or ceases to carry on its business.
  
 11.4 Rights and Obligations upon Termination. Upon the termination of the Agreement for whatever reason:

 

11.4.1 Subject to Section 7, WuXi shall promptly
return to Customer all Customer Know-How, Customer Information and shall dispose of or return to Customer the Customer Materials (and where supplied by Customer the Cell Line) and any materials therefrom, as directed by Customer;

 

11.4.2 Customer shall promptly return to WuXi
all WuXi Know-How and WuXi Confidential Information it has received from WuXi;
  
 11.4.3 Subject to the terms of Section 13, Customer shall not thereafter use or exploit WuXi Confidential Information, the WuXi Patent Rights or the WuXi Know-How in any way
whatsoever;
  

11.4.4 WuXi shall not thereafter use or exploit
the Customer Patent Rights, Customer Know-How or the Customer Information in any way whatsoever;
  
 11.4.5 WuXi and Customer shall do all such acts and things and shall sign and execute all such deeds and documents as the other may reasonably require to evidence compliance with
this Section 11.4.
  

12. Force Majeure

 

12.1 Force Majeure Rights. If either Party
is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure such Party shall give written notice thereof to the other Party specifying the matters constituting Force Majeure together with such evidence
as reasonably can give and specifying the period for which it is
  
 
 

 
12
 

   

 
 

 

 

estimated that such prevention or delay will continue, the Party
claiming Force Majeure shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. Notwithstanding the
foregoing, if the Party claiming Force Majeure estimates that the delay will exceed 30 days, or if the delay has, in fact, exceeded 30 days, the other Party may terminate this Agreement for cause as set forth in Section 9.3, including an additional
30 days notice to remedy the breach.
  

12.2 Force Majeure Definition. The
expression “Force Majeure” shall be deemed to include any cause affecting the performance by either Party of the Agreement arising from or attributable to acts, events, acts of God, omissions or accidents beyond the reasonable control of
the Party claiming the Force Majeure.

 

13. Inventions. WuXi hereby assigns to
Customer all right, title, and interest in all inventions, improvements, designs, formulas, methods, processes and writings, whether or not copyrightable or patentable that embodies Customer Materials and Customer Know-How provided hereunder and
discovered solely as a result of using such Customer Materials and Customer Know-How (collectively, the “Inventions”). WuXi agrees, upon Customer’s request and at Customer’s expense, to do all things reasonably necessary to
obtain patents or copyrights on any Inventions discovered exclusively as a result of performing Services and to execute any documents necessary to formalize the afore-mentioned assignments. Notwithstanding the foregoing, Customer acknowledges that
WuXi possesses certain inventions, processes, know-how, trade secrets, other intellectual property and assets, including but not limited to, discovery methods, production methods, test methods, viral clearance methods and expertise, controls,
procedures, computer technical expertise and software which have been independently developed by WuXi (collectively, the “WuXi Property”). Customer and WuXi agree that any WuXi Property or improvements thereto which are used, improved,
modified or developed by WuXi under or during the term of this Agreement, are the product of WuXi’s technical expertise possessed and developed by WuXi prior to or during the performance of this Agreement and are the sole and exclusive
property of WuXi regardless if such WuXi Property or improvements thereto are incorporated or embedded in any Inventions or Deliverable generated or due hereunder, except that Customer is granted a non-exclusive, world-wide, royalty-free license,
sublicensable in conjunction with a license to Customer Know-How and Customer Patent Rights, to portions of WuXi Property or improvements that are incorporated or embedded in Deliverables to the extent reasonably necessary to allow full lawful use
of the Deliverables that incorporate it. Protocols, methods, controls, SOPs, Specifications, or documents (other than Customer data, reports, and documents specific to Customer Process and Product) that are produced by WuXi for Services
(collectively, “Service Instruments”) are furnished solely with respect to Services, and WuXi will retain all common law, statutory, ownership, and other reserved rights in such Service Instruments. The assignment of inventions and other
intellectual property rights shall include the right to apply for patent and the right to have patent granted in the name of Customer (or its designee). Customer shall have sole discretion in the preparation, filing, prosecution, maintenance, and
enforcement of patents arising from Inventions. WuXi agrees to cooperate with Customer during the preparation, filing, prosecution, issuance and maintenance of patents and patent applications covering Inventions by promptly executing papers and
providing assistance, information and records as needed, in a timely manner.
  
 14. Mediation, Arbitration, Governing Law, Jurisdiction, and Enforceability

 

14.1 Mediation. In the event of any
dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, each Party shall by written notice to the other have the right to have such dispute referred to the senior management of
WuXi and Customer for attempted resolution by good faith negotiations within forty-five (45) days after such notice is received. If such senior management are unable to resolve such dispute within the forty-five (45) day period, and before
arbitration is initiated, the

 

 

 
13
 

   

 
 

 

 

Parties shall participate in a mediation that will last no less than
eight (8) hours unless the dispute is resolved before such time. Notwithstanding the requirement for the Parties to submit to mediation for a minimum of eight (8) hours, neither party will be required to participate in mediation for longer than
sixteen (16) hours. Any mediation will take place a mutually agreeable venue, and will be officiated by a mutually agreeable mediator identified and engaged by the Parties, the cost and fees for whom shall be borne equally by the Parties. In the
event the Parties’ efforts to reach an amicable resolution through mediation or other informal means are unsuccessful, either party may invoke the provisions of Section 14.2. Any settlement reached by the Parties under this Section shall not
be binding until reduced to writing and signed by the above-specified management of WuXi and Customer. When reduced to writing, such agreement shall supersede all other agreements, written or oral, to the extent such agreements specifically pertain
to the matters so settled.
  

14.2 Arbitration. In the event of the
failure to reach a resolution pursuant to Section 14.1, any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by binding arbitration in accordance
with the complex rules of the Commercial Arbitration Rules of the Shanghai Arbitration Association in effect on the date of this Agreement. The place of arbitration will be Shanghai China and the Parties shall share equally filing fees, arbitrator
fees or other costs of such proceedings, except that each Party shall bear its own attorney’s fees, and other out-of-pocket arbitration expenses, unless the arbitrators decides otherwise.

 

14.3 Governing Law and
Jurisdiction. The construction, validity and performance of the Agreement shall be governed by the laws of the State of California, without regard to its conflict of laws provisions.

 

14.4 Waiver. No failure or delay on the
part of either WuXi or Customer to exercise or enforce any rights conferred on it by the Agreement shall be construed or operate as a waiver thereof nor shall any single or partial exercise of any right, power or privilege or further exercise
thereof operate so as to bar the exercise or enforcement thereof at any time or times thereafter.
  
 14.5 Severability. The illegality or invalidity of any provision (or any part thereof) of the Agreement or these Standard Terms and Conditions shall not affect the legality,
validity or enforceability of the remainder of its provisions or the other parts of such provision as the case may be. The Parties shall replace the illegal or invalid provision with a legal and valid provision that as closely as possible reflects
the intent and economic effect of the illegal or invalid provision.
  
 14.6 Agreement Language This agreement has both Chinese and English versions. If there is discrepancy, the Chinese version overrules.

 

15. Miscellaneous

 

15.1 Assignment. Neither
Party shall be entitled to assign, transfer, charge or in any way make over the benefit and/or the burden of this Agreement without the prior written consent of the other which consent shall not be unreasonably withheld or delayed, save that either
Party shall be entitled without the prior written consent of the other Party to assign, transfer, charge, sub-contract, deal with or in any other manner make over the benefit and/or burden of this Agreement to an Affiliate or to any company with
which such assigning Party may merge or to any company to which such assigning Party may transfer its assets and undertakings.

 

15.2 Press Releases. The
text of any press release or other communication to be published by or in the media concerning the subject matter of the Agreement shall require the prior written approval of WuXi and Customer.

 

 

 
14
 

   

   
 
 
  
 15.3 Entire Agreement. The Agreement, the Technology Development Contracts attached hereto embody the entire understanding of WuXi and Customer and there are no promises,
terms, conditions or obligations, oral or written, expressed on implied, other than those contained in the Agreement. The terms of the Agreement shall supersede all previous agreements (if any) which may exist or have existed between WuXi and
Customer relating to the Services. In the event the Parties desire to enter into a Commercial Manufacturing Agreement with each other, such Commercial Manufacturing Agreement shall be on separate terms and conditions from this Agreement.

 

15.4 No Third Party
Beneficiaries. The Parties to this Agreement do not intend that any terms hereof should be enforceable by any person who is not a Party to this Agreement.

 

15.5 Counterparts. This
Agreement may be executed in two or more counterparts, and each such counterpart shall be deemed an original thereof.

 

 

 
15
 

   

   
 
 
  
 IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its duly authorized representatives as of the Effective Date.

 

	WuXi AppTec Biopharmaceuticals Co. Ltd.	 	Zhejiang Medicine Co. Ltd.
	 	 	 
	By:	 	By:	 
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

  
 

  

   

   

 
  

Appendix

 

[See Attached]

 
 

  

   

   

 
  

QUALITY AGREEMENT 
 by and between

 

Zhejiang Medicine Co. Ltd 

(“ZMC”) 
 and

 

WuXi AppTec Biopharmaceuticals Co Ltd.
(“WuXi”)
  

Purpose

 

This Quality Agreement defines the quality responsibilities of the
Parties and their respective affiliates or approved contractors with respect to the services provided by WuXi to ZMC regarding the development, cGMP manufacture, labeling, packaging, testing, release, shipment, and storage of the ZMC materials
itemized in Exhibit A to this Agreement (“Products”).
  
 The allocation of quality responsibilities is summarized in Exhibit B to this Agreement.

 

This Quality Agreement may be amended from time to time and additional
details concerning quality requirements may be provided in addenda in writing signed by the parties to this Quality Agreement. By signing below, the parties acknowledge and agree to the provisions of this Quality Agreement.

 

	Agreed and accepted for:
 WuXi App Tec
 Biopharmaceuticals Co
Ltd
	 	Agreed and accepted for: 
  
 Zhejiang Medicine Co
Ltd

	 	 	 	 
	By:	 	 	By:
	 	 	 	 
	Name:	James Ruan	 	Name:
	Title:	Sr Director,	 	 
	 	Quality Assurance	 	Title:
	Date:	 	 	Date:
	 	 	 

 

Effective Date:

 
 

  

   

   

 
  

Table of contents
  

	1.	BACKGROUND INFORMATION	1
	2.	SCOPE	1
	3.	DEFINITIONS	1
	4.	RESPONSIBILITIES	4
	5.	COMMUNICATION	4
	6.	BATCH DISPOSITION (PRODUCT RELEASE)	5
	7.	LABEL APPROVAL	6
	8.	QUALITY CONTROL	6
	9.	REFERENCE SAMPLES	6
	10.	RETENTION SAMPLES	7
	11.	RECEIVING, SHIPPING, STORAGE AND DESTRUCTION	7
	12.	CHANGE CONTROL	7
	13.	INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (PRE AND POST DISTRIBUTION NC’S)	7
	14.	AUDITS AND INSPECTIONS	8
	15.	DISPUTE RESOLUTION	9
	16.	PRODUCT COMPLAINTS	9
	17.	STOCK RECOVERY	9
	18.	RESPONSIBLE PERSONS: CONTACT INFORMATION	9

  
 

  

   

   
 
 
  

		1.	BACKGROUND INFORMATION

  

		1.1	WuXi AppTec Biopharmaceuticals Co Ltd. (“WuXi”) and Zhejiang Medicine Co Ltd. ( “ZMC”), (referred to individually as “the Party” or
collectively as “the Parties”) have entered into a Master Services Agreement (MSA) pursuant to which WuXi develops, manufactures, labels and packages various source materials and intermediates, clinical drug substance and drug product to
supply clinical trials of an antibody-drug conjugate (ADC). The MSA, effective date Jun 14 2013, stipulates the requirement that the Parties jointly develop and approve a Quality Agreement.

 

		2.	SCOPE

  

		2.1	This Quality Agreement defines the quality obligations of the Parties and their respective affiliates or approved contractors, with respect to the development,
manufacture, labeling, packaging, testing, release, shipment and storage of Products in accordance with the MSA and associated Work Orders.

 

		2.2	The provisions of this Quality Agreement supplement the provisions of the MSA. The terms of the MSA shall remain in full force and effect. In the event of any conflict
between this Quality Agreement and the MSA, in matters of quality, the Quality Agreement shall govern. In matters of business, financial and legal nature, the MSA shall govern.

 

		2.3	This Quality Agreement may be amended only by mutual written agreement of the Parties.

 

		2.4	Exhibits to this Quality Agreement are intended to provide additional definition to the applicable topic and, as such, should be updated to
reflect the current information and business process, as applicable. Amendment of the Exhibits does not require re-approval of the Quality Agreement unless the Quality Agreement itself is affected. Exhibits and all amendments of Exhibits shall be
approved by mutually written agreement by the Parties.

 

		2.5	All activities under this Quality Agreement shall be performed in compliance with standard industry practices, regulatory agency guidelines, ZMC
specifications, and all applicable laws and regulations, including, without limitation, GMP requirements that are acceptable to the PRC SFDA, US FDA, EMA, and TGA.

 

		2.6	This Quality Agreement shall expire at the termination, cancellation, or expiration, as the case may be, of the obligation under the MSA and any associated Work Order(s)
to supply Products for clinical and non-clinical use.

 

		2.7	WuXi and ZMC quality assurance will jointly oversee compliance according to GMP requirements that are acceptable to the PRC SFDA, US FDA, EMA,
TGA, and ICH.

  

		2.8	Use of Products shall be limited to use in certain in vitro, animal, and clinical studies/trials approved jointly by WuXi quality assurance and by
the ZMC Quality Manager as defined in the MSA.

 

		3.	DEFINITIONS

  

		3.1	All capitalized terms not otherwise defined in this Quality Agreement shall have the definitions set forth in the MSA.

 

		3.2	As used in this Quality Agreement, the following terms shall have the following meanings:

 

		CoA	Certificate of Analysis prepared by WuXi for Products representing the analytical results
	 	 	obtained for Products tested per the Quality Specifications.  

		CoC	Certificate of Compliance prepared by WuXi for Products

    
  
 

1
 

   

   

 
  

	 	 	representing that the Products were manufactured according to applicable cGMP requirements and that any Deviations/investigations related to Products have been finalized.
Any departure from SOPs, methods, Quality Specifications, protocols, Batch Records,
	 	Deviation	instructions, processes, process specifications or other documentation related to the Products.
	 	Disposition	WuXi Quality Assurance staff member qualified to perform the comprehensive quality
	 	Manager	assessment and make the disposition decision.
	 	Disposition Package	Documentation set provided that represents the joint batch disposition of the Product. Final dosage form of [Anti-Her2 ADC] containing the [Anti-Her2 ADC Drug
Substance]
	 	Drug Product	formulated with excipients. The bulk active ingredient [Anti-Her2 ADC Drug Substance] that is formulated with excipients and processed to produce the Drug Product.

	 	Drug Substance	Release of Products by WuXi and ZMC in accordance with standard operating procedures (“SOPs”). 
	 	Final Release	All applicable laws and regulations relating to current Good Manufacturing Practice(cGMP) as
	 	cGMP	promulgated by the Chinese Food and Drug Administration (SFDA), US FDA, EMA, TGA and ICH.
	 	IPC	In-Process Control A scheme depicting the origins of a Product Batch (Drug Substance or Drug Product) taking into
	 	Lot Genealogy	consideration specific operations such as splitting and pooling. Release of Products by WuXi according to its SOPs. Manufacturer’s Release signifies
that
	 	Manufacturer’s	Products have been produced using approved processes, in compliance with applicable cGMP
	 	Release	regulations, and meet the specifications established for the Product, as determined by review of all appropriate documentation. A change which materially modifies the
regulatory filing for the Product or is determined by
	 	Material Change	ZMC and/or WuXi to have significant potential to materially affect the Safety, Quality, Identity, Potency, or Purity of the Product. A Deviation incurred during the
manufacture, labeling, packaging, testing, storage or shipment of the Products, which on preliminary evaluation is determined to have the potential to impact the
	 	Major Deviation	Safety, Quality, Identity, Potency, or Purity of the Product, or regulatory commitments/submissions involving the Products. A Deviation which on preliminary evaluation is
determined to have no potential to impact the
	 	Minor Deviation	Safety, Quality, Identity, Potency, or Purity of the Product, or regulatory commitments/submissions involving the Products.
	 	OOS (Out Of Specification) Result	An examination, measurement or test result that does not conform with pre-established Specifications.
	 	Packaging Materials	All materials employed in the packaging of Products, excluding any outer packaging used for transportation or shipment. Packaging Materials are designated as primary or
secondary Packaging

  
 
 

 
2
 

   

   
 
 
  
 

	 	Process	Materials according to whether or not they are intended to be in direct contact with Products.
 A single operation or number of operations employed in the
preparation of the Products.

	 	Process Description	A controlled document, approved by authorized technical and quality representatives of both Parties, that documents the general outline of a specific Process. It includes all relevant Process parameters to be met and equipment and Raw Materials
to be used.
	 	Products	The ZMC materials listed in Exhibit A to this Quality Agreement.
	 	Raw Materials	All materials and components (with the exception of Packaging Materials) used by WuXi in the production of Products under the MSA and associated Work Orders.
	 	Regulatory Authority	A public authority or government agency responsible for protecting and promoting public health through regulation or rulemaking (codifying and enforcing rules and regulations and imposing supervision or oversight for the benefit of the public at
large).
	 	Reserve Sample	Sample collected from the manufacture of Products for the purpose of being analyzed, should the need arise, to support investigations.
	 	Retention Samples	A fully packaged unit from a batch of finished Product stored for identification purposes.
	 	Specifications	A mutually agreed and approved set of tests and acceptance criteria used to judge the identity, quality, purity, potency and safety of all source materials, Raw Materials, and Products.
	 	Stock Recovery	The removal or correction of a non-marketed Drug Product used in a clinical trial for reasons related to product Safety, Quality, Identity, Potency, or Purity, that has not left the direct control of WuXi.

   
 

 
3
 

   

  

 
 
 
 

 

		4.	RESPONSIBILITIES

  

		4.1	Without limiting any other provision of this Quality Agreement, the Parties agree that this Quality Agreement is intended to carry out the
following guiding principles:

  

		4.1.1	The Parties’ quality obligations with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Products
are as set forth in this Quality Agreement and the MSA and associated work orders.

  

		4.1.2	The Parties shall comply with all Applicable Laws in the conduct of activities under this Quality Agreement.

 

		4.1.3	The Parties acknowledge that the Parties shall each have the right to perform responsibilities hereunder through their affiliates and contractors,
subject to the requirements outlined in Section 6.1.

 

		4.1.4	The Parties shall collaborate to address any disagreements.

 

		5.	COMMUNICATION

  

		5.1	The Parties agree to provide verbal communication to one another, in a timely manner, as necessary or appropriate for a given issue. Both Parties also agree to follow-up
and clarify promptly in writing those important verbal communications to ensure clarity of issues. All official communications and documentation between the Parties will be conducted in Chinese.

 

		5.1.1	WuXi shall forward any written communication from the Chinese Regulatory Agency concerning the Products within three (3) business days of the time
of receipt by WuXi in Chinese.

  

		5.1.2	The forwarding of any oral communication from the Chinese Regulatory Agency concerning the Product outlined in this document shall be done within
three (3) business days in Chinese.

  

		5.2	Routine verbal and written communications required herein shall be delivered to the individuals indicated in EXHIBIT B or their
delegates.

  

		6.	SUBCONTRACTING

  
 6.1  Any subcontracting related to manufacture and testing of Products requires the prior approval of ZMC, a contractual agreement between WuXi and the respective contractor,
and qualification of the contractor by WuXi quality assurance. Upon request by ZMC, WuXi shall provide documentation of the qualification of the contractor for ZMC review.

 

		7.	FACILITIES AND EQUIPMENT

  
 7.1  WuXi will operate all equipment, systems, and facilities related to manufacturing, testing, packaging, and storage of Products according to WuXi’s written
procedures.

 

7.2  WuXi shall
perform equipment qualification, preventive maintenance, instrument calibration, computer system validation, and cleaning validation according to WuXi’s written procedures.

 

7.3 WuXi is responsible for maintaining records of
equipment usage, cleaning and any maintenance/calibration performed.

 

 

 
4
 

   

   

 
  

		8.	RAW MATERIALS AND PACKAGING MATERIALS

 

		8.1	WuXi shall use raw materials and raw material vendors and components that have been jointly agreed by ZMC and WuXi.

 

		8.2	Raw Materials and Packaging Materials provided or procured by WuXi shall be obtained from qualified or specified vendors.

 

		8.3	Wuxi shall maintain a vendor assurance program.

 

		8.4	WuXi shall ensure that a Certificate of Analysis or equivalent is obtained with each lot of Raw Materials or Packaging Materials
purchased.

  

		8.5	Specifications for Critical Raw Materials will be agreed to by ZMC.

 

		8.6	WuXi will store all Raw Materials and Packaging Materials and Products in a secure location under appropriate conditions.

 

		9.	PRODUCTION SYSTEMS

  

		9.1	Manufacture of Products will be done at WuXi’s pharmaceutical manufacturing facilities on a campaign basis, using procedures for manufacturing and control of
Products set forth in Master Batch Records according to Process Descriptions approved by ZMC.

  

		10.	BATCH DISPOSITION (PRODUCT RELEASE)

 

		10.1	WuXi Quality Responsibility

  

		10.1.1	WuXi shall be responsible for release of Product batches to ZMC (Manufacturer’s Release) confirming that each Batch supplied is in full accordance with the relevant
Specifications. ZMC and WuXi will mutually approve in writing all IPC, Manufacturer’s Release, and stability Specifications for Products.

 

		10.1.2	WuXi shall prepare a Certificate of cGMP Compliance (CoC) and a Certificate of Analysis (CoA) for each batch of Product and a BSE/TSE
statement.

  

		10.1.3	WuXi shall provide to ZMC’s Quality Manager a Disposition Package for each batch of Product consisting of the CoC, CoA, Lot Genealogy, copy
of the Executed Batch Record and Deviation Summary. The Disposition Package will be prepared and reviewed by a Disposition Manager to confirm completeness of the package and determine the batch disposition based on a comprehensive quality assessment
of the batch.

  

		10.1.4	The Deviation Summary for the batch will list all Deviations incurred during the manufacture, labeling, packaging, testing, or storage of the Products along with
confirmation of satisfactory review and approval of each Deviation. Deviations shall be categorized as Major (determined to have potential to adversely impact the Safety, Quality, Identity, Potency, or Purity of the Products or compliance with
regulatory filings regarding the Products, and subject to formal investigation and resolution according to WuXi procedures) or Minor (determined to have no adverse impact as described above).

 

 

 
5
 

   

   

 
  

		10.2	ZMC and WuXi Joint Quality Responsibility

 

		10.2.1	ZMC and WuXi shall be responsible for the Final Release of the Products for further manufacturing use, animal studies, or clinical distribution
following joint review of the Disposition Packages provided by WuXi. ZMC and WuXi agree to reasonable review periods and completion of document requests.

 

		11.	LABEL APPROVAL

  

		11.1	Physical Label Creation and Approval

 

		11.1.1	Physical labels for Product will be generated and approved according to established GMP procedures of WuXi for any such activities performed for
toxicology or clinical studies.

  

		11.1.2	Label Application

  

		11.1.2.1	WuXi is responsible for labeling and bulk packaging of the toxicology and clinical supplies.

 

		11.1.2.2	WuXi shall apply physical labels to Product prior to all shipments.

 

		12.	QUALITY CONTROL

  

		12.1	WuXi Quality Control Laboratory Testing Responsibility

 

		12.1.1	WuXi will conduct testing of Products according to the relevant Specifications and its approved, qualified or validated methods, policies and procedures. All
Specifications relating to Products will be jointly approved by WuXi and ZMC quality assurance.

  

		12.2	WuXi Importation and Testing Responsibility

 

		12.2.1	WuXi shall be responsible for preparing all documents required for import clearance and entry of shipment with reasonable cooperation from
ZMC.

  

		12.2.2	WuXi is responsible for sampling upon receipt and conducting testing, as required.

 

		12.2.3	ZMC must consent to WuXi using a contract laboratory for raw material/component release testing. Such consent is subject to the requirements
outlined in Section 6.1.

  

		12.2.4	In the case of OOS, an investigation will be performed per Section 13 (INVESTIGATION OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement and WuXi should notify
and obtain consent from ZMC quality assurance immediately.

 

		12.3	Stability Tesing

  

		12.3.1	WuXi will conduct stability testing of Products according to WuXi’s clinical stability program requirements.

 

		12.3.2	WuXi will communicate the expiration/retest date of each Product lot in the Disposition Package.

 

		12.3.3	WuXi shall notify ZMC within five (5) business days of any confirmed stability failure of Products and provide periodic updates on the OOS or Out
of Trend investigations.

  

		12.3.4	WuXi will provide ZMC with periodic Stability Summary Reports, including trending not to exceed six (6) month intervals.

 

		13.	REFERENCE/RESERVE SAMPLES

  
 13.1 WuXi shall retain Reference/Reserve Samples for each lot of Products produced and released for further manufacturing use, or for use in toxicology and clinical studies for the
longer of five (5) years after the lot’s expiration period or two (2) years after the completion (as determined by issuance of a non-clinical or clinical study report) of a non-clinical or clinical study conducted using the lot.

 

 

 
6
 

   

 
 

 
  

13.2 Each Reference/Reserve Sample will consist of at least twice
the quantity necessary to determine whether the Product meets its established Specifications, except for sterility and pyrogen testing.

 

		14.	RETENTION SAMPLES

  

		14.1	WuXi shall retain Retention Samples for 1 year after the expiration date of the Product for each packaged lot of Product released for clinical
distribution per established WuXi procedure.

 

		15.	RECEIVING, SHIPPING, STORAGE and DESTRUCTION

 

		15.1	WuXi is responsible for adequate storage of the raw materials, components and Product throughout the supply chain to meet any temperature or
special storage conditions.

  

		15.2	Shipping excursions will be investigated by WuXi.

 

		15.3	WuXi shall be responsible for the destruction of any unused and partially used Product in accordance with Applicable Laws and
regulations.

  

		16.	CHANGE CONTROL

  

		16.1	WuXi will have a change control procedure in place to address changes to WuXi’s systems, facilities, Processes, Process Descriptions, Master Batch/Labeling/Packaging
Records, Raw Materials and Packaging Materials (and associated specifications.

  

		16.2	Both Parties shall jointly agree and both Parties’ quality assurance personnel approve any material changes of manufacturing of the Product, specifically impacting
the following documents, if applicable: (1) Analytical Methods, (2) Master Batch/Labeling/Packaging Records, (3) Primary Packaging Components Specifications, (4) Product Specifications, (5) Raw Material/Component Specifications, and (6) Major
Facility of Manufacture Changes.

   

		16.3	Within fourteen (14) calendar days after the receipt of such notification both Parties will meet and determine collaboration
requirements.

  

		16.4	If a Material Change requires the approval of a Governmental Authority in China, then, WuXi shall use reasonable efforts to file for such
approval.

  

		16.5	WuXi shall provide updates to ZMC of any regulatory submissions relating to said changes.

 

		17.	INVESTIGATIONS OF DEVIATIONS, NONCONFORMANCES, OOS RESULTS, DISCREPANCIES ( Pre and POST DISTRIBUTION Deviations)

 

		17.1	WuXi will maintain a documented system for handling Deviations, Deviation Investigations, OOS Results, and Corrective and Preventive
Actions.

  

		17.2	It is the responsibility of WuXi to ensure that all Deviations are investigated, documented, and approved prior to release of
Products.

  

		17.3	Prospective (planned) Deviations shall be provided to ZMC for review and approval.

 

		17.4	If a Deviation is identified after a Product lot has been Released and shipped to a clinical site and/or patients have been administered the
Product, then WuXi will notify ZMC immediately of such Deviation.

  

		17.5	Each Party shall inform the other Party as soon as reasonably possible of issues which may adversely impact Product quality, safety, efficacy or
adverse events relating to any batch of Product.

 

 

 
7
 

   

   

 
  

		18.	AUDITS AND INSPECTIONS 18.1 WuXi Audits

 

		18.1.1	ZMC shall be entitled to perform yearly routine audits of WuXi facilities engaged in the provision of contracted services relating to Products. All facilities and areas
involved in manufacturing, testing, filling, labeling, packaging, storage of Products, intermediates, raw materials and components, document review and storage facilities are within the scope of an ZMC audit. Audit scope, agenda, and timing will be
approved by both Parties prior to each audit.

 

		18.1.2	All audits of WuXi facilities will be conducted during regular business hours in the presence of WuXi representatives. Audits shall be conducted by not more than three (3)
ZMC representatives at each WuXi facility, and, unless otherwise agreed upon by WuXi, for not more than four (4) business days at each site. ZMC shall provide WuXi written notification of such audit in a reasonable time period. The written
notification must clearly state the scope of the audit.

 

		18.1.3	In case of serious events (e.g. receipt of an FDA Warning Letter or its equivalent from another Regulatory Authority, recall of clinical Product or series of clinical
Product complaints), WuXi shall host ZMC “For Cause” audits. The scheduling of For Cause audits will be mutually agreed and take into consideration the critical and/or urgent nature of the precipitating event(s).

 

	 	18.2	Audit Findings
	 	 	 
	 	18.2.1	ZMC shall provide WuXi a copy of the audit report within thirty (30) calendar days of completion of an audit. After delivery of the audit report, WuXi shall provide ZMC
with a written response to such report within thirty (30) calendar days from WuXi’s receipt of the report from ZMC. All information in the audit report and subsequent follow up is considered confidential information between both
Parties.
	 	 	
	 	18.3	Regulatory Agency Inspections

  

		18.3.1	WuXi shall notify ZMC of any inspection by a Regulatory Authority related to a facility involved in (i) manufacture, labeling, packaging, testing,
release, shipment, or storage of the Product within one (1) business days of the initiation of the inspection.

  

		18.3.2	WuXi shall provide ZMC with a copy of the final response immediately after submission to the Regulatory Authority.

 

		18.3.3	WuXi shall provide the document in the language provided along with a reasonable translation into English.

 

18.3.4 WuXi shall provide a list and/or copies
of all documents directly related to Products shared with a Regulatory Authority during any inspection.
  
 
 

 
8
 

   

   

 

 

		19.	DISPUTE RESOLUTION

  

		19.1	Disputes relating to non-compliance or nonconformance of Products with the product specifications shall be governed by the terms set forth in the
MSA.

  

		20.	PRODUCT COMPLAINTS

  

		20.1	Any information related to product complaints (i.e., communication that alleges deficiencies relating to the identity, quality, durability, reliability, safety,
effectiveness, or performance of a drug, condition of labeling, or packaging, after it is released by WuXi for toxicology or clinical studies) shall be forwarded to ZMC within one (1) business day after WuXi first becomes aware of such
information.

  

		20.2	WuXi shall investigate according to WuXi’s applicable policy and procedures.

 

		20.3	WuXi shall provide ZMC with periodic updates on any outstanding product complaints and complete a final report within sixty (60) calendar
days.

  

		21.	STOCK RECOVERY

  

		21.1	If any problems are discovered and identified as recall/stock recovery issues related to the Products, the discovering Party shall notify the
other immediately.

  

		21.2	WuXi shall notify ZMC within three (3) business days if it becomes aware that any Product is alleged or proven to be the subject of a recall or
stock recovery in China.

  

		21.3	The Parties shall meet to discuss the circumstances that merit the Product recall or stock recovery and to determine the appropriate course of
action. Such course of action shall be consistent with the WuXi internal SOP.

  

		21.4	If either Party proposes to initiate a Stock Recovery or other corrective action with respect to the Product in the Collaboration Territory, the Parties will promptly
discuss such proposed action. Any decisions by the Parties shall be governed by the terms of the Collaboration Agreement. The Parties shall cooperate, as reasonably necessary, in the implementation of such actions.

 

		21.5	The Parties shall cooperate and promptly perform investigations into the root causes leading up to the Product Stock Recovery, when appropriate.
Investigation reports regarding the defect or cause for such regulatory reporting shall be provided to the corresponding Party within an appropriate timeframe dependent on regulatory reporting requirements.

 

		21.6	The Parties shall each maintain complete and accurate records of any Stock Recovery it has the right to control pursuant to this section of the Quality Agreement for such
periods as may be required by legal requirements, but in any event for no less than three (3) years from the date of Stock Recovery.

  

		22.	RESPONSIBLE PERSONS: CONTACT INFORMATION

 

22.1 The individuals listed in EXHIBIT C shall be the key points
of contact between WuXi and ZMC relating to the rights and obligations of the Parties in this Quality Agreement. The responsible individuals, or their respective delegates, must be notified in official communications as required by this Quality
Agreement.
  

 

 
9
 

   

 
 

 
  

Exhibit A 

List of Products

 

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

 
  

Exhibit B

 

	Definition of Quality Duties and Responsibilities
	 	 	 	 	 	 	[***]	 	 
	 	 	 	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	 	 	 	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	 	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	 	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	 	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	[***]
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	 	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	[***]	 	 
	[***]	 	[***]	 	 	 	 	 	 
	 	 	[***]	 	 	 	[***]	 	 
	 	 	[***]	 	 	 	 	 	[***]

  

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

 
  

	Definition of Quality Duties and Responsibilities
	 	 	 	 	 	[***]	 	 
	 	 	 	[***]	 	[***]	 	[***]
	 	[***]	 	 	 	[***]	 	 
	[***]	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]

 

 
 ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

  

   

   

 
  

	Definition of Quality Duties and Responsibilities
	 	 	 	 	 	[***]	 	 
	 	 	 	[***]	 	[***]	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	 	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	 	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	 	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 

  

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

 
  

	Definition of Quality Duties and Responsibilities
	 	 	 	 	 	[***]	 	 
	 	 	 	[***]	 	[***]	 	[***]
	 	[***]	 	 	 	 	 	[***]
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	 	 	[***]
	[***]	[***]	 	 	 	 	 	 
	 	[***]	 	 	 	[***]	 	 
	 	[***]	 	 	 	[***]	 	 

  

 ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

  

   

   

 
  

EXHIBIT C

 

Responsible Persons and Contact Information

 

	WuXi	 	 	 	 	 
	 	Name	Email Address	Contact Number	 	Responsibility
	James Ruan	 	[***]	[***]	 	Sr. Director, Quality Assurance
	Bob Coldreck	 	[***]	[***]	 	VP, Quality
	 	 	 	 	 	 
	ZMC	 	 	 	 	 
	 	Name	Email Address	Contact Number	 	Responsibility

  
 Exhibit C Version Date: Jun 14 2013
  
 ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

  

   

   

Exhibit 4

 

Work Plan

 

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   

[***]

 

***Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
  
 

  

   

   
 Exhibit 5
  
 Joint Steering Committee
  
 

	Chairperson:	 	Feng Tian, Ph.D, AMBRX Inc.	 	 	 
	 	 	 	 	 	 
	Members	 	 	 	 	 
	 	 	 	 	 	 
	Name	Affiliation	Title	Email	 	Work Phone
	Feng Tian, Ph.D	AMBRX Inc.	Director, EuCode Technology	[***]	 	[***]
	Ho Cho, Ph.D	AMBRX Inc.	Chief Technology Officer	[***]	 	[***]
	Scott Geyer, Ph.D	AMBRX Inc.	Vice president, CMC	[***]	 	[***]
	Xuejun Liang	ZMC	Manager, Biopharmaceutical	[***]	 	[***]
	Baoquan Zhu	Shanghai Institute of Pharmaceutical Industry	Chair, Academic Committee	[***]	 	[***]
	Hong Qian, Ph.D	Novo Biotech Corp.	CEO/BOD	[***]	 	[***]

 

 
 ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.
  
 

  

   

 
Exhibit 6

 

Joint Press Release

 

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop
and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer
  
 San Diego and Shanghai, June 14, 2013 — Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize
ARX788, Ambrx’s most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

 

Under the agreement, Ambrx and ZMC will continue the development of
ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on sales of the product in China. ZMC will manufacture the product to
world-class standards for clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and
clinical trials.
  

“We are excited to initiate this unique collaboration with ZMC
and WuXi, which allows us to team up with China’s leading pharmaceutical and CRO companies to efficiently develop ARX788, our most advanced ADC therapeutic candidate for both breast cancer and gastric cancer indications,” said Lawson
Macartney, Ph.D., Chief Executive Officer of Ambrx. This collaboration allows Ambrx to further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC. Our experience with site-specific ADC technology has
shown that we have the potential to create best-in-class therapeutic candidates, and we look forward to advancing ARX788 into the clinic to understand its full potential.”

 
 

  

   

   

Chunbo Li, Chairman of Zhejiang Medicine, commented, “We are
honored to partner with Ambrx, a leading biotech company, in ADC drugs. We will work with WuXi PharmaTech to accelerate the development and commercialization of ARX788 in China to bring benefits to Her2-positive cancer patients. The partnership will
help ZMC undertake pioneering work in the development of monoclonal antibodies and ADCs. The partnership will also help ZMC establish long-term and mutually beneficial relationships with leading global companies and advance our position in the
biopharmaceutical industry. “
  

“Our collaboration with Ambrx and ZMC on ARX788 is another
example of how WuXi’s comprehensive, integrated, open-access R&D services platform enables our partners to develop innovative products efficiently and cost-effectively to benefit the world’s patients,” said Dr. Ge Li, Chairman
and CEO of WuXi PharmaTech. “We are very pleased to offer our partners integrated services at global standards ranging from toxins to antibodies, from CMC development to pre-clinical studies, from regulatory strategy to clinical
trials.”
  

About Ambrx

 

Ambrx Inc. is a clinical stage biopharmaceutical company using an
expanded genetic code to create best-in-class biotherapeutics, including ADCs, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed
Phase 2b clinical trials. in addition to its most recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly
and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.

 

For additional information, visit www.ambrx.com.

 
 

  

   

   

About Zhejiang Medicine Co. Ltd.

 

Zhejiang Medicine Co. Ltd. (ZMC) is a major China-based pharmaceutical
company listed on the Shanghai stock exchange. It is a leading global manufacturer of fat-soluble vitamins and bacteria-resistant antibiotics. ZMC’s products are exported to the United States and many EU countries. In 2012, total revenue
reached 5.3 billion RMB and total profit reached 855 million RMB. ZMC has strong capabilities in technology innovation and new drug R&D and has received the National High-Tech Enterprise and Model Innovation Enterprise awards in China. ZMC has a
national-level R&D center and post-doctorate R&D sponsorship. Three ZMC research projects were awarded second prize in the National Technology Advancement competition and one was awarded second prize in the National Technology Innovation
competition. To date, ZMC has 126 issued patents, including 15 global patents, and has four class 1 drugs in clinical trials.
  
 For more information, please contact:
  
 ZhuJun Yu or Jing Zhu (Investor Relationship)
  
 Phone: +86-571-87213883
  
 email: sunny_0517@163.com
  
 About WuXi PharmaTech
  
 WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and
customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi
PharmaTech’s services are designed to help its global partners shorten the cycle and lower the cost of drug and
  
 

  

   

   

medical device R&D. The operating subsidiaries of WuXi PharmaTech
are known as WuXi AppTec.
  

For more informaiton, please contact

 

Ambrx

 

Ian Stone

(619) 308-6541

 

WuXI PharmaTech

 

Ronald Aldridge (for investors)

(201) 585-2048

ir@wuxiapptec.com

 

Aaron Shi (for the media)

+86-21-5046-4362

aaron_shi@wuxiapptec.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]